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Abstract  
 
 
RNA polymerase III (pol III) is responsible for transcribing a set of genes that 
are involved in protein synthesis, including transfer (tRNA) and 5S ribosomal RNA (5S 
rRNA). Pol III transcription levels are increased in many cancers, as increased protein 
synthesis is required for tumour growth. Furthermore, it has been shown that a number 
of oncoproteins and tumour suppressor proteins interact directly with the pol III 
machinery. The work presented in this thesis aimed to investigate whether the inhibitor 
of differentiation (ID) and E47 proteins regulate pol III transcription, as well as the 
mechanisms behind these processes.   
 Members of the ID family of helix-loop-helix (HLH) proteins promote cell 
proliferation and inhibit differentiation. ID proteins were identified through their ability 
to bind and antagonise other HLH proteins, such as the E47 transcription factor, but can 
also interact with non-HLH proteins, including ETS (E twenty-six) domain transcription 
factors and the retinoblastoma (RB) protein. Elevated levels of ID proteins are seen in 
many tumour types, including breast and colorectal carcinomas and neuroblastomas. 
Work in this thesis showed that pol III activity is specifically decreased following RNAi 
knockdown of ID1, ID2 or ID3 and that, conversely, overexpression of ID2 can induce 
pol III transcription. Chromatin immunoprecipitation (ChIP) assays demonstrated that 
ID proteins are present at pol III-transcribed genes in vivo, which may be explained by 
interaction with transcription factor IIIB (TFIIIB). To test this hypothesis, mapping 
experiments were performed which showed that TFIIIB and ID proteins co-localise near 
the start of a pol III template. By ChIP assays it was demonstrated that, in an ID2 
knockout cell line, pol III and TFIIIB occupancy at pol III-transcribed genes is 
decreased compared to wild type. By co-immunoprecipitation (co-IP) experiments, it 
was shown that IDs interact with TFIIIB at physiological ratios. Also, in vitro 
transcription and translation experiments demonstrated that glutathione S-transferase 
(GST) fusion proteins GST-ID1, GST-ID2 and GST-ID3 interact with TFIIIB. 
Therefore, ID regulation of pol III activity appears to be through interaction of these 
proteins with TFIIIB.   
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Members of the E-protein family of basic helix-loop-helix (bHLH) transcription 
factors are involved in regulation of cell growth and differentiation. E-proteins have 
been demonstrated to bind to E-boxes and can interact with other members of the HLH 
proteins as homodimers or heterodimers in order to modulate expression of their target 
genes. The ubiquitously expressed E47 transcription factor, which is a member of the E-
protein family, is negatively regulated by direct interaction with ID proteins, which 
prevent its binding to DNA. Work in this thesis showed that pol III activity is 
specifically stimulated following RNAi knockdown of E47 and that overexpression of 
E47 decreased pol III transcription. It was demonstrated by ChIP assays that endogenous 
E47 is present at pol III-transcribed genes in vivo. Mapping experiments were performed 
which showed that TFIIIB and E47 co-localise near the start of a pol III template. Co-IP 
experiments demonstrated an interaction of E47 with TFIIIB. Also, in vitro transcription 
and translation experiments indicated an interaction of GST-E47 fusion protein with 
TFIIIB. ChIP assays suggested that the ID2 protein is recruited to pol III-transcribed 
genes in an E47-dependent manner. 
In conclusion, work in this thesis identified novel functions concerning the role 
of ID and E47 proteins in their involvement in the regulation of pol III transcription. 
These findings have important implications in understanding the molecular basis of 
cancer development. The ID and E47 proteins therefore join the growing list of 
oncogene and tumour suppressor gene products that stimulate or repress pol III output.  
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1.1 Eukaryotic Transcription 
 
 The synthesis of ribonucleic acid (RNA) from deoxyribonucleic acid (DNA) 
templates is called transcription and is catalysed by enzymes known as RNA 
polymerases. One strand of DNA is copied by complementary base pairing to one strand 
of RNA. RNA polymerases start transcription at the initiation site of a gene. This site, 
which is referred to as the +1 start site, allows an RNA polymerase to move downstream 
along the gene and synthesise an RNA strand. This process will continue until the RNA 
polymerase reaches a termination sequence. At this point the RNA transcript is released 
from the DNA. Interestingly, not all DNA sequences are transcribed into RNA. Non-
transcribed regions contain regulatory signals that can direct RNA polymerases to the 
initiation site of a gene. 
 Transcription is the initial stage of gene expression and therefore it is subjected 
to a range of control mechanisms. Post-transcriptional regulation of gene expression can 
also occur, however the most significant and common level of control is through 
transcription (White, 2001). Transcriptional regulation is involved in almost all 
biological processes such as growth and development. This allows the cell to adapt to 
environmental changes and metabolic requirements. Errors in transcription are 
associated with a wide range of diseases, such as developmental abnormalities, diabetes 
and various forms of cancer.   
Eukaryotes have four nuclear RNA polymerases. In the nucleus of eukaryotic 
cells three RNA polymerases (pol I, pol II and pol III) transcribe different sets of genes 
(White, 1998a). Another RNA polymerase, (pol IV), has been discovered and it is 
expressed from an alternative transcript of the mitochondrial RNA polymerase gene 
(Kravchenko et al., 2005). Also, a plant-specific polymerase was found to participate in 
transcriptional silencing (Herr et al., 2005; Wierzbicki et al., 2008). Each RNA 
polymerase is essential for transcription of a specific set of genes and depends on 
transcription factors to recognise promoter sequences.  
Pol I has 14 subunits and pol II and III have 12 and 17 subunits, respectively. Pol 
I is devoted to transcribing one set of genes, the ribosomal RNA genes, which are 
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present in about 400 copies in humans and account for about 35-65% of all nuclear 
transcription (Moss & Stefanovksy, 2002). Pol II transcribes the protein-encoding 
messenger RNA genes (mRNA genes), as well as most small nuclear RNA (snRNA) 
genes (Thomas & Chiang, 2006), and the small nucleolar (sno) and micro (mi) RNA 
genes and provides 20% of nuclear transcription. Pol III is the largest RNA polymerase 
with an aggregate mass of 600-700 kDa. Pol III synthesises short untranslated RNA 
molecules which are usually shorter than 400 base pairs. Many of these have important 
functions in protein synthesis and cell growth, such as 5S ribosomal RNA (rRNA) and 
transfer RNA (tRNA). Pol III also synthesises 7SL RNA, an important component of the 
signal recognition particle, and 7SK RNA, which regulates pol II transcription. 
Mitochondrial RNA processing (MRP), U6 and H1 RNA molecules are also synthesised 
by pol III and are required for post-transcriptional processing of rRNA, mRNA and 
tRNA respectively. Pol III also transcribes short interspersed nuclear elements (SINEs), 
including Alu genes, of which there are over a million in humans. RNA polymerase IV, 
which is of mitochondrial origin, is responsible for the transcription of a number of 
protein-encoding genes (Kravchenko et al., 2005). These polymerases are controlled, so 
that the co-ordination of gene expression can regulate cell fate (White, 2001). 
 Pol I and III products are important for protein synthesis and are therefore 
essential for viability. When cell growth is no longer required, transcription is repressed 
by the p53, retinoblastoma (RB) and alternative reading frame (ARF) proteins (White, 
1998b; Morton et al., 2007). These proteins are targets in cancer where deregulation of 
pol I and III can occur. A number of tumour and transformed cell types express high 
levels of pol III products. Pol III-specific transcription factor IIIB (TFIIIB) can be 
stimulated by transforming agents, such as c-Myc (Gomez-Roman et al., 2003; Kenneth 
et al., 2007). TFIIIB is bound and activated by oncoproteins such as c-Myc. Normally, 
c-Myc is involved in cell cycle and cell growth and c-Myc’s deregulation is associated 
with one seventh of cancer deaths in the United States (U.S.) (Dang, 1999).  
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1.2 RNA polymerases I, II and III in eukaryotic cells 
 
Pol I synthesises only one RNA product, the large ribosomal RNA. A single type 
of promoter is utilised to synthesise the rRNA molecule, which is processed into 5.8S, 
18S and 28S rRNA (Grummt, 2003; Russell & Zomerdijk, 2006). Transcription of 
rRNA genes occurs in the nucleoli and accounts for 35-65% of all nuclear transcription 
(Moss & Stefanovksy, 2002). rRNA is exported to the cytoplasm in the form of 
immature ribosomes where its assembly is finished (Voet & Voet, 1995). High levels of 
ribosome production are required in order to maintain protein synthesis. Pol I activity is 
therefore linked with cellular growth, which can become deregulated in cancer. rRNA 
genes are separated by intergenic spacers where the promoter is present. The core 
promoter is present about 50 base pairs upstream of the initiation site. Because the 
efficiency of the promoter is weak it requires the Upstream Binding Factor (UBF), 
which recruits the selectivity factor 1 (SL1) factor and extends the region of DNA which 
is covered. Initiation starts when pol I is recruited to the promoter (Paule & White, 
2000). 
 Pol II transcribes the protein encoding-genes (mRNA genes), as well as small 
nuclear genes (White, 2000). Pol II transcription occurs in the nucleoplasm and accounts 
for 20% of all nuclear transcription. Pol II transcribes the majority of genes and this is 
evident in a variety of promoter structures. Promoters have binding sites for transcription 
factors. The class II gene promoters are located upstream of the initiation site.  Factor 
recognition sites are also located in the transcribed region or downstream of the 
termination site. Pol II requires six basal transcription factors to start transcription.  
Initially, TATA binding protein distorts the DNA to create a structure to which the basal 
transcription factors can bind. Basal transcription is then initiated by pol II.  
   Pol III transcribes class III genes which encode small RNA molecules, including 
the 5S rRNA and tRNAs that have important functions in protein synthesis and cell 
growth (White et al., 2001). Pol III transcription accounts for 10-20% of all nuclear 
transcription (Moss & Stefanovksy, 2002) and pol III could be an important control 
point in the regulation of growth and proliferation. The location of pol III transcription 
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has been discovered with the help of electron and confocal microscopy. It was shown 
that in HeLa cells pol III transcription occurs in about 2000 sites in the nucleoplasm 
(Pombo et al., 1999). Pol III transcription is regulated by the activities of transcription 
factors such as TFIIIB and TFIIIC. Also, phosphorylation and dephosphorylation can 
regulate the activity of transcription factors.  
   
1.3 RNA Polymerase III transcribed genes 
 
RNA polymerase III transcribes genes that encode a number of small RNA 
molecules that are not translated, and are involved in a number of cellular functions. 
Table 1.1 lists the functions of these molecules. 
 
 
 
Table 1.1: RNA polymerase III gene products and their functions 
 
Pol III products 
 
Known Functions 
 
tRNA 
 
 
Involved in protein synthesis as a translational adaptor 
 
 
5S rRNA 
 
 
Involved in protein synthesis as a component of ribosomes 
 
 
U6 RNA 
 
 
Involved in mRNA splicing 
 
 
H1 RNA 
 
 
Involved in tRNA processing (Rnase P component) 
 
 
MRP RNA 
 
 
Involved in rRNA splicing 
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1.3.1 5S ribosomal RNA 
 
For the synthesis of the ribosome, components from three RNA polymerases are 
needed. Pol I sythesises the 28S, 18S and 5.8S rRNAs (Doudna & Rath, 2002), pol II 
transcribes the genes encoding ribosomal proteins and pol III synthesises the 5S rRNA. 
The four rRNAs are required in equal stoichiometry, one copy of each per ribosome 
(White, 2001). Similarly to other pol III genes, 5S rRNA is transcribed in the 
nucleoplasm, however, it is then transferred to the nucleolus where it is incorporated into 
the large ribosomal subunit (Lafontaine & Tollervey, 2001). 5S rRNA is the smallest 
rRNA, 121 nucleotides long in humans. The human genome contains 300-400 5S rRNA 
genes, most of them in clusters of tandem repeats (International Human Genome 
Consortium, 2004). 
 
 
 
 
 
7SL RNA 
 
 
Involved in intracellular protein transport (component of 
SRP) 
 
 
7SK RNA 
 
 
Involved in controlling transcriptional elongation by pol II 
 
 
SINE transcripts 
 
 
Possible role in cellular stress responses 
 
 
VA RNA 
 
 
Involved in adenovirus translational control 
 
 
EBER RNA 
 
Involved in Epstein-Barr virus translational control 
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1.3.2 Transfer RNAs 
 
tRNAs translate genetic information between the triplet nucleic acid code of 
mRNA and into a particular amino acid sequence of a protein. Transcribed tRNAs are 
processed into mature tRNAs between 70-90 nucleotides in length and have a secondary 
structure as a cloverleaf (Sharp et al., 1984).  There is also at least one tRNA per amino 
acid. In humans there are about 450 tRNA genes which encode 274 different tRNA 
species (Goodenbour & Pan, 2006). tRNAs are covalently linked to particular amino 
acids. They contain a three base region, the anticodon, that can base pair to the 
corresponding base region, codon, on the mRNA nucleotide sequence. This ensures the 
correct synthesis of the polypeptide chain encoded by the mRNA. 
 
1.3.3 7SL 
 
7SL is a pol III-transcribed gene, which encodes a 300 nucleotide long transcript. 
It is an essential component of the signal recognition particle (SRP), involved in protein 
translocation across the endoplasmic reticulum (Walter & Blobel, 1982). The eukaryotic 
SRP consists of six polypeptides bound to 7SL. 7SL forms the backbone of the SRP and 
without it the other constituents of the SRP cannot assemble (Walter & Blobel, 1983). 
7SL is highly conserved throughout evolution, with the human genome containing four 
copies (International Human Genome Consortium, 2004). 
 
1.3.4 7SK 
 
7SK is a 330 nucleotide long pol III transcript which is abundant in eukaryotic 
cells (Mattaj et al., 1993; Murphy et al., 1986). 7SK can function as a negative regulator 
of the positive transcription elongation factor b (P-TEFb) (Nguyen et al., 2001; Yang et 
al., 2001). This interaction between 7SK and P-TEFb is crucial for the regulation of 
transcription of pol II genes (Nguyen et al., 2001; Yang et al., 2001). P-TEFb contains a 
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carboxyl-terminal domain (CTD) kinase, cyclin-dependent kinase 9 (CDK9), and can 
promote transcription elongation. 
 
1.3.5 U6 small nuclear RNA 
 
Spliceosomes are large complexes whose role is to remove introns from the pre-
mRNAs for the formation of the mature mRNA (Valadkhan, 2005). Spliceosomes 
consist of five snRNA species, four of which are synthesised by pol II. The smallest, U6, 
is synthesised by pol III. U6 is the most highly conserved of the spliceosomal RNAs and 
about 106 nucleotides long (Reddy et al., 1987).   
 
1.3.6 H1 and MRP 
 
H1 is a 369 nucleotide component of ribonuclease (RNase) P, an 
endoribonuclease that is involved in the processing of the 5’-termini of pre-tRNAs 
(Bartkiewicz et al., 1989; Lee & Engelke, 1989). The primary sequence of the H1 RNA 
is not homologous between organisms, however the tertiary structure is highly 
conserved in order to maintain its function (Morrissey & Tollervey, 1995). MRP is a 265 
nucleotide component of an endoribonuclease that has the ability to cleave the 
mitochondrial transcript to generate an RNA primer for replication of mitochondrial 
DNA (Chang & Clayton, 1987; Chang & Clayton, 1989). MRP is predominantly found 
in the nucleolus, where it is involved in the processing of pre-RNA (Clayton, 2001). 
 
1.3.7 Viral genes transcribed by pol III 
  
Several viruses that infect cells can employ pol III to express short transcription 
units within their genomes. One of the best characterised examples is the adenovirus 
viral associated I (VAI) and II (VAII) genes which are transcribed by pol III at the late 
stages of viral infection (Akusjärvi et al., 1980; Söderlund et al., 1976). The VA 
transcripts stimulate the translation of adenoviral mRNA during the late stages after 
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infection (Thimmappaya et al., 1982). The Epstein-Barr virus (EBV) contains two genes 
transcribed by pol III that are expressed in viral infections, the Epstein-Barr virus-
encoded RNA 1 (EBER1) and 2 (EBER2) (Rosa et al., 1981). The EBER1 and EBER2 
can functionally substitute for the VA genes in adenovirus infection, and therefore they 
have a similar role in simulating translation (Bhat & Thimmappaya, 1985). EBERs can 
induce growth in soft agar and can have an oncogenic role (Komano et al., 1999; Ruf et 
al., 2000).  
 
1.3.8 Short interspersed nuclear elements 
  
Short interspersed nuclear elements are transcribed by pol III and are the 
majority of pol III templates in mammals. SINEs include the Alu genes found in 
primates (Jelinek et al., 1980), and the B1 and B2 elements which are found in rodents 
(Bennett et al., 1984). The B1 genes show a high homology of about 80% to Alu genes 
and both appear to have evolved from the 7SL gene (Britten, 1994), whereas, the B2 
genes are thought to have evolved from tRNA genes (Batzer & Deininger, 2002). Alu 
genes constitute a significant part of the human genome. There are over a million copies 
of Alu genes in human cells, providing approximately 10% of the human genome 
(International Human Genome Consortium, 2001). The B1 and B2 genes in the rat 
genome are present in approximately 384,000 and 328,000 copies respectively. 
Although SINEs are abundant, little is known about their function. Many years ago they 
were regarded as ‘selfish’ DNA (Orgel & Crick, 1980). Later reports have indicated that 
SINE families are involved in the expression of adjacent genes (Häsler & Strub, 2006). 
B2 elements are involved in the repression of pol II gene expression after heat shock 
(Allen et al., 2004; Espinoza et al., 2004), translational regulation (Häsler & Strub, 
2006) and control of tumour cell proliferation (Pagano et al., 2007). Therefore, although 
SINEs initially were regarded as genomic parasites, it appears now that they have 
important roles. 
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1.4 Promoters used by RNA polymerase III 
 
Most promoters used by pol III contain crucial elements found within the 
transcribed region of a gene (White, 1998a). Promoters contain specific elements that 
direct the recruitment of transcription factors and RNA polymerase (Paule et al., 2000). 
Three types of pol III promoters exist (White, 1998a) (Figure 1.1). Type I and II are 
present downstream of the initiation site, whereas type III are present upstream of the 
site.  
 
1.4.1 Type I promoters 
 
Type I promoters are internal promoters that consist of three elements, which are 
required for efficient transcription of the gene: the A-block (+50 to +64 bp), the 
intermediate element (IE) (+67 to +72 bp), and the C-block (+80 to +97), which is 
known as the internal control region (ICR) (Pieler et al., 1985a; Bogenhagen, 1985). 
Space between these elements is restricted for effective transcription. Mutations in the 
A- and C-blocks can reduce transcription (Pieler et al., 1985a). This is in contrast to the 
flanking regions which display little conservation, showing greater resilience to 
mutations (Pieler et al., 1985b, Pieler et al., 1987). Type I promoters were initially 
characterised in Xenopus laevis (Bogenhagen et al., 1980) and are unique to 5S rRNA 
genes (Figure 1.1A).  
 
 
1.4.2 Type II promoters 
 
Type II promoters contain two important sequence elements: an A-block and a 
B-block with TFIIIC required for promoter recognition (Figure 1.1B). Most pol III-
transcribed genes such as tRNA genes, the adenovirus VA genes and the SINEs contain 
type II promoters (Bartholomew, 1990). The A-block found in type II promoters is 
homologous to the type I promoter A-block, and in some species these elements can be 
interchangeable (Ciliberto et al., 1983). Mutations in the type II elements can lead to 
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reduced gene expression (Traboni et al., 1984). Typically the A- and B-blocks are 
separated by 30-40 bp (Baker et al., 1987), however the distance can vary between them 
and can reach 365 bp, with the blocks still being functional (Fabrizio et al., 1987). The 
space between the two blocks can increase due to short introns in the coding regions of 
certain genes (White, 2001). 
 
1.4.3 Type III promoters 
 
Type III promoters differ in that they are external compared to type I and II. 
They consist of three external elements: a TATA box bound by TFIIIB, which is specific 
for pol III, a proximal sequence element (PSE) bound by snRNA activator protein 
complex/PSE-binding transcription factor (SNAPc/PTF) and a distal sequence element 
(DSE) which is bound by octamer-binding protein 1 (Oct-1) (Schramm & Hernandez, 
2002) (Figure 1.1C). Vertebrate U6 (Krol et al., 1987) and 7SK (Murphy et al., 1986), 
as well as MRP (Topper & Clayton, 1990) and H1 RNA (Baer et al., 1990) genes 
contain type III promoters. In some cases, genes with type I and II promoters also 
contain elements upstream of the initiation site that are required for transcription. 
Surprisingly, yeast U6 snRNA genes have functional A- and B-blocks with homology to 
type II promoters (Brow & Guthrie, 1990), whereas U6 snRNA genes in humans do not 
have them, suggesting that the evolution of an extragenic promoter organisation within 
the pol III system is recent (Paule & White, 2000).   
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T
A) Type I promoter
e.g. 5S rRNA genes
+1 A-block C-block TnIE
B) Type II promoter
e.g. tRNA genes
+1 A-block B-block Tn
C) Type III promoter
e.g. Vertebrate U6 genes
+1DSE PSE TATA Tn
 
Figure 1.1 Structure of the different types of pol III promoters.  
The transcription start site is indicated by +1 and the termination site by Tn 
(termination). The promoters of the 5S rRNA genes are examples of type I promoters. 
The promoters of the tRNA genes are examples of type II promoters. The promoters of 
the U6 snRNA genes are examples of type III promoters. The positions of various 
promoter elements are displayed: intermediate element (IE), distal sequence element 
(DSE) and proximal sequence element (PSE). Adapted from White, 2001. 
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1.5 Transcription Factors used by RNA polymerase III 
 
Transcription by pol III is not specific for a DNA sequence. Pol III requires 
proteins to position it to the initiation site of a gene. Different promoters require 
different transcription factors. Type I and II promoters require the assistance of TFIIIB 
and TFIIIC. Type I promoters also utilise transcription factor IIIA (TFIIIA) (Figures 1.2 
and 1.3). Type III promoters can use the SNAPc/PTF, Oct-1, TFIIIC and TFIIIB 
transcription factors. A way to increase pol III output is by raising the level of 
transcription factors that it requires.  
 
1.5.1 TFIIIA  
 
 Xenopus laevis TFIIIA was the first eukaryotic transcription factor to be purified 
and cloned (Engelke et al., 1980; Ginsberg et al., 1984). TFIIIA can bind specifically 
both RNA and DNA and consists of nine zinc fingers that can bind to 5S ribosomal 
DNA (rDNA) (Miller et al., 1985). TFIIIA can bind to 5S rDNA and then recruit TFIIIC 
to the promoter. Following the TFIIIC recruitment, TFIIIB binds upstream of the 
transcription start site which allows recruitment of pol III (Kassavetis et al., 1995; 
Roberts et al., 1996). TFIIIA is not only a transcription factor, but is also involved in the 
storage, nuclear export and regulation of the production of 5S rRNA (Guddat et al., 
1990; Pieler & Theunissen, 1993).  
 
1.5.2 TFIIIB 
 
 The TFIIIB transcription factor can control the production of 5S rRNA and 
tRNA. TFIIIB is a pol III-specific transcription factor and a determinant of biosynthetic 
capacity. As a result TFIIIB, is a potential target for tumour suppressors such as p53 and 
RB, which can inhibit its function (Cairns & White, 1998; White et al., 1996). On the 
other hand, oncoproteins such as Tax of Human T cell Leukaemia Virus type I (HTLV-
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1) can activate TFIIIB (Gottesfeld et al., 1996). Phosphorylation and dephosphorylation 
can also regulate TFIIIB (Hockman & Schultz, 1996). Deregulation of this factor can be 
important in tumour progression.  
 TFIIIB is recruited by TFIIIC, when the latter is assembled on the promoter. 
TFIIIB consists of TATA box-binding protein (TBP), TFIIB-related factor 1 (Brf1) and 
B double prime 1 (Bdp1). TBP is a 38 kDa factor which is used by pol I, II and III 
(Cormack & Struhl, 1992; White et al., 1992a,b). The carboxyl-terminal (C-terminal) 
domain is widely conserved between species, but the amino-terminal (N-terminal) 
domain is more species-specific. TBP-Brf1 complexes have been found that are not 
bound to DNA. One of the characteristics of TBP is that it can bend DNA alone or in a 
complex with Brf1 (Braun et al., 1992a). TBP can bind to a TATA-box in type III 
promoters without Brf1 or Bdp1 (Hernandez, 2001). However, Brf1 increases the 
affinity of TBP for DNA complexes (Librizzi et al., 1998).  
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Figure 1.2 Transcription complex assembly on a type I promoter. 
The transcription factor TFIIIA binds to the internal promoter. TFIIIC is then recruited, 
followed sequentially by TFIIIB and pol III. Once pol III is recruited, transcription is 
initiated at the transcriptional start site +1. 
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Type III promoters in mammalian cells use an alternative TFIIIB complex. In 
this case the TFIIIB complex consists of TBP, Bdp1 and a Brf family factor known as 
TFIIB-related factor 2 (Brf2) (Schramm et al., 2000). In order to distinguish the two 
different complexes, the complexes consisting of TBP, Bdp1 and Brf2 are referred to as 
TFIIIBα, and the complexes consisting of TBP, Bdp1 and Brf1 referred to as TFIIIBβ 
(Schramm et al., 2000). The C-terminal domain of TBP recruits Brf2 to the TATA box 
of the U6 gene (Cabart & Murphy, 2001). If Brf2 is depleted, this impairs the 
transcription of U6 genes, and even if recombinant Brf2 is added transcription cannot be 
reconstituted (Teichmann et al., 2000). This is an indication that possible Brf2-
associated polypeptides are required for transcription. 
 TFIIIB has also been shown to be a target of various tumour suppressors, such as 
RB and p53. Overexpression of RB can inhibit pol III transcription (White et al., 1996; 
Chu et al., 1997; Larminie et al., 1997; Hirsch et al., 2000). This occurs because RB 
binds to TFIIIB, which can block the interaction with TFIIIC and pol III (Larminie et 
al., 1997; Sutcliffe et al., 2000). RB knockout mice show increased levels of pol III 
transcription and high levels of tRNA and 5S rRNA synthesis when compared with wild 
type cells (White et al., 1996; Scott et al., 2001). Therefore, inactivation of RB will 
derepress TFIIIB and will increase pol III transcription. It is thought that RB must be 
compromised for cancer development. This can occur by mutations in the RB gene.  In 
most cases these mutations are present in the large pocket of RB (Harbour, 1998). This 
domain is important for RB to bind to TFIIIB and repress pol III activity (White et al., 
1996; Chu et al., 1997; Larminie et al., 1997). Also many DNA tumour viruses encode 
oncoproteins that neutralise RB by binding to its pocket (Vousden, 1995). These are the 
E7 product of human papilloma virus (HPV), the large T antigen of simian virus 40 
(SV40) and the E1A product of adenovirus, all of which can release TFIIIB from 
repression and activate pol III transcription (White et al., 1996; Larminie et al., 1999; 
Sutcliffe et al., 1999). One of the most common mechanisms by which RB loses its 
function in tumours is by deregulated hyperphosphorylation by cyclin-D and E-
dependent kinases (Hunter & Pines, 1994; Sherr, 2001). These kinases have the ability 
to stimulate pol III transcription because phosphorylated RB is not able to bind to 
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TFIIIB (Scott et al., 2001). Therefore it has been shown that derepression of TFIIIB can 
result from mechanisms that control RB function. 
 TFIIIB is also repressed by p53 (Cairns & White, 1998; Crighton et al., 2003). 
When bound by p53, TFIIIB cannot associate with TFIIIC or become recruited to pol III 
templates (Crighton et al., 2003). As a result, p53 activation will cause a decrease in 
TFIIIB activity and pol III transcription. It has been shown that in p53 knockout mice, 
synthesis of 5S rRNA and tRNA increases (Cairns & White, 1998; Crighton et al., 
2003). Oncoproteins such as human double minute 2 (HDM2) and HPV E6 can target 
p53 for degradation and derepress a pol III reporter (Stein et al., 2002). Mutations in p53 
are found in half of human cancers and 75% of these contain substitutions in the central 
core domain (Hollstein et al., 1994). Therefore, these (Cairns & White, 1998) 
experimental data indicate that loss of p53 will contribute to derepression of TFIIIB in a 
large number of cancers.  
 TFIIIB is also a target for a number of oncoproteins that can stimulate its 
activity. c-Myc can interact with TFIIIB in humans and in mice and have a stimulatory 
effect on pol III transcription (Gomez-Roman et al., 2003). Chromatin 
immunoprecipitation (ChIP) experiments have shown that endogenous c-Myc is present 
at pol III-tranascribed genes in transformed and untransformed cells (Felton-Edkins et 
al., 2003a; Gomez-Roman et al., 2003). The oncogenic kinase casein kinase II (CK2) 
can bind and phosphorylate TFIIIB in yeast and mammals (Hockman & Schultz, 1996). 
It can cause lymphomas in mice and is hyperactive in various human cancers 
(Notterman et al., 2001). Another oncogenic kinase which has been shown to stimulate 
the assembly of pol III transcription complexes is the extracellular signal-regulated 
kinase (ERK) (Felton-Edkins et al., 2003b). This occurs due to the binding of ERK to 
the Brf1 subunit of TFIIIB, which becomes phosphorylated (Felton-Edkins et al., 
2003b). One of the components of TFIIIB is TBP and TBP expression was shown to be 
raised by hepatitis B virus (HBV) and Ras activation. Also, high levels of TBP are 
sometimes found in colon cancer (Johnson et al., 2003). Nuclear pol I, II and III use 
TBP, so increased levels will likely have an effect on a number of genes (Hernandez, 
1993). One of the subunits of TFIIIB, Bdp1 has been shown to be expressed in high 
levels in cell lines transformed by polyomavirus (Felton-Edkins & White, 2002). The 
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third subunit of TFIIIB, Brf1 was found to have elevated expression in cervical 
carcinomas (Daly et al., 2005). 
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A-block B-block
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A-block B-block
TFIIICTFIIIB
A-block B-block
TFIIICTFIIIB
 
Figure 1.3 Transcription complex assembly on a type II promoter. 
Transcription factor TFIIIC binds to the A- and B-block on the promoter. Once TFIIIC 
is bound to DNA it recruits TFIIIB by protein-protein interactions. TFIIIB subsequently 
recruits pol III and transcription is initiated. The transcription start site is indicated by 
+1. 
Chapter 1 Introduction  
44 
 
1.5.3 TFIIIC 
 
TFIIIC in Saccharomyces cerevisiae (S. cerevisiae) consists of six subunits, 
TFC1, TFC3, TFC4, TFC6, TFC7 and TFC8, with a cumulative mass of 520 kDa 
(Manaud et al., 1998; Deprez et al., 1999; Geiduschek & Kassavetis, 2001). These six 
subunits form two domains: the τA which consists of TFC1, TFC4 and TFC7 that 
recognises the A-block, and the τB which consists of TFC3, TFC6 and TFC8, that 
recognises the B-block (Huang & Maraia, 2001). TFC8 allows TFIIIC to contact both 
blocks. When the space between the blocks of DNA is long, TFIIIC can loop out the 
DNA in order to bind the two blocks simultaneously (Schultz et al., 1989). Human 
TFIIIC consists of six polypeptides: TFIIIC220, TFIIIC110, TFIIIC102, TFIIIC90, 
TFIIIC63 and TFIIIC35 (Kovelman & Roeder, 1982; Dumay-Odelot et al., 2007). All 
the subunits are required for pol III transcription of class III genes consisting of type I 
and II promoters.  
The TFIIIC220 subunit binds to the B-block (L’Etoile et al., 1994). The C-
terminal domain interacts with TFIIIC102 and TFIIIC63, whereas the N-terminal 
domain interacts with TFIIIC110 (Shen et al., 1996). TFIIIC110 is the second largest 
subunit of TFIIIC and was isolated using a complementary DNA (cDNA) library from a 
human myeloid cell line (Sinn et al., 1995). A blast search has revealed sequence 
homology between human TFIIIC110 and TFC6 from S. cerevisiae (Huang et al., 2000). 
The TFIIIC110 gene is located on chromosome 2. The TFIIIC102 gene is located on 
chromosome 9 and has the highest homology of all the human subunits with the yeast 
counterpart TFC4 subunit (Hsieh et al., 1999a). The N-terminal domain consists of 
acidic regions, a helix-loop-helix (HLH) motif and contains 11 tetratricopeptide repeats 
(TPRs) (Hsieh et al., 1999a). Through its TPRs, TFIIIC102 associates with TFIIIC63 
and TFIIIC90 and can recruit TFIIIB to the promoter by its interaction with both Brf1 
and Bdp1. The yeast counterpart TFC4 interacts with Brf1, and this interaction is 
mediated by the first 168 residues of TFC4. Another subunit, TFIIIC90, was cloned with 
the use of a cDNA library (Hsieh et al., 1999b). The TFIIIC90 subunit can specifically 
acetylate the K14 on histone H3. Pol III interaction with TFIIIC90 has also been shown 
(Hsieh et al., 1999b). It acts as a linker between the 220 and 110 subunits that are 
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located on the B-block and the 63 and 102 subunits that are present on the A-block. The 
TFIIIC90 gene is located on chromosome 9. The gene of the TFIIIC subunit TFIIIC63 is 
also located on chromosome 9. TFIIIC63 interacts with TFIIIC102, TFIIIC90 and the 
pol III subunit C62 (Hsieh et al., 1999a). The TFIIIC63 protein contains a central helix-
turn-helix domain and a C-terminal acidic region.  
 In order to increase pol III output, the levels of some of its transcription factors 
can be raised. It has been shown that adenoviral infection can raise the levels of TFIIIC 
(Hoeffler & Roeder, 1985). Five of the subunits of TFIIIC are overexpressed at both the 
mRNA and protein levels in 3T3 fibroblast cells transformed by polyomavirus (Felton-
Edkins & White, 2002). Elevated levels of TFIIIC were found in each of nine human 
ovarian cancers compared to control tissue (Winter et al., 2000).       
 
1.5.4 SNAPc/PTF and Oct-1  
 
U6 and 7SK genes, which contain type III promoters, are expressed by 
transcriptional complexes containing TFIIIBα but not TFIIIC (Figure 1.4). The PTF, 
also called SNAPc, is a factor of five subunits which interacts with the PSE (Schramm et 
al., 2000; Teichmann et al., 2000). The initiation complex is assembled with the binding 
of the PSE by SNAPc (Henry et al., 1996; Wong et al., 1998). The SNAP43 and 
SNAP19 interact with the N-terminal domain whereas the SNAP45 associates with the 
C-proximal region of SNAP190 (Mittal et al., 1999). Oct-1 binds the upstream DSE to 
make contact with SNAPc and stimulates promoter occupancy by protein-protein 
interactions (Mittal et al., 1996; Murphy et al., 1992). Oct-1 contains activation domains 
and a POU domain. The POU domain contains a bipartite DNA binding domain which 
consists of two joined helix-turn-helix structures, the N-proximal POU specific and the 
C-proximal POU homeodomain (Herr & Cleary, 1995). SNAPc can also regulate the 
binding of TBP to DNA. Oct-1 is not essential for basal transcription (Hu et al., 2003). 
Assembly of the TFIIIB/SNAPc complex at the type III promoters recruits pol III.        
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1.6 RNA Polymerase III 
 
Pol III is the largest and most complex of the eukaryotic nuclear RNA 
polymerases. Pol III consists of 17 subunits in yeast and human, all of which are 
essential in yeast, and has an aggregate mass of 600-700 kDa (Geiduschek & Kassavetis, 
2001; Schramm & Hernandez, 2002; White, 2001). Pol III shares common subunits with 
pol I and pol II. Of the 17 subunits, ten are unique to pol III, five are common to pol I, II 
and III and two are common to pol I and pol III (Schramm & Hernandez, 2002; White, 
2001). The 17 subunits are essential for cell viability and function (Chédin et al., 1998; 
Ferri et al., 2000). The 17 subunits range from 10 to 160 kDa. The ten subunits which 
are unique to pol III are the following: C11, C17, C25, C31, C34, C37, C53, C82, C128 
and C160. The five which are shared by the three polymerases are the following: ABC 
10α, ABC 10β, ABC 14.5, ABC23, ABC27. The two common subunits in pol I and pol 
III are AC19 and AC40 (Bréant et al., 1983; Buhler et al., 1980; Chédin et al., 1998). 
The two largest polypeptides of pol III are homologous to the two largest subunits of pol 
I and pol II. The conserved subunits together with the shared subunits are thought to 
form the RNA polymerase catalytic core (White, 2001). The unique subunits are likely 
to perform other roles such as interaction with transcription factors (Geiduschek & 
Kassavetis, 2001). Therefore, it is no surprise that the three RNA polymerases carry out 
a similar role, transcribing a DNA template to produce a complementary RNA strand. 
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Figure 1.4 Transcription complex assembly on a type III promoter. 
TFIIIB and SNAPc cooperatively bind to the TATA box and PSE respectively on type 
III promoters. Binding of Oct-1 to the upstream DSE enhances SNAPc/TFIIIB 
recruitment. Pol III binds and transcription is initiated following the SNAPc/TFIIIB 
recruitment. The transcription start site is indicated by +1. 
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1.7 Transcription by RNA polymerase III 
 
1.7.1 Transcript initiation 
 
Pol III recruitment to TATA-less promoters is well characterised in yeast, where 
several steps are involved. Initially, TFIIIC binds to the promoter. The locations of 
TFIIIC subunits have been found by photocrosslinking to chemical probes (Bartolomew, 
1990). Binding to tDNA (DNA encoding tRNA) is ensured by TFC3 and TFC6 
interacting with the B-block (Arrebola et al., 1998). TFC1 and TFC7 bind to the A-block 
at opposite sites of the DNA helix (Bartolomew, 1990). TFC4 binds DNA upstream of 
the initiation site, which is occupied by TFIIIB, and downstream between the A- and B-
blocks. Finally, TFC8 is not thought to bind DNA.        
 When TFIIIC binds to tDNA it recruits TFIIIB. Initially, Brf is recruited to 
DNA, by interacting with TFC4 (Moir et al., 2000). Brf recruits TBP which is bound to 
it. This stabilises the TFIIIC-DNA complex by enhancing the cross-linking of TFC4 to 
DNA. When the Brf/TBP-TFIIIC-DNA complex has been formed, Bdp1 enters the 
complex. TFC4 and Brf1 recruit Bdp1 (Dumay-Odelot et al., 2002; Ishinguro et al., 
2002). TFIIIC is essential in determining the position that TFIIIB occupies at the tDNA. 
TBP can scan a region to choose an optimal site, where it occupies a region about 40 bp 
upstream of the transcription start site (Braun et al., 1992b). Bdp1 and Brf1 are present 
at opposite sides of the TBP-DNA core. Brf binds the TBP-DNA complex 15 bp 
downstream of the TATA-like sequence and 1 bp upstream of it through its C-terminal 
region (Colbert et al., 1998). The N-proximal segment of Bdp1 cross-links to the 
upstream end of the TFIIIB-DNA complex 8 bp upstream of the TATA-like sequence 
(Shah et al., 1999).  
Pol III is recruited to the initiation site when the TFIIIC-TFIIIB-tDNA complex 
is formed. However, TFIIIB alone is capable of recruiting pol III. This was evident from 
the stability of the TFIIIB-DNA complex in yeast, where high concentrations of salt or 
heparin cannot dissociate the complex. On the contrary, TFIIIA and TFIIIC are easily 
removed (Kassavetis et al., 1990). Following these treatments, pol III can still be 
recruited to class III genes by TFIIIB (Kassavetis et al., 1990). Pol III is recruited 
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through Brf-C34 interactions, however Brf-C17 and TBP-C34 interactions can also 
occur (Wang & Roeder, 1997; Ferri et al., 2000). At the tDNA, C34 binds upstream at -
17 bp and -3/-2 bp of the initiation site of the non-transcribed strand, whereas C53 
makes contact near the downstream end (Persinger & Bartholomew, 1996; Tate et al., 
1998). When pol III binds to DNA, the double stranded DNA melts and a bubble forms 
that extends from -11 bp and propagates downstream of the initiation site. The double 
stranded DNA is separated spontaneously and, unlike pol II, without ATP hydrolysis 
(Kassavetis et al., 1992). Brf unpairs DNA around the initiation site, whereas Bdp1 is 
involved in unpairing the upstream sequences (Kassavetis et al., 2001).  
 
1.7.2 Transcript elongation, termination and reinitiation 
 
As pol III moves into the gene, the bubble of melted DNA moves with it 
(Kassavetis et al., 1992). TFIIIC and TFIIIA are present in regions that will be 
transcribed by pol III, but this does not affect transcription by the enzyme. This leads to 
an important question on how pol III can transcribe through the DNA when factors such 
as TFIIIC and TFIIIA are stably bound to it, covering the entire gene without being 
removed after several rounds of transcription (Bogenhagen et al., 1982; Jahn et al., 
1987). A possibility is that pol III transiently displaces a particular factor during 
transcription, but the factor remains associated with another factor, and because of 
protein-protein interactions remains bound to DNA sites (White, 2001). The TFIIIC 
obstacle delays pol III by 0.2 seconds at a site upstream of the B-block without affecting 
total transcription rates. If, however, pol III transcribes in the antisense direction, TFIIIC 
will pause for 9 seconds before continuing through the B-block (Bardeleben et al., 
1994). tRNA elongation in yeast at 20°C occurs at a rate of about 20 nt/second 
(Matsuzaki et al., 1994). 
 Whereas pol I and II require accessory factors to terminate transcription, pol III 
can recognise termination sites accurately without help from other factors. While pol III 
is sufficient for termination, additional factors may be involved in human cells. Pol III 
transcription usually terminates at simple clusters of four or more thymidine (T) residues 
(Bogenhagen & Brown, 1981). The region surrounding the T cluster can affect the 
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termination signal recognition by pol III (Braglia et al., 2005). Pol III does not dissociate 
from the template after the synthesis of the first transcript, allowing multiple rounds of 
transcription (Jahn et al., 1987). TFIIIB and TFIIIC are involved in polymerase 
recapture and re-initiation of transcription (Ferrari & Dieci, 2008; Ferrari et al., 2004). 
Because of the bending of DNA by pol III transcription factors, re-attachment of pol III 
to the transcription unit is more rapid. During multiple rounds of tRNA gene 
transcription, synthesis occurs every 35 seconds, whereas initiation of the first transcript 
takes about 5 minutes (Dieci & Sentenac, 1996).       
 
1.8 The cell cycle 
 
In order for a cell to proliferate it has to increase its mass as well as its DNA 
content. The cell cycle is a period between two mitotic divisions. Cell growth is a 
continuous process, whereas DNA replication occurs at a specific point. The cell cycle is 
comprised of four phases. During the M phase or mitosis, a cell divides into two cells. In 
the G1 phase, which follows the mitotic phase, RNA and proteins continue to be 
synthesised. During the S phase, the DNA is replicated. In the G2 phase, the cell 
continues to grow until the next mitosis begins. Each cell cycle phase is controlled by 
proteins expressed periodically and this regulation occurs at the transcriptional level 
(Lewin, 2000).   
 
1.9 Cell growth and RNA polymerase III 
 
Normal cell proliferation requires an equilibrium between cell growth and the 
cell cycle. Cells grow by increasing their levels of protein and macromolecules (Baxter 
& Stanners, 1978). Since 80-90% of the dry mass of a cell is protein, the growth rate is 
proportional to the rate of accumulation of protein (Zetterberg & Killander, 1965). Even 
a 50% decrease in protein synthesis will cause cells to exit the cell cycle and quiesce 
(Brooks, 1977). Therefore, an increase in protein synthesis is essential for cell growth. 
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Ribosomes and tRNAs are part of the translational machinery and their availability is 
important for the rate of translation. Because 5S rRNA and tRNA are pol III products, 
increased pol III transcription is essential for cell growth. In yeast it has been 
demonstrated that reduced levels of the initiator tRNA affects cell growth and prolongs 
cell doubling time (Francis & Rajbhandary, 1990). Recently, it was shown that increased 
levels of tRNAiMet synthesis can stimulate cell proliferation and oncogenic 
transformation (Marshall et al., 2008). Pol I and pol III are required to maintain high 
rates of transcription to sustain ribosome synthesis and therefore protein production 
(Clarke et al., 1996). The discovery of the requirement for high levels of pol I and pol III 
transcription came from studies that restricted rRNA and tRNA synthesis. Halving the 
concentration of tRNAiMet can cause a threefold increase in cell mass doubling time, as 
was demonstrated in S. cerevisiae (Francis & Rajbhandary, 1990).  
 
1.10 Regulation of pol III transcription 
 
Pol III transcription is linked to cell growth (increase in cell mass), which is 
important for cell proliferation and leads to an increase in cell number. Pol III is 
responsible for the transcription of tRNA and 5S rRNA, which are required for protein 
synthesis and growth. The level of pol III transcription varies according to the 
requirements of the cell. When the cells are stimulated by serum it has been shown that 
pol III can be activated (Johnston et al., 1974; Mauck & Green, 1974). To increase pol 
III output, the levels of the transcription factors that are limiting pol III transcription can 
be raised (White, 2001). In the following sections, a number of factors that regulate pol 
III transcription will be discussed.    
 
1.10.1 Overexpression of pol III transcription factors 
 
Overexpression of the basal transcription factors TFIIIB or TFIIIC can occur in 
transformed cells. The three subunits of TFIIIB have been found at elevated levels in 
transformed cell types (Felton-Edkins & White, 2002; Larminie et al., 1999). TBP can 
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be induced following infection with hepatitis B virus (Wang et al., 1997). TBP is also 
expressed at high levels in colon carcinomas (Johnson et al., 2003). The Brf1 subunit 
has been found at elevated levels in cervical carcinomas (Daly et al., 2005). TFIIIC 
overexpression can result following transformation by simian virus 40, polyomavirus, 
adenovirus infection and Epstein-Barr virus (White et al., 1990; Felton-Edkins & White, 
2002; Hoeffler et al., 1988; Felton-Edkins et al., 2006). Also, a study comparing human 
ovarian carcinomas relative to healthy adjacent tissue, revealed elevated levels of TFIIIC 
and pol III transcripts in the ovarian tumours (Winter et al., 2000). 
 
 
1.10.2 Repressors of pol III transcription 
 
1.10.2.1 The retinoblastoma protein 
 
The retinoblastoma protein is a 105 kDa nuclear phosphoprotein that is 
ubiquitously expressed in normal mammalian cells (Knudsen & Knudsen, 2006). 
Overexpression of RB can inhibit pol III transcription (White et al., 1996; Chu et al., 
1997; Larminie et al., 1997; Hirsch et al., 2000). RB knockout mice show increased 
levels of pol III transcription and high levels of tRNA and 5S rRNA synthesis when 
compared with wild type cells (White et al., 1996; Scott et al., 2001). RB is involved in 
controlling the cell cycle if growth factors are limiting. The RB protein regulates the cell 
cycle by preventing the passage of cells from G1 into S phase. This occurs due to RB’s 
ability to bind and repress several transcription factors, such as TFIIIB and E2F. When 
TFIIIB is bound to RB it is unable to interact with Pol III and TFIIIC and remains 
inactive (Sutcliffe et al., 2000). RB binds and represses TFIIIB only in the 
underphosphorylated form which occurs during the G0 and early G1 phase (Scott et al., 
2001). Increased tRNA synthesis occurs at the G1/S transition, which corresponds with 
hyperphosphorylation of RB by cyclin-dependent kinases.   
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1.10.2.2 p53 
 
p53 is a tumour suppressor protein that inhibits pol III transcription. The p53 
protein is lost or mutated in more than 50% of human cancers and 75% of these 
mutations comprise substitutions in the central core domain (Hollstein et al., 1991; 
Hollstein et al., 1994; Vousden, 2000). p53 is induced by hypoxia and oncogenic stimuli 
which can lead to cell death or cell cycle arrest (Vousden & Lu, 2002). p53 interacts 
with TFIIIB and sequesters it away from the promoter, inhibiting pol III transcription 
(Crighton et al., 2003). This interaction occurs through TBP. The binding of p53 to 
TFIIIB blocks the interaction of TFIIIB with TFIIIC (Crighton et al., 2003). Also, high 
levels of tRNA and 5S rRNA are present in fibroblasts from p53-knockout mice (Cairns 
& White, 1998). Fibroblasts from patients with Li-Fraumeni syndrome, that inherit a 
mutated p53 allele, also exhibit high levels of pol III transcription (Stein et al., 2002). 
p53 can be neutralised by the HPV E6 or HDM2, which leads to elevated levels of pol 
III transcription (Stein et al., 2002). Therefore, experimental data indicate that loss or 
mutation of p53 will contribute to derepression of TFIIIB in a large number of cancers. 
 
1.10.2.3 Maf1 
  
 Maf1 has been shown to negatively regulate pol III transcription (Goodfellow et 
al., 2008; Johnson et al., 2007; Upadhya et al., 2002). Pol III transcription is repressed 
by a variety of signalling pathways that are activated in response to nutrient deprivation, 
DNA damage and secretory defects (Upadhya et al., 2002; Desai et al., 2005). 
Repression of pol III transcription requires Maf1 to incorporate the different signals and 
regulate the polymerase recruitment (Desai et al., 2005; Willis & Moir, 2007). Maf1 
homologues are found in mammals and plants (Pluta et al., 2001). Also, human Maf1 
directly binds tRNA promoters and interacts with TFIIIB and pol III (Johnson et al., 
2007). Maf1 can be phosphorylated or dephosphorylated under various conditions 
(Oficjalska-Pham et al., 2006). Maf1 is dephosphorylated under repressing conditions 
and accumulates in the nucleus, where it represses pol III transcription.  
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1.10.3 Activators of pol III transcription 
 
1.10.3.1 Myc  
 
Myc plays an important role as a regulator of tumourigenesis in human cancers 
(Schmidt, 1999). Inhibiting Myc significantly affects tumour growth and proliferation 
(Ponzielli et al., 2005; Stewart et al., 2001; Stewart et al., 2002). c-myc N-Myc and L-
Myc show oncogenic activity in cancers (Marcu et al., 1992; Nau et al., 1985). Under 
physiological conditions, these three oncoproteins are expressed in foetal development. 
c-myc is an immediate-early response gene whose expression is important for G1/S 
progression (Heikkila et al., 1987).  
The c-myc oncogene encodes the c-Myc transcription factor and was first 
identified as the cellular homologue of the viral oncogene v-myc of the avian 
myelocytomatosis retrovirus (Vennstrom et al., 1982). Elevated levels or deregulation of 
c-Myc have been detected in a wide range of cancers and is often associated with 
aggressive and poorly differentiated tumours. These cancers include, breast, colon, 
cervical, small cell lung carcinomas, osteosarcomas, glioblastoma, melanoma and 
myeloid leukaemias (Dang, 1999; Nesbit et al., 1999). c-Myc not only functions as a 
regulator of gene transcription of RNA pol II-transcribed genes, but is involved in the 
regulation of RNA pol I and III-transcribed genes. Chromatin immunoprecipitation 
assays have shown that c-Myc is present at chromosomal 5S rRNA, tRNA and B2 genes 
in untransformed fibroblast cells, ovarian epithelial cells and in the HeLa transformed 
cervical cell line (Felton-Edkins et al., 2003a; Gomez-Roman et al., 2003). This 
recruitment occurs due to protein-protein interactions of TFIIIB with the N-terminal 
transactivation domain of c-Myc, which leads to direct activation of transcription. 
Experiments using RNA interference to knockdown c-myc in HeLa cells and c-myc 
knockout rat fibroblasts showed that the expression of the 5S rRNA, tRNA and B2 genes 
was compromised (Felton-Edkins et al., 2003a; Gomez-Roman et al., 2003). These data 
suggest that c-myc contributes significantly to the level of pol III transcription in 
mammalian cells. Experimental data show that Myc and Myc associated factor X (Max) 
bind at non canonical E-box sequences located within the ribosomal DNA. This is 
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followed by the recruitment of transactivation/transformation domain associated protein 
(TRRAP), enhanced histone acetylation, recruitment of pol I and activation of rDNA 
transcription (Grandori et al., 2005).   
 
1.10.3.2 CK2 
 
CK2 is a ubiquitous active Ser/Thr protein kinase with a high number of 
substrates that is implicated in cellular growth and proliferation (Meggio & Pinna, 
2003). CK2 has been found to activate pol III transcription by binding to TFIIIB 
(Johnston et al., 2002). CK2 binds directly to and phosphorylates Brf1, which causes 
recruitment of TFIIIB to TFIIIC. Overexpression of CK2 is associated with human 
cancers, including breast (Landesman-Bollag et al., 2001), head and neck (Faust et al., 
1996) and prostate (Yenice et al., 1994). CK2 appears to have oncogenic activity in 
transgenic mice (Seldin & Leder, 1995).  
 
1.10.3.3 ERK 
  
Several kinases have been demonstrated to have a direct role in regulating pol III 
transcription. They respond to mitogenic stimuli through a signalling pathway and one 
example is the mitogen activated protein (MAP) kinase cascade. Induction of this 
pathway causes activation of ERK. ERK responds through a signalling cascade that 
involves the Ras-Raf-Mek pathway (Downward, 2003). Ras mutations are found in 
about 20% of human cancers (Downward, 2003). Because of the mutations in Ras and 
Raf and other abnormalities, the ERK kinases are hyperactive in 30% of cancers 
(Downward, 2003). ERK can also interact with and phosphorylate the Brf1 subunit of 
TFIIIB. This results in stimulating transcription of tRNA and 5S rRNA genes (Felton-
Edkins et al., 2003b; Goodfellow & White, 2007).    
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1.11 The inhibitor of differentiation (ID) family of helix-
loop-helix transcription factors 
 
1.11.1 The ID family 
 
The ID family of helix-loop-helix proteins function as positive regulators of cell 
growth and as negative regulators of differentiation. The human prototype of a 
subfamily of these proteins was discovered nearly 20 years ago (Benezra et al., 1990). It 
was named ID1, which relates to its functional properties as both an inhibitor of DNA 
binding and an inhibitor of differentiation. Mammalian genes that encode for other ID 
proteins were discovered by homology cloning (ID2, ID4) (Sun et al., 1991; Biggs et al., 
1992; Riechmann et al., 1994) or as mitogen-responsive early response genes (ID3) 
(Christy et al., 1991; Deed et al., 1993). Homologues of ID genes have been identified 
in Drosophila (Ellis et al., 1990; Garrell & Modohell, 1990), Xenopus (Wilson & 
Mohun, 1995) and zebrafish (Sawai & Campos-Ortega, 1997). The four members of the 
ID family (ID1, ID2, ID3 and ID4) in humans are all present on different chromosomes 
(20q1, 2p25, 1p36 and 6p22-21 respectively) (Mathew et al., 1995; Deed et al., 1994; 
Pagliuca et al., 1995). The HLH family of transcription factors consists of >200 
members (Norton, 2000). Basic HLH transcription factors can bind DNA as homodimers 
or heterodimers. The ID proteins lack a basic DNA binding domain and function as 
dominant-negative regulators of basic HLH proteins by forming inactive ID-bHLH 
(basic HLH) heterodimers. ID family proteins interact with the ubiquitously expressed 
bHLH E-protein transcription factors that include HEB, E2-2, and the E2A gene 
products, E47 and E12, which regulate differentiation linked genes (Massari & Murre, 
2000) (Figure 1.5). ID proteins interact with other proteins such as the RB protein 
(Iavarone et al., 1994), the ETS (E twenty-six) proteins and the Pax (paired box) DNA 
binding proteins (Iavarone & Lasorella, 2004; Roberts et al., 2001; Yates et al., 1999). 
In this way, the cell can regulate proliferation and differentiation by altering the activity 
of one gene. 
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Figure 1.5 Cell fate determination by ID and E-proteins. 
(a) Cells are sustained in state 1 by the ID proteins, which lack the basic DNA binding 
region. In state 1, E-proteins are sequestered by ID proteins resulting in inhibition of E-
box-dependent gene expression. This results in block of differentiation and stimulation 
of proliferation. (b) In state 2, the E-protein transcription factors activate transcription by 
binding to promoter E-boxes as E-protein–E-protein homodimers or as E-protein–tissue-
specific bHLH factor heterodimers. Formation of ID protein–E-protein dimers prevents 
E-proteins from forming DNA-binding transcriptionally active complexes. This results 
in induction of differentiation and inhibition of proliferation (state 2) (taken from Perk et 
al., 2005).  
 
1.11.2 The structure of ID genes and proteins 
 
All ID proteins range from 13 kDa to 20 kDa in size (Norton et al., 1998). The 
HLH domain for the ID proteins is highly conserved, however the rest of the sequence is 
very divergent, except for four small domains. The HLH region consists of two 
amphipathic α helices, which are 15-20 residues long, and are separated by an 
intervening loop. The HLH domain confers homo- or hetero-dimerisation, which is 
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required for DNA binding and transcriptional regulation. The HLH monomers form a 
four-α-helix structure which is stabilised by a combination of polar and electrostatic 
interactions at the interface of the monomer (Wibley et al., 1996). Heterodimerisation 
appears to depend on the variable loop region and ID-bHLH dimers may be stabilised by 
forming a multiple oligomeric state (Pesce & Benezra, 1993; Fairman et al., 1993). ID 
family genes have a similar genomic organisation of exon-intron boundaries in their 
coding regions, which might suggest that they have evolved from a familial ancestral ID 
gene (Deed et al., 1994).   
 
1.11.3 Functions of ID transcription factors 
 
One of the best characterised interactions of ID proteins are with the E-protein 
transcription factors. ID proteins inhibit cell differentiation by binding and sequestering 
bHLH transcription factors that are responsible for regulating differentiation linked 
genes (Ruzinova & Benezra, 2003). Slight changes in the equilibrium of heterodimeric 
interactions between ID and bHLH proteins cause remarkable changes in cell fate 
determination (Barndt & Zhuang, 1999; Jan & Jan, 1993). Even though all ID proteins 
bind to E-proteins, they have different preferences for E-proteins (Langlands et al., 
1997; Deed et al., 1998). In some cases, ID proteins can act as transcriptional activators. 
Fused ID proteins to a heterologous Gal4-DNA binding domain can cause activation of 
Gal4-dependent transcription (Bounpheng et al., 1999a). Although this occurs through 
sequestering bHLH proteins, which are involved in transactivation, the ID-bHLH 
heterodimers cannot bind DNA making this system unlikely to be physiological. 
Nevertheless, ID proteins could have a role as part of DNA-bound transcriptional 
complexes.    
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1.11.4 Role of ID proteins in cancer  
 
 In human tumours, elevated levels of IDs have been reported in breast cancer 
(Lin et al., 2000), prostate cancer (Ouyang et al., 2002a), ovarian cancer (Schindl et al., 
2003), thyroid cancer (Kebebew et al., 2000) and colon cancer (Wilson et al., 2001). 
Overexpression of ID proteins is associated with loss of differentiation and enhanced 
malignancy (Lasorella et al., 2001; Perk et al., 2005). Also, ID proteins have been 
shown to be involved in tumour progression (Fong et al., 2004). In breast cancer, the 
overexpression of ID1 is associated with infiltrating, more aggressive tumours, which 
suggests a relationship between the expression of ID1 and disease progression (Lin et 
al., 2000). ID overexpression has been shown to exhibit oncogenic properties (Benezra 
et al., 2005). When overexpressed with B cell lymphoma 2 (Bcl-2) they can immortalise 
primary fibroblasts (Norton & Atherton, 1998) and ID1 can immortalise primary 
keratinocytes (Alani et al., 1999). In mice, overexpression of ID1 or ID2 in thymocytes 
results in T cell lymphoma (Kim et al., 1999; Morrow et al., 1999). ID proteins can be 
regulated by a number of oncoproteins such as Ras, Myc and the EWS (Ewing sarcoma) 
- ETS fusion protein, found in Ewing’s sarcoma. The Ras signalling pathway leads to 
the activation of early growth response 1 (Egr1), which causes induction in the levels of 
ID1 (Tournay & Benezra, 1996) and ID3 (Bain et al., 2001). ETS1 can become inhibited 
by ID proteins, which in turn inhibit p16INK4a expression and allow phosphorylation of 
RB (Ohtani et al., 2001). Myc oncoproteins can directly bind to the ID2 
promoter/enhancer and activate expression of ID2 (Lasorella et al., 2000). Increased 
levels of ID2 are required by Myc to overcome RB-mediated cell cycle arrest. ID1 and 
ID3 are also downstream targets of Myc. Elevation of ID1 is essential for Myc to drive 
breast cancer cells to enter S phase (Swarbrick et al., 2005). Myc also binds to the E-box 
in the ID3 promoter/enhancer similar to ID2. In Ewing’s sarcoma, the EWS-ETS fusion 
protein activates ID2 by binding to the promoter directly (Nishimori et al., 2002; 
Fukuma et al., 2003). This was examined by retroviral transduction of EWS-ETS that 
lead to transcriptional activation of ID2.  
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1.11.5 ID proteins as a therapeutic target 
 
 ID proteins are overexpressed in tumour cells and are involved in proliferation, 
invasiveness, metastasis and angiogenesis (Lasorella et al., 2000; Perk et al., 2005; 
Ruzinova & Benezra, 2003). Therefore, ID proteins are now regarded as interesting 
targets for anti-cancer drugs against tumour progression. ID proteins are expressed at 
low levels in adult tissue but are reactivated in cancer. Target therapy that has low 
toxicity and that is able to aim at the tumour and its support network would be very 
attractive.  However, transcription factors are difficult to inhibit as they are present in 
the cell’s nucleus and act through protein-protein or protein-DNA interactions. Small 
molecules have been used to target protein-protein interactions (Berg, 2003). The Myc-
Max interaction has been inhibited as well as the interaction between β-catenin and  
cAMP response element-binding protein (CREB) (Berg, 2003; Emami et al., 2004). In 
the case of ID proteins, a developed antitumour agent has been shown to downregulate 
ID1 in tumour cells in vivo (Henke et al., 2008). An antisense oligonucleotide fused to a 
peptide was used, which homed to tumour neovessels, and when delivered caused a 
decrease in the ID1 protein levels. Delivery of the drug lead to inhibition of primary 
tumour growth and metastasis, effects which are similarly seen in ID1 knockout mice. 
When combined with the heat shock protein 90 (Hsp90) inhibitor 17-(allylamino)-17-
demethoxygeldanamycin, this resulted in complete growth suppression of breast 
tumours (Henke et al., 2008). 
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1.12 E2A basic helix-loop-helix transcription factors 
 
The basic HLH proteins are categorised in different classes depending on 
functional and biochemical properties. E-proteins belong to class I HLH proteins and are 
transcription factors that have been demonstrated to bind to E-boxes (Lazorchak et al., 
2005; Sun, 2004). E-proteins are widely expressed and can interact with other members 
of the HLH proteins as homodimers or heterodimers in order to modulate expression of 
their target genes. The E-protein family consists of four members in mammals, the E47, 
E12, E2-2 and HEB. The E2A genes encode two transcription factors, E47 and E12, 
which were discovered by expression screening of a lymphoid library using a DNA 
probe that corresponded to an E-box (Murre et al., 1989; Sun & Baltimore, 1991). E-
proteins are regarded to play a crucial role in regulating cell growth and differentiation 
(Slattery et al., 2007).  
The E2A gene consists of four coding exons and one non-coding exon (Hata & 
Mizuguchi, 2004). The DNA-binding and dimer assembly domains of E47 and E12 are 
present on the C-terminal regions. The transcriptional activity is located on two 
domains, AD1 and AD2, which have been mapped to the N-terminal domain (Aronheim 
et al., 1993; Henthorn et al., 1990). More information has emerged on the 
transactivation properties of E-proteins. The p300 activator has been shown to interact 
with E47 when E47 is bound to DNA (Eckner et al., 1996). Since p300 has 
acetyltransferase activity, it is possible that E-proteins recruit enzymes that play a role in 
chromatin modification (Bannister & Kouzarides, 1996; Ogryzko et al., 1996; Eckner et 
al., 1996). MyoD and p300 interact at the bHLH region of MyoD and do not require the 
transactivation domains. This was unexpected, since the bHLH domain does not have 
intrinsic transactivation potential. Also, it has been shown that a conserved motif, LDFS, 
found in the AD1 domain binds to a histone acetyltransferase (HAT) complex named 
SAGA. Some of the subunits of SAGA are the HAT general control nonderepressible 5 
(Gcn5), the transcriptional adaptor (Ada) and suppressor of Ty (Spt) proteins (Grant et 
al., 1998a; Ogryzko et al., 1996). Therefore, it is possible that E2A could recruit a 
nuclear HAT such as p300 or a SAGA complex such as Gcn5 to target genes and affect 
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the acetylation of nucleosomal histones (Ogryzko et al., 1996). E2A proteins can be 
negatively regulated by the ubiquitin-proteasomal pathway (Huggins et al., 1999). CK2 
has been shown to phosphorylate two sites within the residues N-terminal to the bHLH 
domain (Sloan et al., 1996). The phosphorylation of these residues resulted in inhibiting 
the DNA binding ability of E47 homodimers (Sloan et al., 1996).  
Several studies have indicated that E-proteins play a role in regulating cell 
growth. E47 is capable of growth suppression in NIH3T3 cells. When E47 was 
overexpressed in colony forming assays this suppressed the growth of NIH3T3 cells 
(Peverali et al., 1994). E-proteins have been implicated in various forms of cancer. Mice 
that are E47 deficient develop T cell lymphoma (Yan et al., 1997; Bain et al., 1997). 
Cells from patients with T lymphoblastic leukaemia have chromosomal translocations 
involving the bHLH T cell acute lymphoblastic leukaemia 1 (TAL1) gene (Park et al., 
1999). The E-protein transcriptional activity is inhibited by TAL1 that causes leukaemia 
in mice (O’Neil et al., 2004). Therefore, it is proposed that E-proteins act as tumour 
suppressors in human T lineage cells (Bain et al., 1997). In childhood pro-B and pre-B 
leukaemias, E-proteins are thought to be involved. Chromosomal translocation events in 
both types of leukaemias replace the E2A bHLH region with a leucine zipper within the 
hepatic leukaemia factor (HLF) gene or homeodomain pre-B cell leukaemia homeobox 1 
(Pbx1) domain (Inaba et al., 1992; Aspland et al., 2001). The regulation of E47 by Ras 
signalling through activation of ID genes raises the question whether E47 has a role in 
various developmental systems as a tumour suppressor (Perk et al., 2005). ID proteins 
are overexpressed in several cancers and it is possible that the E47 protein is a target of 
Ras-mediated transformation. Since E47 proteins regulate cell growth, suppressing their 
activity may be crucial for the development and progression of several malignancies.     
 
 
 
 
 
Chapter 1 Introduction  
63 
 
1.13 Aims of PhD 
 
Pol III transcription can be regulated by various proteins and conditions. 
Conditions such as cell cycle progression, growth, differentiation and transformation can 
be regulated by several proteins such as transcription factors. The transcription factors 
ID1, ID2 and ID3 are important due to their oncogenic potential. The E47 transcription 
factors are regarded as suppressors of cell growth. Elucidating the function of these 
proteins in pol I/III transcription would be novel, since no studies have been reported on 
whether these proteins regulate pol I and/or pol III, and of great importance in the field. 
The work in this thesis attempts to uncover the role of these novel proteins in the 
regulation of pol III transcription.  
One of the first goals was to determine if ID1, ID2, ID3 and E47 transcription 
factors can activate or repress pol III transcription. Another goal was to determine the 
precise interaction of these transcription factors with the pol III transcription machinery. 
This will give us an insight into the mechanism underlying the regulation of pol III 
transcription. Finally, this thesis will investigate the synergistic role of ID1, ID2, ID3 
and E47 transcription factors on the regulation of pol III transcription. By understanding 
of the role of these proteins in cancer, tools to explore these proteins as therapeutic 
targets can be provided. 
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2.1 Cell culture  
 
A class II hood was used for all cell culture work, using aseptic techniques and 
sterile equipment and reagents. 
 
2.1.1 Cell lines and maintenance 
 
HeLa, HEK 293, MEF ID2+/+ and MEF ID2-/- cells were maintained in DMEM 
(Dulbecco’s Modified Eagle Medium, Cambrex) supplemented with 10% foetal bovine 
serum (FBS, Sigma), 2 mM L-Glutamine (Sigma), 100 U/ml penicillin (Sigma) and 100 
U/ml streptomycin (Sigma). ID1 U2OS and ID3 U2OS stable cell lines were maintained 
in the same way as the above cell lines, with the addition of 300 µg/ml G418 (Promega) 
in the culture medium. Stably transfected HeLa TET-ON cells were maintained in 10% 
FBS (tetracycline free), 100 U/ml penicillin, 100 U/ml streptomycin, 100 µg/ml G418 
and 100 µg/ml hygromycin. Expression of HA-Brf1 (haemagglutinin tagged Brf1) was 
induced for 48 hours before harvesting by the addition of 1 µg/ml doxycycline.  
Cells were maintained at 37°C in a humidified atmosphere containing 5% CO2 
and passaged when sub-confluent, approximately every 2-3 days. In order to passage the 
cells, the medium was aspirated from the flask and 2 ml of buffered trypsin-EDTA 
[0.05% (w/v) trypsin, 0.02% (w/v) EDTA, Sigma] were added to the cells in a 75cm2 
flask and aspirated immediately. A further 2 ml were added and left for approximately 3 
minutes at 37°C. Following the addition of trypsin, fresh medium was immediately 
added to the dissociated cells which were then centrifuged at 1,000xg for 5 minutes. The 
medium was removed and the pelleted cells were resuspended in fresh medium and 
transferred to new flasks. 
 
 
 
 
 
Chapter 2 Materials and Methods  
66 
 
2.1.2 Adenoviral infection of cells 
 
Cell culture using adenoviruses was performed in a category II hood, using 
aseptic techniques and sterile equipment and reagents. HeLa and HEK 293 cells were 
plated 1 day prior to adenoviral (Ad) infection. The cells were infected with an 
adenovirus expressing ID2 (Ad-ID2), E47 (Ad-E47) or with the parental virus 
adenovirus-cytomegalovirus 5’ internal ribosomal entry site green fluorescent protein 
(Ad-CMV5-IRES-GFP) (Ad-Vector) at a multiplicity of infection of 100. The infection 
was allowed to proceed for 2 hours prior to termination by the addition of excess culture 
medium to the plates.   
 
2.1.3 Cryo-storage of cells 
 
Cryo-freezing was used for the storage of all cell lines. Cells were trypsinised as 
described and, after pelleting by centrifugation at 1,000xg for 5 minutes, were 
resuspended in a solution of 80% DMEM, 10% FBS and 10% dimethyl sulphoxide 
(DMSO, Sigma). From a sub-confluent 75 cm2 flask, 1.5 ml of cells were aliquoted into 
2 ml cryo-tubes and frozen in two steps. Initially, the cells were placed at -80°C 
overnight before being transferred to liquid nitrogen for long-term storage. The cells 
were recovered by placing the cryo-tubes in a water bath at 37°C until thawed. Cells 
were mixed with fresh media and pelleted by centrifugation. The supernatant was 
aspirated to ensure removal of DMSO and the cells were resuspended in maintenance 
media. 
 
2.2 Transformation of competent Escherichia coli (E. 
coli) cells 
 
For plasmid propagation, E. coli XL-1 blue supercompetent cells (Stratagene) 
were transformed with plasmid DNA. The supercompetent cells, which are highly 
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temperature sensitive, were stored at -80°C and thawed on ice, to avoid loss of their 
transformation ability. 50 µl of competent cells were incubated with 20 ng of plasmid 
DNA on ice for 30 minutes. The cells were heat-shocked at 42°C for 30 seconds and 
quickly transferred on ice for a further 2 minutes. The cells were incubated at 37°C for 1 
hour on an orbital shaker (250 rpm) following the addition of 500 µl of SOC medium 
(LB Broth, 0.05% glucose, 10 mM MgSO4, 10 mM MgCl2). LB-agar plates (LB Broth, 
2% agar, 100 µg/ml ampicillin) were then plated with 150 µl of the transformation 
mixture and incubated at 37°C overnight to allow growth and colony formation. 
 
2.3 Preparation of plasmid DNA 
 
A single isolated bacterial colony was selected from the LB-agar plates and was 
used to inoculate 5 ml of LB medium containing 100 µg/ml ampicillin as the selection 
antibiotic. The culture was incubated for 6 hours at 37°C in an orbital shaker (250 rpm). 
1 ml was transferred to a larger culture containing 500 ml of LB-broth and was 
incubated overnight at 37°C in an orbital shaker (250 rpm). The cells were harvested by 
centrifugation at 4500 rpm for 30 minutes at 4°C. Plasmid DNA was isolated by 
Molecular Technology Services using a Qiagen 9600 robot. The concentration of 
plasmid DNA was measured spectrophotometrically using the BioPhotometer 
instrument (Eppendorf) and a quartz cuvette, according to the formula 1 A260 = 50 µg/µl 
dsDNA. Plasmids were stored at -20°C. For a description of the plasmids see table 2.1. 
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Table 2.1: Description of plasmids 
 
2.4 Restriction endonuclease digestion 
 
EcoRI and BamHI (Promega) restriction endonucleases were used to digest 
plasmid DNA. Six plasmids based on the PGex2T vector were analysed to confirm the 
presence of the ID1, ID2, ID3, ID2-HLH, ID2–δHLH and E47 inserts. The reactions 
contained 1 µl of each restriction enzyme, 1 µg of plasmid DNA and 3 µl of the 
MULTI-CORE buffer (Promega) in a final volume of 30 µl. The DNA was left to digest 
for 1 hour at 37°C. The sample products were mixed with 6x agarose gel DNA loading 
buffer [0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol, 30% (v/v) glycerol] 
to give a final 1x loading buffer concentration and analysed by 1% (w/v) agarose gel 
Plasmid Description Origin 
PGex2T Encoding GST, used as a 
control 
Gift from Bob Eisenman 
(Gomez-Roman et al., 2003) 
PGex2T-ID1 Encoding full length ID1 
protein 
Gift from Antonio Iavarone 
(Lasorella et al., 1996) 
PGex2T-ID2 Encoding full length ID2 
protein 
Gift from Antonio Iavarone 
(Lasorella et al., 1996) 
PGex2T-ID3 Encoding full length ID3 
protein 
Gift from Antonio Iavarone 
(Lasorella et al., 1996) 
PGex2T-ID2-HLH Encoding helix-loop-helix 
domain of ID2 protein 
Gift from Antonio Iavarone 
(Lasorella et al., 1996) 
PGex2T-ID2-δHLH Encoding ID2 protein lacking 
the helix-loop-helix domain  
Gift from Antonio Iavarone 
(Lasorella et al., 1996) 
PGex2T-E47 Encoding full length E47 
protein 
Gift from Antonio Iavarone 
(Lasorella et al., 1996) 
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electrophoresis. Electrophoresis was allowed to proceed in 1x TAE buffer (40 mM Tris-
acetate, 1 mM EDTA pH 8.0) containing 0.1 µg/ml ethidium bromide (Sigma) and DNA 
was visualised under ultraviolet (UV) light.  
 
2.5 Expression of recombinant glutathione-S-
transferase (GST) fusion proteins  
 
E. coli BL21 Rosetta competent cells were transformed for plasmid propagation. 
Competent cells were stored at -80°C and thawed on ice for transformation. 50 µl of 
thawed cells and 20 ng of plasmid DNA were mixed by agitation. The cells were 
incubated for 20 minutes on ice and heat-shocked at 42°C for 30 seconds. The cells were 
recovered by the addition of 500 µl SOC medium (LB-Broth, 0.05% glucose, 10 mM 
MgSO4, 10 mM MgCl2) and incubated at 37°C for 30 minutes. 150 µl of cells were 
plated onto LB-agar plates (LB-Broth, 2% agar, 100 µg/ml ampicillin) and incubated at 
37°C overnight. Single colonies were picked and grown overnight in 10 ml of LB broth 
containing 100 µg/ml ampicillin at 37°C in an orbital shaker. The 10 ml culture was 
used to inoculate 500 ml of LB broth containing 100 µg/ml ampicillin, and the culture 
was grown at 37°C in an orbital shaker until reaching an OD595 of 0.6-0.8. An uninduced 
control sample of 1 ml was taken at this stage. The sample was pelleted by 
centrifugation at 13,000xg for 1 minute and resuspended in 50 µl 4x SDS sample buffer 
(150 mM Tris-HCl pH 6.8, 1% SDS, 10% β-mercaptoethanol, 20% glycerol, 0.5% 
bromophenol blue). The culture was induced with 0.1 mM final concentration IPTG and 
grown for 2 hours at 37°C in an orbital shaker. An induced sample of 1 ml was taken, 
pelleted by centrifugation at 13,000xg for 1 minute, and resuspended in 4x SDS sample 
buffer. The large culture was harvested by centrifugation at 4,500 rpm for 20 minutes at 
4°C. The pellet was snap frozen on dry ice and stored at -80°C. The induced and 
uninduced samples were resolved by SDS-PAGE (polyacrylamide gel electrophoresis), 
and the gel was stained with SimplyBlue™ SafeStain (Invitrogen), to confirm the 
induction of the proteins. The cells were resuspended in 20 ml 1x TBS (2.5 mM Tris-
HCl pH 7.6, 15 mM NaCl), and sonicated 10x for 30 seconds on ice using the vibra cell 
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sonicator (Sonics). The crude lysate was then centrifuged at 8,500xg for 20 minutes at 
4°C. The clarified extract was aliquoted and snap frozen on dry ice. 
 
2.6 In vitro transcription and translation of proteins in 
reticulocyte lysate     
 
For in vitro transcription and translation of proteins the TNT reticulocyte kit 
(Promega) was used, according to the manufacturer’s instructions. The synthesised 
proteins were labelled with 35S-methionine and 1-2 µl of the samples were analysed by 
SDS-PAGE. The gels were incubated with fixing solution [10% (v/v) acetic acid, 30% 
(v/v) methanol] for 30 minutes at room temperature and washed with distilled H2O for 
15 minutes. The gels were incubated with autofluor (National Diagnostics) for 2 hours at 
room temperature on an orbital shaker. The gels were vacuum dried for 2 hours at 80°C 
and the radiolabelled proteins visualised by autoradiography. 
 
2.7 GST pull down assay 
 
GST and GST-fusion proteins were coupled to glutathione-agarose beads 
(Sigma). GST and GST-fusion proteins containing clarified extracts were incubated with 
20 µl of packed glutathione agarose beads for 2 hours at 4°C. Following this, 1-2 µl of 
the in vitro translated protein was incubated with 20 µl packed pre-washed glutathione 
agarose beads in a total volume of 600 µl made up with 1x TBS, to pre-clear the in vitro 
translated protein. The recombinant GST-fusion proteins bound to the beads were 
washed five times to remove non-specific binding of bacterial proteins and 250 µl of 
pre-cleared reticulocyte lysate were added to these beads. The samples were incubated 
for 2 hours rotating at 4°C. The beads were washed five times with 1 ml of 1x TBS to 
remove non-specific binding to the recombinant proteins and 4x protein sample buffer 
was added to the beads. The samples were resolved by SDS-PAGE and the proteins 
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detected by SimplyBlue™ SafeStain (Invitrogen) in order to confirm equal loading. The 
rpn800e full-range rainbow molecular weight marker (GE Healthcare) was run next to 
the samples. Samples were destained (30% methanol, 10% acetic acid). The gels were 
incubated with fixing solution [10% (v/v) acetic acid, 30% (v/v) methanol] for 30 
minutes at room temperature and washed with distilled H2O for 15 minutes. The gels 
were incubated with autofluor (National Diagnostics) for 2 hours on an orbital shaker, to 
enhance the radio-labelled signal, vacuum dried and exposed to autoradiographic film 
overnight at -80°C. Pull-down assays using HeLa nuclear extracts were also carried out. 
1-2 µl of in vitro transcribed and translated protein were added to the beads as well as 
200 µg of HeLa nuclear extracts in a total volume of 500 µl in 1x TBS. The incubation 
took place for 2 hours rotating at 4°C. The beads were washed five times with 1x TBS 
and mixed with an appropriate volume of protein sample buffer. The samples were 
analysed by western blotting. 
  
2.8 Preparation of protein extracts for western blots and 
co-immunoprecipitations (co-IPs) 
 
Whole cell protein extracts were prepared from cells cultured in 10 cm dishes or 
6-well plates, when cells reached a confluency of approximately 80%. The procedure 
was performed on ice rapidly and all solutions and plasticwear were kept cold to 
maintain cell activity and avoid protein degradation. The maintenance medium was 
aspirated and the culture cells were washed three times with ice-cold PBS. The cells 
were scraped with a plastic spatula into cell lysis buffer (20 mM HEPES pH 7.8, 150 
mM NaCl, 25% glycerol, 50 mM NaF, 0.2 mM EDTA, 0.5% Triton X-100, 0.5% NP-
40, 10 mM β-glycerophosphate, 1 mM sodium orthovanadate, 1 mM 
phenylmethylsulfonyl fluoride (PMSF), 1 mM DTT, 0.5 µg/ml leupeptin, 1.0 µg/ml 
trypsin inhibitor, 0.5 µg/ml aprotinin and 40 µg/ml bestatin) and transferred to 
microfuge tubes. 150 µl of buffer was used for each well of the 6-well plates and 500 µl 
of buffer for each 10 cm dish. The lysates were passed three times through a 26G needle 
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and centrifuged at 13,000xg for 10 minutes at 4°C. The supernatants were aliquoted and 
snap frozen on dry ice. The whole cell extracts were stored at -80°C.  
 
2.9 Determination of protein concentrations 
 
The protein concentration of samples was determined using Bradford’s reagent 
(BioRad) diluted 1 in 5 with distilled H2O. The colour reaction produced by the mixing 
of the reagent with protein was quantified by the absorbance at 595 nm using a 
spectrophotometer. The values measured were indicative of the amount of protein in 
each sample. The standard curve for each experiment was constructed by measuring the 
absorbance at 595 nm of 1, 2, 3, 4, 5, 6, 8, 10, 12 and 14 µg of BSA in 1 ml of 
Bradford’s reagent. For each sample, absorbance readings were performed in triplicate 
and compared to the standard curve to determine the protein concentration. 
 
2.10 Adenovirus titre immunoassay analysis 
 
To calculate the viral titre, the QuickTitretm Adenovirus Titre Immunoassay kit 
(Cell Biolabs) was used. HEK 293 cells were harvested and resuspended in DMEM 
culture medium at 2.5x 105 cells/ml. In each well of a 24-well plate 1 ml of the 
resuspended cells were incubated at 37°C, 5% CO2 for 1 hour. Following that, a 10-fold 
serial dilution of the viral sample in medium was performed. The infected cells were 
incubated at 37°C for 2 days. After two days, the culture medium was aspirated and the 
infected cells were fixed to the plates by the addition of 0.5 ml ice-cold methanol. The 
cells were incubated for 20 minutes at -20°C and washed three times with 1x PBS, each 
wash for 5 minutes. The cells were blocked with 1% BSA in PBS for 1 hour at room 
temperature. 250 µl of 1x anti-Hexon antibody were added to each well and the cells 
were incubated for 1 hour at room temperature. The cells were washed with 1x PBS 
three times, each wash for 5 minutes. 250 µl of 1x secondary antibody were added to 
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each well and the cells were incubated for 1 hour at room temperature. The cells were 
washed five times with 1x PBS, each wash for 5 minutes. Freshly made 1x DAB 
substrate solution was added to each well, and the cells were incubated for 10 minutes at 
room temperature on an orbital shaker. Infected cells appeared dark brown. To calculate 
the positive cells (dark brown colour) five separate fields were selected using a light 
microscope. The number of positive cells and the viral titre, in infectious units/ml, were 
calculated. 
 
2.11 Separation of proteins by SDS-polyacrylamide gel 
electrophoresis   
 
50 µg of protein extracts were resolved by denaturing SDS 7.8% or 12% 
polyacrylamide (National Diagnostics) minigels (375 mM Tris pH 8.8, 0.1% SDS), with 
4% polyacrylamide stacking gels (125 mM Tris pH 6.8, 0.1% SDS) according to 
molecular weight by electrophoresis. Prior to loading, samples were boiled for 3 minutes 
in 1x protein sample buffer (62.5 mM Tris pH 6.8, 0.5% β-mercaptoethanol, 10% 
glycerol, 0.125% bromophenol blue). Electrophoresis was performed in 1x SDS running 
buffer (0.1% SDS, 76.8 mM glycine, 10 mM Tris, pH 8.3), at an initial voltage of 75 V 
while the dye moved through the stacking gel; the voltage was then increased to 160 V 
until the bromophenol blue dye moved to the bottom of the gel. 
 
2.12 Western blot analysis 
 
Following SDS-PAGE separation, proteins were transferred to a nitrocellulose 
membrane (BioRad) using the BioRad Mini Trans-Blot Electrophoretic Transfer Cell 
System. Transfer was carried out in 1x transfer buffer (76.8 mM glycine, 10 mM Tris 
pH 8.3, 20% methanol) at 100 V for 1 hour or overnight at 4°C. Nitrocellulose 
membranes were stained with Ponceau S (Sigma) to ensure transfer of the proteins to the 
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membrane. Membranes were washed with 1x TBS for 10 minutes and blocked in milk 
buffer (32.5 mM Tris, 150 mM NaCl, 0.2% Tween-20, 4% skimmed milk powder 
(Marvel) for 30 minutes at room temperature. Membranes were incubated with primary 
antibodies for 3 hours at room temperature or overnight at 4°C (see table 2.2 for the 
antibody dilutions used). Excess primary antibody was washed three times for 5 minutes 
in PBS containing 0.5% Tween-20. Following the washes, membranes were incubated 
for 1 hour at room temperature in the presence of the appropriate horseradish 
peroxidase-conjugated secondary antibody (1:1000 dilution in milk buffer) (Dako). 
Membranes were washed three times with western wash buffer (32.5 mM Tris, 150 mM 
NaCl, 0.2% Tween-20) for 5 minutes, followed by two washes for 15 minutes. 
Membranes were washed for 5 minutes with 1x TBS (2.5 mM Tris-HCl pH 7.6, 15 mM 
NaCl) and antibodies were detected using the enhanced chemiluminescence method 
(ECL, Amersham), following the manufacturer’s instructions.  
 
2.13 Co-immunoprecipitation 
 
Antibodies for immunoprecipitation experiments were bound to either protein-A 
sepharose or protein-G sepharose beads (Sigma). For each immunoprecipitation, 25 µl 
of packed protein beads were used. The beads were washed five times using 1 ml for 
each wash of low salt microextraction buffer (LS-MEB) (150 mM NaCl, 50 mM NaF, 
20 mM HEPES pH 7.8, 25% glycerol, 1 mM DTT, 0.5 mM (PMSF), 0.2 mM EDTA, 40 
µg/ml bestatin, 1 µg/ml trypsin inhibitor, 0.7 µg/ml pepstatin, 0.5 µg/ml aprotinin, 0.5 
µg/ml leupeptin) prior to incubation with 5 µl of anti-ID1, anti-ID2, anti-ID3, anti-E47 
and anti-Brf1 (128); the final volume was made up to 50 µl with LS-MEB and the 
antibodies were incubated with the beads by rotating for 2 hours at 4°C. Following 
binding, the beads were washed five times with LS-MEB to remove excess antibody. 
300 µg of HeLa protein extracts (Computer Cell Culture, Mons, Belgium) were added to 
the beads and left to incubate for 1 hour at 4°C. The beads were washed five times with 
LS-MEB and 50 µl of 4x protein sample buffer were added. Samples were heated at 
95°C for 3 minutes and analysed by SDS-PAGE and western blotting. 
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Table 2.2: Antibodies used for western blots 
 
 
2.14 RNA extraction 
 
Total cellular RNA was extracted from cells grown in 10 cm culture dishes using 
TRI reagent (Sigma). The maintenance medium was aspirated and the cells were washed 
four times with ice-cold PBS. The cells were scraped into 1 ml or 500 µl of TRI reagent, 
for 10 cm dishes or per well of 6-well plates respectively, and transferred into microfuge 
tubes. The samples were incubated for 10 minutes at room temperature in order to 
achieve dissociation of nucleoprotein complexes prior to the addition of 200 µl of 
chloroform to each sample. The samples were mixed by vortexing for 1 minute, 
incubated for 10 minutes at room temperature and centrifuged at 13,000xg for 15 
Protein Antibody Dilution Type Company 
ID1 C-20 1:1000 Polyclonal Santa Cruz 
ID2 C-20 1:1000 Polyclonal Santa Cruz 
ID3 C-20 1:1000 Polyclonal Santa Cruz 
E47 N-649 1:1000 Polyclonal Santa Cruz 
TFIIB C18 1:1000 Polyclonal Santa Cruz 
Actin C-11 1:5000 Polyclonal Santa Cruz 
Brf1 128 1:1000 Serum In House 
Brf1 330 1:1000 Serum In House 
TBP MTBP-6 1:250 Monoclonal In House 
HA F-7 1:1000 Monoclonal Santa Cruz 
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minutes at 4°C. Samples separated into three phases: a lower red organic phase 
containing the protein, a white intermediate phase containing the DNA and an upper 
colourless aqueous phase containing the RNA. The RNA-containing phase was carefully 
transferred into a clean microfuge tube and 0.5 ml of isopropanol was added to the 
samples to precipitate the RNA. The tubes were mixed by inverting, incubated at room 
temperature and centrifuged at 13,000xg for 10 minutes at 4°C. The RNA pellet was 
washed with 1 ml of 75% ethanol and centrifuged at 13,000xg for 5 minutes at 4°C. The 
supernatant was aspirated and the pellets were air dried for 20 minutes at room 
temperature. The RNA was resuspended in 20 µl of RNase-free water and the samples 
were heated at 50°C to facilitate resuspension. RNA concentration was determined by 
spectrophotometry at 260 nm, using the following equation: 1 OD unit at 260 nm  =  40 
µg/ml of RNA. The samples were stored at -80°C. 
 
2.15 cDNA preparation 
 
2 µg of RNA were added to 200 ng of hexanucleotide primers (Roche) and made 
up with RNase-free water to a final volume of 20 µl. Samples were incubated at 80°C 
for 10 minutes for primer annealing. The tubes were transferred on ice and 8 µl of 5x 
First Strand Buffer (Invitrogen), 4 µl of 0.1 M DTT (Invitrogen), 2 µl of 10 mM dNTP 
mix (Promega) and 1 µl (200 U) of Superscript II Reverse Transcriptase (Invitrogen) 
were added to initiate transcription. The reverse transcription reaction was placed for 50 
minutes at 42°C. The reaction was terminated by heating the samples for 15 minutes at 
70°C to inactivate the enzyme. The cDNA samples were stored at -20°C.  
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2.16 Reverse-Transcriptase Polymerase Chain Reaction 
(RT-PCR) 
 
The PCR reactions were performed using the DNA Engine Dyad Peltier Thermal 
Cycler (BioRad). Each PCR reaction had a final volume of 20 µl and contained 2 µl of 
cDNA with 20 pmol of primers. The reaction contained 0.5 U Taq DNA polymerase 
(Promega), 1x Taq DNA polymerase buffer (Promega) containing 1.5 mM MgCl2, 0.2 
mM of each dNTP plus 1.8 µCi of [α32P] dCTP (Amersham). Primer cycling parameters 
and sequences are listed in table 2.3. The PCR products were diluted 1:1 with 
formamide loading buffer (98% formamide, 10 mM EDTA pH 8.0, 0.025% 
bromophenol blue, 0.025% xylene cyanol FF) and resolved on 7% polyacrylamide 
(National Diagnostics) sequencing gels containing 7 M urea and 1x TBE (45 mM Tris, 
45 mM boric acid, 0.625 mM EDTA pH 8.0). Gels were pre-run at 40 W for 30 minutes 
in 1x TBE and 2 µl of sample was loaded after being heated at 95°C for 2 minutes and 
quenched on ice. Electrophoresis was performed for 1 hour at 40 W and the gels were 
vacuum-dried at 80°C for 1 hour before being exposed to autoradiography film to detect 
the radiolabelled products. In some cases, PCR products were detected using SYBR 
Gold Nucleic Acid Gel Stain (Invitrogen). In this case, the above final 20 µl PCR 
reaction mixture, the 1.8 µCi of [α32P] dCTP was replaced with distilled H2O. 5 µl of 
Orange G loading dye (Sigma) were added to each 20 µl PCR product sample and 
mixed. The samples were resolved on 5% polyacrylamide (National Diagnostics) gels. 6 
µl of sample was loaded for 30 minutes and electrophoresis was performed in 1x TBE at 
150 V. The gels were stained with 1x SYBR Gold Stain for 30 minutes, protecting the 
stain solution from light by placing it in the dark. The gels were visualised under UV 
light. 
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Table 2.3: Primers and cycling parameters for RT-PCR 
Transcript Primers 5’-3’ 
Forward 
Reverse 
Cycle 
number 
Product 
length 
PCR conditions 
(denaturing; 
cycling;  final 
elongation) 
ARPP P0 5’ GCACTGGAAGTCCAACTACTTC 3’ 
5’ TGAGGTCCTCCTTGGTGAACAC 3’  
18-20 266 bp 95°C for 2 min; 
95°C for 1 min, 
58°C for 30 s, 
72°C for 1 min; 
72°C for 5 min 
ID1 5’ CGCATCTTGTGTCGCTGAAG 3’ 
5’ GGTGACTAGTAGGTGTGCAG 3’ 
27-29 228 bp 95°C for 2 min; 
95°C for 1 min, 
53°C for 30 s, 
72°C for 1 min; 
72°C for 5 min 
ID2 5’ ATGAAAGCCTTCAGTCCCGT 3’ 
5’ TTCCATCTTGCTCACCTTCTT 3’ 
25-27 189 bp 95°C for 2 min; 
95°C for 1 min, 
58°C for 30 s, 
72°C for 1 min; 
72°C for 5 min 
ID3 5’ TCAGCGCTTCCTCATTCTTT 3’ 
5’ AAGGCACGCCTCTTTATTCA 3’ 
28-30 154 bp 95°C for 2 min; 
95°C for 1 min, 
59°C for 30 s, 
72°C for 1 min; 
72°C for 5 min 
E2A 5’ TGTGCCAACTGCACCTCAA 3’ 
5’ GGGATTCAGGTTCCGCTCTC 3’ 
22-24 116 bp 95°C for 2 min; 
95°C for 1 min, 
62°C for 30 s, 
72°C for 1 min; 
72°C for 5 min 
5S rRNA 5’ GGCCATACCACCCTGAACGC 3’ 
5’ CAGCACCCGGTATTCCCAGG 3’ 
18-20 107 bp 95°C for 3 min; 
95°C for 30 s, 
58°C for 30 s, 
72°C for 1 min; 
72°C for 5 min 
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tRNA Leu 5’ GAGGACAACGGGGACAGTAA 3’ 
5’ TCCACCAGAAAAACTCCAGC 3’ 
25-27 88 bp 95°C for 3 min; 
95°C for 30 s, 
68°C for 30 s, 
72°C for 30 s; 
72°C for 5 min 
tRNA Tyr 5’ AGGACTTGGCTTCCTCCATT 3’ 
5’ GACCTAAGGATGTCCGCAAA 3’ 
25-27 84 bp 95°C for 3 min; 
95°C for 1 min, 
65°C for 30 s, 
72°C for 15 s; 
72°C for 1 min 
tRNA Arg 5’ GGCTCTGTGGCGCAATGGATA 3’ 
5’ TTCGAACCCACAACCTTTGAATT 3’ 
25-30 74 bp 95°C for 2 min; 
95°C for 30 s, 
66°C for 30 s, 
72°C for 15 s; 
72°C for 5 min 
tRNA Sec 5’ GGATGATCCTCAGTGGTC  3’ 
5’ GGTGGAATTGAACCACTC 3’ 
25-27 74 bp 95°C for 3 min; 
95°C for 30 s, 
54°C for 30 s, 
72°C for 30 s; 
72°C for 5 min 
7SL 5’ GTGCCGCACTAAGTTCGGCATC 3’ 
5’ 
TATTCACAGGCGCGATCCCACTACTGAGATC 
3’ 
10-20 150 bp 95°C for 2 min; 
95°C for 20 s, 
62°C for 30 s, 
72°C for 30 s; 
72°C for 10 min 
7SK 5’ CGATCTGGCTGCGACATCTG 3’ 
5’ CGTTCTCCTACAAATGGAC 3’ 
14-16 248 bp 95°C for 3 min; 
95°C for 30 s, 
57°C for 30 s, 
72°C for 30 s; 
72°C for 10 min 
MRP 5’ CGTGCTGAAGGCCTGTATC 3’ 
5’ GGTGCGCGGACACGCAC 3’ 
25-30 232 bp 95°C for 3 min; 
95°C for 30 s, 
58°C for 30 s, 
72°C for 30 s; 
72°C for 5 min 
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U6 snRNA 5’ GCTCGCTTCGGCAGCACATATAC 3’ 
5’ TATCGAACGCTTCACGAATTTGCG 3’ 
18-20 96 bp 95°C for 3 min; 
95°C for 1 min, 
60°C for 30 s, 
72°C for 1 min; 
72°C for 5 min 
Pre-rRNA 5’ GCTTGGGTCTGTCGCGGT 3’ 
5’ CACCTCGGGGAAATCGGGA 3’ 
23-25 151 bp 95°C for 3 min; 
95°C for 1 min, 
65°C for 30 s, 
72°C for 15 s; 
72°C for 1 min 
 
 
 
 
2.17 RNA Pol III in vitro transcription assay 
 
In vitro transcription of class III genes was reconstituted using 15 µg of HeLa 
nuclear extracts (Computer Cell Culture, Mons, Belgium) to provide the basal pol III 
transcription components. This was supplemented with the addition of 250 ng of plasmid 
DNA to supply a specific pol III template and reactions were carried out in a 25 µl 
volume with a final concentration of 12 mM HEPES pH 7.9, 60 mM KCl, 7.2 mM 
MgCl2, 0.28 mM EDTA, 1.2 mM DTT, 10% (v/v) glycerol, 1 mM creatine phosphate, 
0.5 mM each of rATP, rCTP and rGTP and 10 µCi [α32P] UTP (400 mCi/mmol) 
(Amersham). The transcription components were assembled on ice, and the reaction was 
performed in a waterbath at 30°C for 1 hour. Transcription was terminated with the 
addition of 250 µl of 1 M ammonium acetate/0.1% SDS containing 20 µg of yeast 
tRNA, which acts as a stabiliser for synthesised RNA. In order to remove protein and 
DNA, phenol-chloroform extraction of the samples was performed by addition of 250 µl 
of a 25:24:1 ratio of PhOH/CHCl3/IAA. The samples were vortexed, microcentrifuged at 
13,000xg for 5 minutes and 200 µl of the upper aqueous layer was transferred to a new 
microfuge tube containing 750 µl of 96% ethanol, and samples were mixed thoroughly. 
To precipitate the RNA, the samples were inverted several times and placed at -20°C 
overnight before being centrifuged at 13,000xg for 30 minutes to pellet the precipitated 
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RNA. The supernatant was removed and the pellet was washed with 750 µl of 70% 
ethanol. The samples were centrifuged and the pellets were dried by heating at 50°C for 
5-10 minutes. 4 µl of formamide loading buffer (98% formamide, 10 mM EDTA pH 8.0, 
0.025% bromophenol blue, 0.025% xylene cyanol FF) were added to each sample, 
which was vortexed for 1 hour to ensure the RNA was fully redissolved. From each 
sample, 1.5 µl was loaded on a pre-run 7% polyacrylamide sequencing gel consisting of 
7 M urea and 1x TBE (45 mM Tris, 45 mM boric acid, 0.625 mM EDTA pH 8.0) after 
being heated at 95°C for 2 minutes and quenched on ice. Electrophoresis was carried out 
at 40 W for 1 hour in 1x TBE, and gels were vacuum-dried and exposed to 
autoradiography film to detect the radiolabelled transcripts. 
 
2.18 Small interfering RNA (siRNA) 
 
2.18.1 siRNA targeting 
 
Commercially available siRNAs (Santa Cruz Biotechnology), which had been 
validated, were acquired for the knockdown of Oct-1, ID1, ID2, ID3 and E2A. siRNAs 
targeting Oct-1 (Oct-1 siRNA (h): sc-36119, Santa Cruz Biotechnology), ID1 (ID1 
siRNA (h): sc-29356, Santa Cruz Biotechnology), ID2 (ID2 siRNA (h): sc-38000, Santa 
Cruz Biotechnology), ID3 (ID3 siRNA (h): sc-38002, Santa Cruz Biotechnology) and 
E2A (E2A siRNA (h): sc-35245, Santa Cruz Biotechnology) were used to reduce the 
expression of their targets. 
 
 
 
 
2.18.2 Transient transfections using Lipofectatime 2000 
 
Lipofectamine 2000 (Invitrogen) was used to perform transfections according to 
the manufacturer’s instructions. 10 µl siRNA were used per reaction and added to 
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Optimem (Gibco) medium to a final volume of 100 µl. 2.5 µl Lipofectamine 2000 were 
added to 97.5 µl Optimem. The mixtures were incubated for 10 minutes at room 
temperature, combined and incubated at room temperature for 25 minutes. In the 
meantime, cells that that had reached about 70-80% confluency on 6-well plates were 
washed twice with Optimem and 800 µl of Optimem were added to each well. To each 
well, 200 µl siRNA/Lipofectamine 2000 mixture were added. The 1 ml final volume 
was left in each well for 6 hours, and then replaced with 2.5 ml of DMEM culture 
medium. Fresh medium was added after 24 hours and the cells were harvested 48 hours 
after transfection, unless stated otherwise.  
 
2.19 Chromatin immunoprecipitation assay 
 
Cells were grown in 10 cm tissue culture dishes until reaching a confluency of 
about 80%. One 10 cm dish was used per immunoprecipitation. Formaldehyde was 
added to the culture medium to a final concentration of 1% in order to cross-link the 
DNA-protein complexes. The reaction was allowed to proceed for 10 minutes at 37°C. 
To stop the crosslinking, glycine was added at a final concentration of 0.125 M and the 
dishes were transferred to ice for harvesting. The cells were harvested in the plating 
media/formaldehyde/glycine mix and pelleted by centrifugation at 500xg for 5 minutes 
at 4°C. The cell pellets were resuspended/washed in ice-cold PBS and centrifuged at 
500xg for 5 minutes at 4°C. The last step was repeated twice. At this stage the cell 
pellets could be frozen on dry ice and stored at -80°C. 
Cell pellets were resuspended/washed with ice-cold PBS/0.5% NP-40 and 
centrifuged at 500xg for 5 minutes at 4°C. The supernatant was removed and cells were 
resuspended in 40 ml of high salt buffer (0.5% NP-40, PBS, 1 M NaCl), and incubated 
on ice for 30 minutes. After the incubation period, the cells were pelleted by 
centrifugation at 1,500 rpm for 5 minutes at 4°C and washed with 40 ml PBS/1% NP-40. 
The cells were resuspended in 40 ml low salt buffer (0.5% NP-40, 10 mM Tris HCl, pH 
8.0, 1 mM EDTA, 0.1 M NaCl) and placed on ice for 30 minutes. Following the 
incubation, the cells were centrifuged at 500xg for 5 minutes at 4°C. The cells were 
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resuspended in 1 ml of low salt buffer and passed through a 26G needle four times. The 
suspension was made up to a final volume of 2.7 ml by the addition of low salt buffer. 
300 µl of 20% sarcosyl were added to the suspension in order to lyse the nuclei. The 
suspension was transferred to a sucrose cushion and centrifuged at 4,000xg for 10 
minutes at 4°C. The supernatant was removed and the pellet resuspended in 3 ml TE. A 
second cushion was used and the suspension was centrifuged again at 4,000xg for 10 
minutes at 4°C. The resulting pellet containing the genomic DNA and cross-linked 
proteins was further resuspended in 2 ml TE (10 mM Tris pH 8.0, 1 mM EDTA), and 
the DNA was sheared into smaller fragments by sonication (10x 30 seconds, duty cycle 
30%). 0.2 ml of 11x NET Buffer (1.56 M NaCl, 5.5 mM EDTA, 5.5% NP-40, 550 mM 
Tris-HCl, pH 7.4) were added to the 2 ml sonicated sample, which was centrifuged at 
13,000xg for 5 minutes. The supernatant was aliquoted evenly in microfuge tubes, and 
10% of the aliquoted sample was used as input control. The amount of antibody added 
per aliquot (Table 2.5) was 25 µl for the in house made antibodies or 5 µg for the 
commercial antibodies. The microfuge tubes were rotated overnight at 4°C. 
The following day, 50 µl of protein A or G sepharose beads (Sigma) (beads were 
washed five times with 1x NET buffer) were added to each tube and incubated rotating 
for 2 hours at 4°C. The beads were recovered on polypropylene columns (Pierce), 
washed twice with 10 ml ice-cold RIPA (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% 
SDS, 0.5% deoxycholate, 1% NP-40) buffer, twice with ice-cold 10 ml LiCl buffer (10 
mM Tris-HCl, 250 mM LiCl, 0.5% NP-40, 0.5% deoxycholate, 1 mM EDTA, pH 8.0) 
and twice with ice-cold TE. The beads were incubated with 400 µl TE/1% SDS at room 
temperature and the protein-DNA complexes were eluted into microfuge tubes. 
Proteinase K (0.125 mg/ml) was added to the eluted sample in order to degrade the 
antibodies and proteins. The eluted material was incubated overnight at 42°C.  
The DNA was extracted twice using 400 µl phenol/chloroform/isoamylalcohol 
(25:24:1) and once with 400 µl of chloroform. To precipitate DNA, 1 ml ethanol and 40 
µl of 3 M sodium acetate were added and the tubes were mixed by inversion and left at -
20°C overnight. The following day, the samples were centrifuged at 13,000xg for 20 
minutes to pellet the precipitated DNA. The supernatant was removed and the pellets 
were washed with 1 ml of 75% ethanol. The samples were centrifuged again at 13,000xg 
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for 5 minutes and air dried before adding 40 µl of TE to resuspend the DNA. Samples 
were kept at 4°C and analysed by PCR. The primer sequences and antibodies for ChIP 
assays are displayed in table 2.4 and table 2.5 respectively. 
 
 
Table 2.4: Primers and cycling parameters for ChIP assays 
Transcript Primers 5’-3’ 
Forward 
Reverse 
Cycle 
number 
Product 
length 
PCR conditions 
(denaturing; 
cycling; final 
elongation) 
7SL set 1 5’ CCGTGGCCTCCTCTACTTG 3’ 
5’ TTTACCTCGTTGCACTGCTG 3’ 
26-28 171 bp 95°C for 2 min; 
95°C for 1 min, 
58°C for 30 s, 
72°C for 1 min; 
72°C for 3 min  
7SL set 2 5’ CGTCACCATACCACAGCTTC 3’ 
5’ CGGGAGGTCACCATATTGAT 3’ 
26-28 194 bp 95°C for 2 min; 
95°C for 1 min, 
58°C for 30 s, 
72°C for 1 min; 
72°C for 3 min 
7SL set 3 5’ GTTGCCTAAGGAGGGGTGA 3’ 
5’ TCTCTTGAGAGTCCAAAATTAA 3’ 
26-28 174 bp 95°C for 2 min; 
95°C for 1 min, 
58°C for 30 s, 
72°C for 1 min; 
72°C for 3 min 
7SL set 4 5’ TTTTTGACACACTCCTCCAAGA 3’ 
5’ ATCTGGTCAAAGCAACATACACTG 3’ 
26-28 150 bp 95°C for 2 min; 
95°C for 1 min, 
58°C for 30 s, 
72°C for 1 min; 
72°C for 3 min 
7SL set 5 5’ TGCCTCCAGATAAAACTGCTC 3’ 
5’ ACCCCACTAGAACCCTGACA 3’ 
26-28 156 bp 95°C for 2 min; 
95°C for 1 min, 
58°C for 30 s, 
72°C for 1 min; 
72°C for 3 min 
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ARPP P0   5’ GCACTGGAAGTCCAACTACTTC 3’ 
5’ TGAGGTCCTCCTTGGTGAACAC 3’ 
18-20 266 bp 95°C for 2 min; 
95°C for 1 min, 
58°C for 30 s, 
72°C for 1 min; 
72°C for 5 min 
5S rRNA 5’ GGCCATACCACCCTGAACGC 3’ 
5’ CAGCACCCGGTATTCCCAGG 3’ 
18-20 107 bp 95°C for 3 min; 
95°C for 30 s, 
58°C for 30 s, 
72°C for 1 min; 
72°C for 5 min 
7SL 5’ GTGCCGCACTAAGTTCGGCATC 3’ 
5’ 
TATTCACAGGCGCGATCCCACTACTGAGATC 
3’ 
10-20 150 bp 95°C for 2 min; 
95°C for 20 s, 
62°C for 30 s, 
72°C for 30 s; 
72°C for 10 min 
tRNA Leu 5’ GAGGACAACGGGGACAGTAA 3’  
5’ TCCACCAGAAAAACTCCAGC 3’ 
25-27 88 bp 95°C for 3 min; 
95°C for 30 s, 
68°C for 30 s, 
72°C for 30 s; 
72°C for 5 min 
tRNA Tyr 5’ AGGACTTGGCTTCCTCCATT 3’ 
5’ GACCTAAGGATGTCCGCAAA 3’ 
25-27 84 bp 95°C for 3 min; 
95°C for 1 min, 
65°C for 30 s, 
72°C for 15 s; 
72°C for 1 min 
tRNA Arg 5’ GGCTCTGTGGCGCAATGGATA 3’ 
5’ TTCGAACCCACAACCTTTGAATT 3’ 
25-30 74 bp 95°C for 2 min; 
95°C for 30 s, 
66°C for 30 s, 
72°C for 15 s; 
72°C for 5 min 
U6 snRNA 5’ GTTTCGTCCTTTCCACAAG 3’ 
5’ TTCTTGGGTAGTTTGCAG 3’ 
18-20 116 bp 95°C for 3 min; 
95°C for 30 s, 
55°C for 30 s, 
72°C for 1 min; 
72°C for 5 min 
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Table 2.5: Antibodies for ChIP assays 
Protein Antibody Type Company 
TBP MTBP-6 Monoclonal In House 
RPC 155 1900 Serum In House 
Brf1 128 Serum In House 
TFIIIC 220 Ab7 Serum In House 
TFIIA FL-109 Polyclonal Santa Cruz 
TFIIB C18 Polyclonal Santa Cruz 
TAFI48 M19 Polyclonal Santa Cruz 
ID1 C-20 Polyclonal Santa Cruz 
ID2 C-20 Polyclonal Santa Cruz 
ID3 C-20 Polyclonal Santa Cruz 
E47 N-649 Polyclonal Santa Cruz 
 
 
 
 
 
 
 
 
 87 
 
                  
                  Chapter 3 
 
 
 
 
 
Activation of RNA 
Polymerase III 
Transcription by ID1, ID2 
and ID3 
 
 
Chapter 3 Acivation of RNA Polymerase III Transcription by ID1, ID2 and ID3  
88 
 
3.1 Introduction 
 
3.1.1 The role of ID proteins in tumourigenesis  
 
 High expression levels of ID protein family members are associated with several 
types of human tumours. In particular, overexpression of ID proteins is linked with 
disease severity and poor prognosis. ID proteins contribute to tumourigenesis by 
inhibiting differentiation, promoting proliferation and affecting invasiveness (Lasorella 
et al., 2001; Perk et al., 2005; Fong et al., 2003). ID protein deregulation in addition to 
affecting the proliferation of tumour cells is also implicated in tumour progression (Fong 
et al., 2004; Perk et al., 2005). Some of these features are the potential of tumour cells to 
metastasise and become involved in the formation of new blood vessels (Minn et al., 
2005).  
Elevated protein levels of ID1 correlate with poor prognostic outcome in breast 
cancer patients and when ID1 was ectopically expressed in breast cancer cells this led to 
invasiveness of the basement membrane (Schoppmann et al., 2003; Desprez et al., 
1998). In addition, expression of ID1 in prostate tumours increases with tumour grade 
(Ouyang et al., 2002a). Also, high levels of ID1 expression correlate with poor 
histological grade in ovarian tumours and aggressive clinical behavior (Schindl et al., 
2001). ID2 has been identified as a prognostic variable in neuroblastoma patients, where 
high ID2 expression is associated with a poor outcome (Lasorella et al., 2002). High 
levels of ID2 correlate with Ewings sarcoma EWS-ETS fusion protein in fibrosarcoma 
cells (Fukuma et al., 2003). Studies have also revealed that ID3 is linked to human 
tumourigenesis. ID3 has been demonstrated to be overexpressed in human ovarian 
cancer cells and in small cell lung cancer (Shepherd et al., 2008; Kamalian et al., 2008). 
When ID proteins are ectopically expressed, this leads to inhibition of differentiation in 
a number of cell types, such as muscle and erythroleukaemia cells (Jen et al., 1992; 
Shoji et al., 1994). Overexpression of ID1 in SCp2 epithelial cells causes increased 
proliferation and when ID1 is targeted using antisense oligonucleotides, this reduces cell 
proliferation and inhibits invasiveness (Fong et al., 2003). ID proteins are also thought 
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to be involved in a process known as oncogenic mimicry, where overexpression of ID 
proteins can regulate the activity of a target gene. The oncogenic acute myeloid 
leukaemia - eight-twenty-one (AML-ETO) fusion protein is formed due to a 
chromosomal translocation and results in acute myeloid leukaemia. It has been shown 
that AML-ETO binds to E-proteins and inhibits their function (Zhang et al., 2004). It is 
therefore possible that ID proteins mimic the AML-ETO function and this promotes 
carcinogenesis.   
 
3.1.2 ID mouse models  
 
ID function is essential in mice for development and mouse models have been 
used to understand the role of IDs in cancer. It has been shown that overexpression or 
loss of function of ID proteins affects cancer progression in mouse models (Yokota et 
al., 1999; Morrow et al., 1999; Lyden et al., 1999; Kim et al., 1999). When ID1 was 
overexpressed in the intestinal epithelium of mice, three of the seventeen mice 
developed intestinal adenomas (Wice & Gordon, 1998). In another study, 
overexpression of ID1 in T cells led to the development of T cell lymphoma, suggesting 
an oncogenic role for the ID1 protein (Kim et al., 1999). ID1 overexpression arrests T 
cell development, an effect which is more severe than the one observed in E2A and HEB 
knockout mice (Bain et al., 1997). Because ID1 inhibits the function of E-proteins, it is 
possible that it interferes with E-proteins which are expressed in T cells. Overexpression 
of E47 can rescue the T cell deficiency exhibited in ID1 overexpressed mice (Kim et al., 
1999). All combinations of double knockout embryos of ID1, ID2 and ID3 are not viable 
and die before birth (Lyden et al., 1999; Benezra R, unpublished observations cited in 
Ruzinova & Benezra, 2003). The double knockouts of ID1-ID3 in mice display vascular 
malformations and premature withdrawal of neuroblasts from the cell cycle and 
inappropriate expression of neural markers (Lyden et al., 1999). In ID1+/- ID3-/- mice, 
the endothelial vasculature of tumour xenographs was affected, which led to failure in 
tumour growth and metastasis (Lyden et al., 1999). Crosses of ID1- and ID3- mice 
lacking 1-3 copies of the four ID1 and ID3 alleles were carried out with phosphatase and 
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tensin homologue (PTEN)+/- tumour-prone strains, which develop lymph node 
hyperplasia, uterine carcinomas and prostate neoplasias (Ruzinova et al., 2003). 
However, the partial loss of IDs had little effect on the tumours of this model.  
Transgenic mice that overexpressed ID2 were generated, with five out of six 
founder lines developing aggressive T cell lymphomas (Morrow et al., 1999). The 
hyperproliferation is similar to the growth of transformed cells, however, the cells are 
not monoclonal, indicating that the expanded T cells in the tumourous ID2 mice arise 
from multiple independent transformation processes. Therefore, overexpressing the ID2 
protein has an important role in T cell development and oncogenesis. Also, studies have 
demonstrated that the ID2 knockout mice display the most severe phenotype compared 
to the other ID proteins. Knocking out ID2 in mice lead to ~25% perinatal mortality and 
the surviving ID2-null mice displayed retarded growth (Yokota et al., 1999). The ID2-
null mice lacked lymph nodes and Peyer’s patches, had fewer natural killer cells, fewer 
Langerhan’s cells and a lactation defect was observed in female mice (Hacker et al., 
2003; Yokota et al., 1999; Kusunoki et al., 2003; Mori et al., 2000).    
 
3.1.3 ID role in Drosophila 
 
 The role of ID proteins has been mostly studied in mouse and humans which 
consist of four members (ID1-ID4) and in Drosophila whose extramachrochaetae (emc) 
gene encodes a transcription factor which is similar to an ID protein (Garrell et al., 1990; 
Ellis et al., 1990). The emc protein contains an HLH domain without the basic region, 
which is involved in interaction with DNA. Emc forms heterodimers with bHLH 
proteins preventing them from binding DNA (Jan & Jan, 1993). Studies have 
demonstrated that emc is required in developmental processes in Drosophila during 
wing morphogenesis (Garrell et al., 1990; Ellis et al., 1990).  
Loss of function (LOF) and gain of function (GOF) mutants have demonstrated 
that the emc protein is a negative regulator of the achaetae-scute bHLH proteins which 
are required in neurogenesis and sex determination (Garrell et al., 1990; Ellis et al., 
1990). Emc null alleles are embryonic lethal. Studies using clones of LOF and GOF 
alleles of emc have revealed that emc is involved in cell proliferation and vein 
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differentiation (García-Alonso & García-Bellido, 1988). Emc appears to interact with 
genes involved in regulating Drosophila wing development. Proteins of the Ras 
signalling pathway (torpedo, vein, veinlet and gap) cooperate with emc during cell 
proliferation and act antagonistically during vein differentiation (Baonza & García-
Bellido, 1999). Baonza and García-Bellido proposed two models in which emc and the 
genes of the Ras signalling pathway interact during cell proliferation and differentiation. 
In the first model, mutants of emc and genes of the Ras pathway have smaller wings, 
due to a smaller number of cells, than normal wings in both cases (of LOF and GOF 
mutants of emc with LOF mutants of the Ras pathway) indicating a possible co-
operation of emc and genes of the Ras signalling pathway in cell proliferation. In the 
second model, the extraveins phenotype of the GOF mutant of the Ras signalling 
pathway is enhanced by interaction with the LOF alleles of emc, and is suppressed with 
the GOF mutants of emc, suggesting that emc and the Ras pathway operate 
antagonistically in vein differentiation.  
Also, a strong genetic interaction between emc and components of the Notch 
signalling pathway has been demonstrated, indicating a possible functional interaction 
between them (Baonza et al., 2000). Notch encodes a transmembrane protein that 
functions as a receptor in several developmental processes during embryonic and adult 
life (Artavanis-Tsakonas et al., 1995). Some of the phenotypes in the wings of 
Drosophila caused by emc are similar to those observed in Notch mutants. The emc 
protein expression levels are higher in areas where Notch is activated. Studies have 
demonstrated that the expression of emc at the dorso/ventral border relies on the activity 
of the Notch signalling pathway (Baonza et al., 2000). In vein differentiation and wing 
formation, emc is thought to be regulated by Notch and cooperates with Notch-
downstream genes. Since the Ras and Notch signalling pathways are crucial in these 
processes, these studies could give insight into how ID proteins function in human 
molecular signalling pathways.         
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3.1.4 Role of ID proteins in the cell cycle 
 
 ID proteins are involved in negatively regulating cell differentiation as well as 
positively affecting the cell cycle. When ID proteins are expressed ectopically in 
mammalian cell lines they can stimulate cell growth (Lister et al., 1995; Desprez et al., 
1995). Also, the use of antisense oligonucleotides and antibody-microinjection methods 
to inhibit ID protein expression and function have revealed a positive regulatory role for 
ID proteins in the G0 to S phase transition in the cell cycle (Hara et al., 1994; Peverali et 
al., 1994). On the other hand, when E47 was overexpressed in mammalian cell lines 
cells were arrested in the G1 phase of the cell cycle (Peverali et al., 1994). ID proteins 
are present at low levels in quiescent cells, although after mitogenic stimulation ID 
expression is increased within 1-2 hours, similarly to other early response genes 
(Norton, 2000). ID protein expression is maintained throughout the G1 phase and is 
upregulated when cells enter the S phase of the cell cycle (Hara et al., 1994; Norton et 
al., 1998).  
ID proteins can affect the cell cycle by interacting with a number of proteins 
such as the RB (Iavarone et al., 1994; Lasorella et al., 1996), E47 (Zheng et al., 2004) 
and ETS proteins (Figure 3.1) (Yates et al., 1999). Studies have shown that the ID2 
protein interacts with the RB protein, and that ID2 can reverse the cell cycle arrest 
caused by the overexpression of the tumour suppressor RB protein and the related 
‘pocket’ proteins p107 and p130 (Iavarone et al., 1994). More information on the 
interaction of ID2 with RB is presented in chapter 4.  
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Figure 3.1: Model for ID function in cell cycle progression. 
ID1, ID2 and ID3 family proteins act by inhibiting the E-proteins and ETS family 
members. ID1 and ID3 indirectly inactivate the RB protein by suppressing the 
expression of cyclin-dependent kinase inhibitors such as INK4a, also known as p16, 
which leads to the phosphorylation of RB. ID2 directly interacts with RB and interferes 
with its cell cycle regulatory functions (adapted from Perk et al., 2005).  
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The ID1, ID2 and ID3 proteins are positive regulators of cell growth and 
negative regulators of differentiation (Ruzinova & Benezra, 2003). Studies have 
suggested that several human tumour types depend, at least in part, on ID expression for 
increased proliferation and other phenotypic features of malignancy (Kleeff et al., 1998; 
Lin et al., 2000). Therefore, it is important to investigate other changes resulting from 
the overexpression of ID proteins. It has been shown that pol III transcripts are present 
in increased levels in ovarian tumours compared to the normal tissues from the same 
individual patients (Winter et al., 2000). Moreover, the overexpression of pol III 
transcripts has been demonstrated in breast, cervical and thyroid cancers with the same 
types of carcinomas observed when ID1, ID2 or ID3 are overexpressed (Chen et al., 
1997a,b; Lasorella et al., 2001). Studies have revealed that oncoproteins such as c-Myc, 
CK2 and ERK are likely to affect cell growth by regulating pol III activity (Gomez-
Roman et al., 2003; Johnston et al., 2002; Felton-Edkins et al., 2003a,b). Pol III-
transcribed genes are essential for cell growth and their expression becomes 
downregulated in differentiating cells (White, 2001; Alzuherri & White, 1998). Given 
that pol III activity and the above ID family members are required in the same processes, 
it would be interesting to investigate whether the expression of ID proteins would have 
an effect on pol III transcription. The following experiments presented in this chapter 
were performed to determine if indeed this is occurring. The results here demonstrate 
that pol III transcription is regulated by the ID1, ID2 and ID3 proteins.  
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3.2 Results 
 
3.2.1 Knockdown of endogenous ID1, ID2 or ID3 by siRNA 
reduced the levels of pol I and pol III transcripts 
 
To investigate the role of ID1, ID2 and ID3 in the regulation of pol III 
transcription in vivo, ID1, ID2 or ID3 were knocked-down using small interfering RNA. 
HeLa cells were transfected with siRNA targeting ID1, ID2 or ID3 and the control Oct-
1. The cells were treated for 72 hours, harvested and protein and RNA extracts were 
analysed. RNA was analysed by RT-PCR in order to confirm the knockdown of ID1, 
ID2 or ID3 RNA levels in comparison to the control (Figure 3.2, A; Figure 3.4, A; 
Figure 3.6, A). Western blotting showed that ID1, ID2 or ID3 proteins levels decreased 
compared to the control (Figure 3.2, B; Figure 3.4, B; Figure 3.6, B). 
To ensure the specificity of ID1, ID2 and ID3 siRNA the expression levels of 
their related proteins was investigated. Western blot analysis revealed that in ID1 
siRNA-transfected HeLa cells the related proteins ID2 and ID3 and the associated E47 
remained at the same levels (Figure 3.2, B). Knockdown of ID2 by siRNA targeting 
HeLa cells established the specificity of ID2 siRNA with the levels of the ID1, ID3 and 
E47 protein expression remaining unaltered (Figure 3.4, B).  Also, it was found that in 
ID3 siRNA-transfected cells the knockdown effect was specific and the expression 
levels of ID1, ID2 and E47 were not affected (Figure 3.6, B). Therefore, specific 
silencing of a particular ID protein did not result in the silencing or overexpression of 
another related ID family member or the associated E47 protein. 
The next step was to investigate if the knockdown of protein and RNA levels of 
the ID family members would have an effect on pol III transcription. RT-PCR analysis 
demonstrated that the knockdown of ID1, ID2 or ID3 resulted in reduced levels of pol 
III-transcribed 5S rRNA, tRNAArg, tRNALeu, 7SL RNA, 7SK RNA, MRP RNA and U6 
snRNA compared to the control siRNA transfection (Figure 3.3; Figure 3.5; Figure 3.7). 
Moreover, the knockdown of ID2 or ID3 decreased the levels of the pol I transcript, 
precursor rRNA (pre-rRNA) (Figure 3.5; Figure 3.7). These effects are specific, since 
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the pol II-transcribed acidic ribosomal phosphoprotein P0 (ARPP P0) mRNA does not 
change due to ID1, ID2 or ID3 knockdown. In conclusion, these results here suggest that 
all three ID family members analysed can have a positive effect on pol III activity in 
vivo, with ID2 or ID3 regulating pol I transcription as well.  
RNA interference is a system for post-transcriptional gene silencing that can be 
applied to the study of gene function. siRNAs target the homologous mRNA transcripts 
for destruction. In the case of sequence identity between the siRNA and random mRNA 
transcripts, RNAi can lead to the suppression of non-targeted genes, a phenomenon 
known as off-target effects. Computational studies have shown that off-target effects 
mediated by RNAi in the Homo sapiens, Schizosaccharomyces and Caenorhabtitis 
elegans genomes range from 5 to 80% in each organism (Qiu et al., 2005). It was also 
demonstrated that the optimal length for siRNAs was 21 nt in order to achieve high 
target efficiency and decreased off-target effects. When the siRNA length increased this 
led to higher chances of non-specific targeting (Qiu et al., 2005). dsRNAs are also 
implicated in the induction of the innate immune response (Sledz et al., 2003). The use 
of siRNAs which are longer than 23 bp can have an effect on cell viability and cause an 
interferon response, demonstrated by an upregulation of the dsRNA receptor TLR3, in a 
cell type-dependent manner (Reynolds et al., 2006). The length threshold for siRNA 
stimulation of the interferon response varies in different cell lines (Reynolds et al., 
2006). The transfection of 21 bp ds siRNA used for gene silencing leads to interferon 
mediated activation of the Jak-Stat signalling pathway and the induction of interferon 
stimulated genes (Sledz et al., 2003). These results are due to the protein kinase PKR, 
since this kinase becomes induced by siRNA and INF-β activation. The stimulation of 
interferon and other signalling pathways demonstrates that siRNAs also have targets 
other than specifically silenced target genes (Sledz et al., 2003).  
Furthermore, off-target effects can occur due to seed-sequence-dependent 
binding (Jackson et al., 2006). Microarray experiments have demonstrated that the use 
of siRNA leads to the silencing of several off-target transcripts (Jackson et al., 2003; 
Scacheri et al., 2004). Analysis of the off-target transcripts showed sequence 
complementarity with the 5’ end of the siRNA guide strand (Lin et al., 2005). This 
region of the guide strand has analogy to the seed region at the 5’ end of a microRNA 
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that is involved in gene silencing (Lai, 2002). It has been shown that the sequence 
complementarity to the seed region of the siRNA is an important determinant of the 
regulation of unintended target transcripts (Jackson et al., 2006). The interpretation of 
results using siRNA to knockdown expression of genes should be carefully evaluated 
since off-target effects represent a real concern. Strategies could be used to identify off-
target genes as false positives and remove them from regulated transcripts. These off-
target effects should be taken into account, since the use of RNAi technology has moved 
towards therapeutic applications.   
The ID family members have been reported to be involved in the regulation of 
cell growth (Barone et al., 1994). Antisense oligonucleotides against ID1, ID2 and ID3 
were used to determine the effect on growth induction. DNA synthesis, measured by 
BrdU incorporation was decreased upon addition of the above antisense oligonucleotides 
in NIH 3T3 fibroblasts (Barone et al., 1994). When all three oligonucleotides were 
added together the inhibition on cell proliferation was even greater. To determine 
whether the effect from adding antisense oligonucleotides was reversible, the 
oligonucleotides were removed which led to an increase of BrdU incorporation and after 
12 hours the recovery was complete. This demonstrated that the treatment of cells with 
these oligonucleotides was not toxic and the reduction in DNA synthesis could be 
reversed. Also, depletion of ID1 and ID2 using an antisense oligonucleotide strategy in 
TIG-3 cells resulted in inhibition of cell proliferation (Hara et al., 1994). Cells were 
labelled with [3H] thymidine at 6 hour intervals and the radioactivity incorporated into 
acid-insoluble material was monitored. In cells treated with the antisense 
oligonucleotides, DNA synthesis was reduced by half compared to the TIG-3 cells 
treated with the control oligonucleotide (Hara et al., 1994). These results suggest that G1 
progression and entry into S phase was reduced by the depletion of the ID1 and ID2 
protein levels. Furthermore, in order to investigate the role of ID expression in 
mammary epithelial cell proliferation, ID1 was silenced using an siRNA approach 
(Swarbrick et al., 2005).  In MCF-7 cells treated with siRNA against ID1, DNA 
synthesis was reduced to about one-third within 24-48 hours post transfection. Flow 
cytometry analysis detecting both parameters such as BrdU/DNA content demonstrated 
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that siRNA against ID1 led to the accumulation of cells in G1 phase (Swarbrick et al., 
2005). Therefore, downregulation of ID1 resulted in impaired proliferation.   
 Other studies have demonstrated that the knockdown of ID1 and ID2 in the RIE-
1 (rat intestinal epithelial 1) cells induces apoptosis (Cao et al., 2009). siRNA to target 
ID1, ID2 and ID3 gene expression was used. The efficiency of siRNA knockdown of 
both protein and RNA levels was measured by western blotting and Q-PCR. The 
targeting of ID2 by siRNA lead to the induction of apoptosis, with the effects being 
greater when compared to ID1, whereas ID3 siRNA did not show induction of apoptosis. 
Apoptotic cells were stained with Annexin V-FITC and the RIE-1 cells were analysed 
by flow cytometry (Cao et al., 2009). In further experiments the knockdown of ID1 and 
ID3 by siRNA resulted in decreased proliferation, however, the loss of ID2 did not have 
an effect on cell proliferation in the LNCaP and DU145 prostate cancer cell lines 
(Asirvatham et al., 2006). The results were further investigated by FACS (Fluorescence-
Activated Cell Sorting) analysis. It was demonstrated that in the ID2 siRNA transfected 
LNCaP cells there was an increase in the percentage of cells undergoing apoptosis 
(Asirvatham et al., 2006). These results demonstrate that ID2 is involved in cell survival. 
Since ID proteins are involved in cell proliferation and cell survival the biological 
consequences of knocking down ID proteins should be further investigated. A possible 
explanation for the effects demonstrated upon knockdown of ID proteins on pol III 
transcription could be indirect effects attributed to the decrease in cell proliferation. The 
reduction of cell growth could then result in the decrease of pol III activity. However, 
chromatin immunoprecipitation assays and co-immunoprecipitation experiments in the 
next chapter reveal a possible direct effect of ID proteins on pol III transcription. 
Therefore, it is possible that the ID proteins are able to control cell proliferation and cell 
survival by directly affecting pol III transcription, since pol III products are involved in 
protein synthesis and cell growth.     
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Figure 3.2: Knockdown of endogenous ID1 by siRNA.   
HeLa cells were transfected with ID1 siRNA and siRNA targeting Oct-1 was used as 
control. A. RT-PCR analysis for ID1 depletion by siRNA. mRNA from the pol II-
transcribed ARPP P0 gene was used as loading control. B. Western blot analysis of ID1, 
ID2, ID3 and E47 expression, following transfection with siRNA against ID1. Actin was 
used as loading control.  
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Figure 3.3: Knockdown of ID1 by RNAi reduces the levels of pol III transcripts. 
Effects after ID1 knockdown by siRNA in HeLa cells, 72 hours post-transfection. RNA 
was harvested and analysed by RT-PCR for the expression of the pol III transcripts 5S 
rRNA, tRNAArg, tRNALeu, 7SL RNA, 7SK RNA, MRP RNA and U6 snRNA. The pol I 
transcript pre-rRNA was also analysed. mRNA from the pol II-transcribed ARPP P0 
gene was used as loading control. 
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Figure 3.4: ID2 knockdown by siRNA.   
HeLa cells were transfected with ID2 siRNA or the control Oct-1 siRNA and harvested 
72 hours later. A. RT-PCR for ID2 depletion by siRNA. mRNA from the pol II-
transcribed ARPP P0 gene was used as loading control. B. Western blot analysis of ID1, 
ID2, ID3 and E47 expression, following transfection with siRNA against ID2. Actin was 
used as loading control.  
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Figure 3.5: Knockdown of endogenous ID2 by RNAi decreases the levels of pol I 
and pol III transcripts. 
Effects of ID3 siRNA knockdown in HeLa cells 72 hours post transfection. RNA was 
harvested and analysed by RT-PCR for the expression of the pol III transcripts 5S 
rRNA, tRNAArg, tRNALeu, 7SL RNA, 7SK RNA, MRP RNA and U6 snRNA. The pol I 
transcript pre-rRNA was also analysed. mRNA from the pol II-transcribed ARPP P0 
gene was used as loading control. 
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Figure 3.6: Knockdown of ID3 by siRNA.   
HeLa cells were transfected with ID3 siRNA or the negative control Oct-1 siRNA and 
harvested 72 hours later. A. RNA was analysed by RT-PCR for ID3 depletion by 
siRNA. mRNA from the pol II-transcribed ARPP P0 gene was used as loading control. 
B. Western blot analysis of ID1, ID2, ID3 and E47 expression, following transfection 
with siRNA against ID3. Actin was used as loading control.  
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Figure 3.7: Knockdown of ID3 by RNAi diminishes the levels of pol I and pol III 
transcripts. 
HeLa cells were transfected with ID3 siRNA and harvested 72 hours after transfection. 
RNA was analysed by RT-PCR for the expression of 5S rRNA, tRNAArg, tRNALeu, 7SL 
RNA, 7SK RNA, MRP RNA and U6 snRNA. RT-PCR analysis was also performed for 
the pol I transcript pre-rRNA. mRNA from the pol II-transcribed ARPP P0 gene was 
used as loading control. 
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3.2.2 Overexpression of ID2 raises the levels of pol III 
transcripts 
 
Since ID2 overexpression can stimulate cell growth (Iavarone et al., 1994), it 
would be interesting to determine whether ID2 can upregulate pol III transcription in 
vivo in human cells using adenoviral infection methods to achieve ID2 expression. HeLa 
cells were infected with the parental virus adenovirus-cytomegalovirus 5’ internal 
ribosomal entry green fluorescent protein (Ad-Vector) or with an adenovirus expressing 
ID2 (Ad-ID2). Cells were infected with the above adenoviruses for 30 hours and then 
harvested. Western blot analysis demonstrated that infection of cells with the ID2 
adenovirus resulted in overexpression of the ID2 protein levels compared to the control 
vector (Figure 3.8, A). This is due to a specific effect since actin was used as loading 
control and the levels in both lanes remained the same. RNA was analysed by RT-PCR 
and revealed that infected ID2 cells resulted in an increase in the RNA levels of ID2 
compared to the control vector (Figure 3.8, B). The ARPP P0 mRNA was used as 
loading control and was the same in both conditions suggesting that this effect is 
specific. To examine the role of the increased protein and RNA levels of ID2 on pol III 
transcripts, RT-PCR experiments were performed.  The results showed that the levels of 
pol III-transcribed tRNALeu, 5S rRNA, tRNATyr, MRP RNA, tRNALeu and U6 snRNA 
are raised compared to the control vector. The effect is specific, as the pol II-transcribed 
ARPP P0 does not change in response to ID2 overexpression. These data demonstrate 
that overexpression of ID2 induces pol III transcription.   
To investigate the effect of ID2 on cell proliferation and in cell cycle 
progression, ID2 has been overexpressed in the human osteosarcoma cell line U2OS 
(Iavarone et al., 1994). The human ID2 cDNA was cloned into a pMEP4 vector which 
has a metalloprotein promoter regulating the expression of ID2. The pMEP4(ID2) was 
then transfected into the U2OS cell line. The U2OS cell line expresses functional p53 
and RB therefore it can be employed to study cell proliferation. To demonstrate the 
effect of ID2 overexpression on cell proliferation two expression vectors were 
compared, the pMEP4(ID2) vector and the control pMEP4. ID2 overexpression led to 
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the shortening of the cell doubling time (Iavarone et al., 1994). Also, the saturation 
density of cells where ID2 was overexpressed was higher than that of cells transfected 
with the control vector. To determine the effect of ID2 overexpression on cell cycle 
progression FACS analysis was employed. Flow cytometry was used to monitor cells 
labelled with BrdU. The ID2 expressing population demonstrated an increase in the 
number of cells in S phase and a decrease in the number of cells in G1 phase (Iavarone 
et al., 1994). In another study, the neuroblastoma SK-N-SH cell line was used to 
determine the effect of ID2 overexpression (Rothschild et al., 2006). ID2 was 
overexpressed in the SK-N-SH cell line using an adenovirus expression system and 
compared to cells infected with a control vector. Cells were infected and labelled with 
BrdU. BrdU incorporation assays demonstrated that infection with adeno-ID2 lead to 
increased entry of cells into S phase within 20 hours (Rothschild et al., 2006). 
Collectively these results demonstrate that ID2 expression can affect the growth 
potential of cells.  
 An important feature of the tumour suppressors RB and p53 is their ability to 
inhibit cell proliferation (Huang et al., 1988; Baker et al., 1990). It has been 
demonstrated that the SAOS-2 cell line does not have functional RB and p53 and the 
expression of these two suppressors in these cells leads to decreased proliferation of 
SAOS-2 cells (Diller et al., 1990; Qin et al., 1992). In order to investigate whether the 
effect of enhancement of cell proliferation upon ID2 expression in U2OS cells was due 
to regulation of RB or p53, ID2 was co-expressed with RB and p53 in SAOS-2 cells 
(Iavarone et al., 1994). The expression of RB in SAOS-2 cells inhibited the colony 
formation of these cells by 63%-73%. In contrast, when ID2 was co-expressed this 
resulted in a reduction of colony formation by about only 15%-30% (Iavarone et al., 
1994). However, when p53 was expressed in SAOS-2 cells, ID2 co-expression was 
unable to affect the suppression of cell growth exhibited by p53. From previous work, 
p53 has been demonstrated to be involved in the regulation of ID proteins (Qian & 
Chen, 2008; Wilson et al., 2001). ID1, ID2 and ID3 protein expression levels correlate 
with p53 expression in human colorectal adenocarcinomas (Wilson et al., 2001). ID 
protein levels are increased in p53 knockout mice (Wilson et al., 2001). In addition, ID1 
has been found to be downregulated by DEC1. Interestingly, DEC1 has been found to be 
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targeted by p53. The DEC1 protein is present at the promoter of the ID1 gene and this 
leads to the suppression of ID1 expression (Qian & Chen, 2008). The HEK 293 cell line 
used in this thesis expresses functional RB. HeLa cells have been shown to express the 
E7 oncoprotein, which binds and inactivates RB (Gage et al., 1990). Two mechanisms 
have been proposed to be involved in the inactivation of RB by E7. The first one 
involves the competition with E2F for the binding to RB. This is proposed since the RB-
E2F binding complex is lacking in cell lines tested (Chellappan et al., 1992). In vitro 
experiments have also demonstrated that E7 can inhibit the association of E2F with RB 
(Chellappan et al., 1992). The second mechanism of inactivation of RB by E7 is by the 
destabilisation of RB. The expression of E7 decreases the levels of RB in several cell 
lines and this is due to posttranslational events (Berezutskaya et al., 1997; Boyer et al., 
1996). It has been demonstrated that the E7 oncoprotein induces degradation of the RB 
protein through the ubiquitin proteasomal pathway (Boyer et al., 1996). In the case of 
HeLa cells p53 is expressed in low levels, which are altered in function as a 
consequence of association with the HPV E6 oncoprotein (Scheffner et al., 1991). 
Whereas the HEK 293 cells express functional p53. In the future, in addition to HeLa 
cells another cell line could be used which expresses functional p53 and RB, in order to 
repeat these experiments and correlate these results to the presence of p53 and RB. The 
ID2 protein has been demonstrated to bind to the RB protein family members and 
suppress their function. In addition, it has been shown that ID2 competes with RB for 
TFIIIB and this could be one mechanism by which ID2 stimulates pol III transcription 
(Gomez-Roman N, unpublished observations). Furthermore, the overexpression of ID2 
in fibroblasts derived from RB knockout mice still resulted in induction of pol III 
transcription, although this was lower than in wild-type control cells, suggesting that 
ID2 can also activate pol III transcription by an RB-independent mechanism (Gomez-
Roman N, unpublished observations). In the future, experiments should be performed on 
pol III transcription to study the biological response on cell growth and apoptosis after 
depletion or overexpression of ID proteins. FACS analysis should be used to determine 
the biological consequences such as cell cycle progression and cell viability upon 
depletion or overexpression of ID proteins.  
 
Chapter 3 Acivation of RNA Polymerase III Transcription by ID1, ID2 and ID3  
108 
 
 
 
ARPP P0Actin
ID2 ID2
A B
 
Figure 3.8: ID2 overexpression by adenoviral infection. 
HeLa cells were infected using an ID2 adenovirus expressing vector or control vector. 
A. Western blotting analysis of ID2 after cells were infected for 30 hours with adeno-
ID2 (Ad-ID2) or adenovirus vector (Ad-Vector). Actin was used as control. B. RT-PCR 
analysis for the overexpression of ID2 mRNA. mRNA from the pol II-transcribed ARPP 
P0 gene was used as loading control. 
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Figure 3.9: Overexpression of ID2 by adenoviral infection raises the levels of pol III 
transcripts. 
Effects from using an ID2 expressing vector in HeLa cells. Cells were harvested 30 
hours post infection with Ad-ID2 or Ad-Vector. RNA was harvested and analysed by 
RT-PCR for the expression of the pol III transcripts tRNALeu, 5S rRNA, tRNATyr, MRP 
RNA, tRNALeu and U6 snRNA. The ARPP P0 mRNA was used as control. 
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3.2.3 ID2 stimulates pol III transcription in vitro 
 
 Since previous experiments shown in figures 3.5 and figure 3.9 have 
demonstrated that ID2 regulates pol III transcription in vivo when using RNAi or 
adenoviral infection, it would be interesting to investigate if this is the case in vitro. To 
further confirm that endogenous ID2 stimulates pol III transcription, HeLa nuclear 
extracts were depleted using an antibody against ID2. In vitro transcription was 
performed using the adenovirus VA1 gene as template. As a negative control the pol II-
specific factor TFIIB was used, whereas, as positive control nuclear extracts were 
depleted of TBP, since this protein is required for pol III transcription. Given that ID2 
depletion in vivo by RNAi was shown to reduce pol III activity in HeLa cells, depletion 
of ID2 in vitro is likely to affect pol III activity. HeLa extracts depleted of TBP 
demonstrate a reduction in VA1 transcription compared to the control TFIIB-depleted 
extracts (Figure 3.10). The extracts depleted from ID2 using an anti-ID2 antibody show 
decreased VA1 transcription (Figure 3.10). Therefore these data suggest that 
endogenous ID2 can stimulate pol III activity in vitro. Further experiments should be 
done in order to determine the effect of the immunodepletion of ID2 on pol III 
transcription. Immunodepletion of ID1 and ID3 could also be performed to investigate 
the effects of these proteins on pol III transcription. Control experiments should be 
included such as the use of an undepleted control. Also, a secondary control that does 
not affect pol III transcription should be used. In order to eliminate the possibility that 
the effect on pol III transcription shown after immunodepletion of ID2 was not due to 
non-specific immunodepletion of other proteins, pre-immune serum against ID2 should 
be used as a control. Rescue with addition of ID2 could also be done as a control. 
Furthermore, western blot analysis should be done in order to assess the specificity and 
efficacy of immunodepletion. Detection of the levels of ID2, TFIIB and TBP proteins 
compared to the undepleted controls should be performed by western blotting to 
measure the efficacy of the immmunodepletion of these proteins. The above experiments 
should be repeated in order to assess the reproducibility of the experiments and to 
quantify the levels of immunodepletion of the above proteins and the effect on pol III 
transcription using the ImageJ program. 
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Figure 3.10: ID2 immunodepletion reduces pol III activity. 
In vitro transcription of the VA1 gene was analysed in HeLa nuclear extracts. Samples 
were immunodepleted for 2 hours on ice with antibodies against the TFIIB control (C-
18), TBP (mTBP-6) or ID2 (C-20).  
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3.3 Discussion 
 
The ID1, ID2 and ID3 family members are known to function in the regulation of 
cell growth by impinging on cell proliferation, cell fate determination and angiogenesis 
(Norton et al., 1998; Israel et al., 1999). One of the ID members, ID2, is a direct 
functional target of the RB suppressor protein and deregulated expression of ID proteins 
may lead to proliferative progression of tumours (Lasorella et al., 2000). Therefore, it is 
possible that tumour cells promote the expression of ID2 to inhibit the RB pathway 
which is implicated in cancer (Iavarone et al., 1994; Lasorella et al., 1996). Also, the 
ID1 and ID3 genes might be involved in the recruitment of blood vessels in human 
tumourigenesis (Lyden et al., 1999). The disruption of ID1 and ID3 resulted in the 
failure to support the growth of tumours and metastasis in mice, suggesting a role for 
these proteins in neoangiogenesis, which is an important process required for tumour 
growth. Overexpression of ID proteins stimulates an increased rate of cell proliferation 
in erythroleukaemia and myoblast cells in addition to inhibiting cell differentiation 
(Lister et al., 1995; Atherton et al., 1996). So, ID proteins function by positively 
affecting cell growth and pol III transcripts are required for maintaining cell growth. 
Therefore, it is likely that positive regulators of cell growth could induce pol III 
transcription.  
In order to determine if ID1, ID2 or ID3 are able to regulate pol III activity in 
human cells in vivo an RNAi approach was used. HeLa cells were transfected with 
siRNA targeting ID1, ID2 or ID3 and this treatment resulted in successful knockdown of 
RNA and protein levels of ID1, ID2 or ID3 compared to the controls (Figure 3.2; Figure 
3.4; Figure 3.6). Previous studies have shown that the knockdown of ID family members 
transfected with siRNA was specific. Silencing of one of the ID1, ID2 or ID3 members 
by siRNA did not result in repression or overexpression of other ID family members in 
prostate cancer cell lines (Asirvatham et al., 2007). Furthermore, knockdown of the ID1 
gene by siRNA was specific with the expression of the other ID proteins remaining the 
same compared to the control siRNA treated cells (Zheng et al., 2004).  To investigate 
the efficiency and specificity of ID1, ID2 or ID3 siRNA transfected cells, the levels of 
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their targets were determined. Western analysis revealed that the knockdown of ID1 by 
siRNA did not alter the protein levels of other ID family members and the associated 
E47 protein (Figure 3.2, B). Similarly, the ID2 or ID3 knockdowns were efficient and 
this depletion did not lead to the silencing or overexpression of their related proteins and 
the associated E47 protein (Figure 3.4, B; Figure 3.6, B). These data demonstrate that 
the knockdown of ID family members is specific and suggest the absence of any 
regulatory cross-talk between the ID members or the E47 expression levels. 
Oct-1 has some limitations as a control since it is a basal transcription factor which 
enhances SNAPc/TFIIIB recruitment although it is not essential for transcription. It is 
present on type III promoters such as those of the U6 and 7SK pol III genes. Oct-1 
removal causes a delay of 30 minutes for the onset of transcription. This might be a 
cause for concern because Oct-1 is involved in transcription of type III genes (Hu et al., 
2003). In siRNA experiments knocking down ID proteins, additional controls to which 
the knockdown of ID proteins and the effects on pol III transcripts should be compared 
should be used. These include a mock control and non-silencing controls. Non-silencing 
controls refer to siRNA which does not target any protein sequence, but which is able to 
activate the siRNA pathway. This is important because a non-silencing control does not 
target a protein and should avoid non-specific targeting due to the use of siRNA. Also, a 
mock control using only lipofectamine 2000 without adding siRNA should be employed 
to investigate whether there is an effect mediated by the transfection reagent on the cells. 
Other techniques for the knockdown of ID proteins should be used in the future, in order 
to further validate the effects observed here. RT-PCR was used here, which has some 
limitations. Firstly, it provides a semi-quantitative measurement of the levels of 
transcripts. In the future, Q-PCR could be used. The advantages of Q-PCR are its large 
dynamic range being able to detect >107 fold differences in expression, and its 
sensitivity, potentially being able to detect even a single copy (Bustin et al., 2005; Please 
see Introduction section, 9th sentence of 1st paragraph). Q-PCR gives the Ct (threshold 
cycle) values, which are compared by relative quantitation of samples. In the future, 
western blot experiments could be performed to detect the expression levels of the other 
ID protein family members, ID1 and ID3, and also of the associated E47 protein upon 
overexpression of ID2. Studies have demonstrated that when the ID2 or E47 proteins are 
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overexpressed the protein levels of each other are not affected (Rothschild et al., 2006). 
Also, immunofluorescence could be used in order to determine where ID and E47 
proteins are localised in the cell and whether they co-localise.  
 The following step involved the determination of whether these depletions 
would have an effect on pol III transcription. The results demonstrated that the 
expression of the pol III transcripts 5S rRNA, tRNAArg, tRNALeu, 7SL RNA, 7SK RNA, 
MRP RNA and U6 snRNA was reduced in comparison to the controls (Figure 3.3; 
Figure 3.5; Figure 3.7). Furthermore, the ID2 or ID3 knockdown but not the ID1 
depletion resulted in the decrease of the pol I transcript pre-rRNA (Figure 3.3; Figure 
3.5; Figure 3.7). Possible explanations for this difference in the effect of this knockdown 
could be that in the case of the ID1 knockdown a more efficient depletion of ID1 protein 
and RNA levels might result in reduced expression of the pol I transcript pre-rRNA. 
Another possibility might be that although the family members share similarity in the 
HLH domain, differences in the rest of the sequence of ID members may be important 
for their interaction with factors of the pol I machinery. However, more studies are 
required to determine the role of ID members in the regulation of pol I transcription. 
These results demonstrate that the depletion of ID family members can regulate pol I 
and pol III transcription and indicates a role for IDs as activators in human cells in vivo. 
To investigate the effect of expressing ID2 on pol III transcription in human cells in 
vivo, HeLa cells were infected with adenoviruses expressing the ID2 or the control 
vector. Infection with the ID2 adenovirus resulted in increased expression of ID2 protein 
and RNA compared to the control (Figure 3.8). Moreover, the levels of the pol III 
transcripts tRNALeu, 5S rRNA, tRNATyr, MRP RNA and U6 snRNA were raised after 
overexpression of ID2 in comparison to the control vector (Figure 3.9). From these 
results, it can be concluded that in both cases, knockdown or overexpression, ID family 
members demonstrated a positive effect on pol III activity. 
 The results in this chapter demonstrated that ID members can regulate pol III 
transcription in vivo indicating a positive role for this family in pol III activity under 
both siRNA and adenoviral expression conditions. To determine whether the above is 
true in vitro, nuclear extracts were depleted of ID2. In HeLa extracts the depletion of 
ID2 resulted in reduction of pol III transcription, in comparison to the pol II specific 
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factor TFIIB, used as control (Figure 3.10). These data indicate that the endogenous ID2 
can positively regulate pol III transcription in vitro.   
The results in this thesis demonstrate that both the knockdown and overexpression of ID 
proteins affect pol III transcription. In the next chapter ID proteins are shown to 
associate with the pol III transcription apparatus. ID proteins appear to possibly interact 
directly with the basal transcription factor Brf1. However, indirect effects mediated by 
knockdown or overexpression of ID proteins cannot be excluded. The knockdown of 
proteins by siRNA can lead to off-target effects mediated by the induction of the 
interferon response and by seed region sequence complementarity (Sledz et al., 2003; 
Jackson et al., 2006). Experiments using siRNA against the widely used control GFP 
have shown that other unintended genes are targeted in the cell lines tested (Tschuch et 
al., 2008). Since GFP is a widely used negative control for siRNA experiments, genome 
wide expression analysis was carried out to detect the complete set of unintended target 
genes. The results demonstrated that even siRNAs without physiological targets can lead 
to off-target effects (Tschuch et al., 2008). The knockdown of ID proteins can also lead 
to biological consequences such as the induction of apoptosis (Cao et al., 2009; 
Asirvatham et al., 2006). Induction of apoptosis could activate signalling pathways, 
which can indirectly lead to regulation of pol III transcription. Overexpression of ID 
proteins at high levels that are not physiological may not represent a real situation in 
cells. However, it may reflect an example of what may happen in cancer where ID 
proteins are expressed in high levels in many tumour samples (Lin et al., 2000; Schindl 
et al., 2003; Wilson et al., 2001). Since ID proteins are shown to potentially affect cell 
growth by interacting with the RB protein family as well as with the E-protein 
transcription factors and ETS binding proteins, the possible indirect effects mediated by 
the overexpression of ID proteins should be taken into account (Iavarone et al., 1994; 
Perk et al., 2005; Yates et al., 1999). Since ID proteins could affect pol III transcription 
indirectly by interacting with the tumour suppressor RB, which has been demonstrated 
to sequester TFIIIB and result in the repression of pol III transcription (Sutcliffe et al., 
2000). Also, in this thesis in chapter 5 E47 is shown to repress pol III transcription. 
Therefore, it is possible that ID proteins, which are known to function by sequestering 
E-proteins, could indirectly affect pol III transcription by forming transcriptionally 
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inactive complexes with E-proteins. In addition, the increased or decreased growth rate 
of cells could provide a possible explanation for the effects mediated by the 
overexpression or knockdown of ID proteins on pol III transcription. The increased or 
decreased growth rate of cells could be the result of indirect, and not direct, effects 
caused by the alteration of ID protein levels. In order to try to avoid indirect effects 
caused by the knockdown or overexpression of ID proteins, cell lines that contain 
functional p53 and RB that represent a more physiological state should be used instead 
of the HeLa cell line used. Also, the specificity and efficiency of the siRNA used to 
target ID proteins could be improved to avoid off-target effects that can lead to indirect 
effects. Furthermore, in vitro transcription assays should be performed investigating the 
effect on more pol III transcripts, since the results obtained from these experiments 
might be less likely to be affected by indirect consequences. 
In conclusion, the data presented in this chapter suggest that the ID1, ID2 and 
ID3 family members activate pol III transcription, indicating a possible role through 
which these transcription factors may regulate cell growth. Since preliminary 
experiments expose an effect of ID proteins on pol I activity, it would be interesting to 
determine whether these proteins can also regulate pol I transcription. 
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4.1 Introduction  
 
4.1.1 ID protein interaction with the RB family 
 
 ID proteins are important proliferative factors in a number of cell types (Hara et 
al., 1994; Lasorella et al., 2002). Serum induction results in rapid expression of ID 
proteins with high levels being maintained throughout S phase (Hara et al., 1994; 
Lasorella et al., 2000). Several studies have suggested that G1 progression relies on the 
activity of ID proteins on their targets (Norton, 2000; Roberts et al., 2001; Yates et al., 
1999). In particular, IDs are functional targets of the RB tumour suppressor protein and 
the related proteins p107 and p130 (Iavarone et al., 1994; Lasorella et al., 1996; 
Lasorella et al., 2000). Overexpression of ID2 in osteosarcoma U2OS cells promoted 
proliferation, with a larger population of cells in the S phase compared to controls 
(Iavarone et al., 1994). The tumour suppressor RB regulates the cell cycle by binding 
and inactivating transcription factors such as E2F-DP1, whose activity is required for G1 
to S phase progression (Harbour et al., 1999). Only the unphosphorylated active form of 
RB can bind to transcription factors, whereas the phosphorylated form is inactive. The 
ID2 protein, but not ID1 or ID3, can bind to the unphosphorylated form of RB in vitro 
and in vivo (Iavarone et al., 1994; Lasorella et al., 1996). The binding of ID2 to RB and 
the related proteins p107 and p130 is dependent on the HLH domain of ID2. The HLH 
domain of ID2 associates with the pocket domain of RB, which is required for growth 
inhibition. A mutant lacking the HLH domain was unable to inhibit the growth 
suppression caused by RB. ID2 was able to reverse the growth inhibition caused by RB 
when these were co-transfected in the osteosarcoma cell line Saos-2 that lacks RB. Also, 
overexpression of ID2 in U2OS cells reversed the cell cycle arrest induced by cyclin-
dependent kinase inhibitors p16 and p21, by inactivating RB (Lasorella et al., 1996). 
Knockout experiments of ID2 and RB in mice demonstrated a genetic interaction 
between ID2 and RB during development. Specifically, the embryonic lethality of RB-
null mice can be rescued by elimination of ID2 (Lasorella et al., 2000).  
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In addition to binding RB directly to inhibit its function, ID proteins may affect 
the activity of RB indirectly. ID1, and possibly other ID family members, can inhibit the 
expression of the cyclin-dependent kinase inhibitor p21Cip1/Waf1 by binding and 
sequestering E47, which mediates its expression (Prabhu et al., 1997). This reduces the 
suppression from p21Cip1/Waf1 and allows cyclin E/CDK2 to phosphorylate and inactivate 
RB, which leads to activation of genes needed to promote the G1 to S progression. It has 
also been demonstrated that p57kip2, which is the only CDK inhibitors required for 
normal development, is a target of both ID2 and E47 (Rothschild et al., 2006). The ID2 
protein inhibits activation of p57kip2 and leads to progression into S phase with the RB 
protein reversing this activity, whereas E47 induces p57kip2 mediated cell cycle arrest 
and prevents progression into S phase. Studies have demonstrated that ID1 expression 
can downregulate p16INK4a which leads to RB phosphorylation (Ouyang et al., 2002b). 
The inactivation of the p16INK4a/RB pathway by ID1 may be required for induced cell 
proliferation in prostate cancer cells. The ETS family transcription factor members 
ETS1 and ETS2 have been shown to interact with and activate the p16INK4a gene (Ohtani 
et al., 2001). ETS family members are negatively regulated by the ID family of HLH 
proteins, with ETS2 binding directly to ID1 in vitro. ID1 can reduce the activation of 
p16INK4a by ETS2. Therefore, ETS2 and ID1 have antagonistic effects on p16INK4a.  
 
4.1.2 ID cellular localisation and regulation by bHLH proteins 
 
 Appropriate subcellular localisation is important for the proper function of 
several proteins. Some proteins are constitutively nuclear, whereas others are actively 
imported into and exported out of the nucleus, by a signal dependent or independent 
mechanism (Mattaj & Englmeier, 1998; Gorlich & Kutay, 1999). Shuttling of large 
proteins between the cytoplasm and the nucleus is accomplished through nuclear pore 
complexes mediated by nuclear export signals (NES) and nuclear localisation signals 
(NLS) present on these proteins. The NES and NLS are identified by export and import 
receptors (Macara, 2001; Suntharalingam & Wente, 2003). However, small proteins 
with molecular weights of less than 40kDa can freely pass through the nuclear pore 
(Mattaj & Englmeier, 1998; Macara, 2001). The molecular weights of the ID protein 
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family members range from 13kDa to 20kDa which suggests that they may enter and 
exit the nucleus by passive diffusion. However, other mechanisms that regulate the 
subcellular localisation of ID proteins have emerged (Deed et al., 1996; Trausch-Azar et 
al., 2004; Kurooka & Yokota, 2005; Lingbeck et al., 2005; Makita et al., 2006).   
ID proteins have been reported to be distributed both in the cytoplasm and 
nucleus under physiological conditions in growing cells (Jen et al., 1992; Iavarone et al., 
1994). When ID3 was transiently expressed in COS cells and in the absence of the E47 
protein it localised in the cytoplasm/perinuclear region (Deed et al., 1996). However, 
when E47 and ID3 were co-transfected, the ID3 protein was translocated to the nucleus, 
whereas E47 was not sequestered into the cytoplasm. Similarly to other early response 
genes, ID3 protein levels are rapidly turned over with a short half-life (t1/2) of 1 hour, 
whereas the E47 protein has a longer half-life of 24 hours. After co-transfection of ID3 
and E47 the half life of the ID3 protein was extended to 3 hours and that of the E47 
protein was reduced to 16 hours. In order to investigate the effect of nuclear localisation 
on the stability of ID3, co-transfection experiments of ID3 with a truncated form of the 
E12 protein, E12r, were carried out. The E12r protein was able to heterodimerise with 
ID3, however ID3 was not able to localise to the nucleus. The half life of the co-
transfected E12r was reduced, similarly to E47, from 18 to 12 hours and the half life of 
ID3 was extended to about 4 hours (Deed et al., 1996). Therefore, heterodimerisation 
and not nuclear localisation is thought to mediate for these effects on protein stability. 
To conclude, E47 can act as a nuclear chaperone and can regulate the availability of ID 
proteins. Other studies have also confirmed that E47 and E12 can regulate cellular 
localisation and degradation of ID proteins (Lingbeck et al., 2005).  
 Myogenic determination (MyoD) is a bHLH protein that is a key regulator of 
muscle differentiation and forms complexes with ID1. MyoD is another example of a 
bHLH protein that modulates the degradation of an ID family member (Trausch-Azar et 
al., 2004). Mutagenesis to the NLS motif of ID1 (ID1NLS) resulted in enhanced 
localisation of the protein to the cytoplasm and increased the rate of degradation (t1/2 
~0.5 hour) compared to wild type ID1 (t1/2 ~1 hour). Co-transfection of MyoD with ID1 
or ID1NLS resulted in increased localisation of ID1 or ID1NLS to the nucleus and also 
reduced the rate of degradation of ID1 or ID1NLS. The converse, however, does not 
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occur, as the degradation and localisation of MyoD was unaltered by expression of ID1 
(Trausch-Azar et al., 2004). In another study, the shuttling of ID2 between the nucleus 
and cytoplasm was investigated (Kurooka & Yokota, 2005).  A functional NES was 
revealed in the C-terminal region of the ID2 protein which is required for cytoplasmic 
localisation. Inhibiting nuclear export led to accumulation of ID2 to the nucleus without 
the co-expression of E-proteins. Also, the HLH domain of ID2 is important for 
exhibiting NLS activity. Other findings have established that the ID1 proteins, in 
addition to the ID2 proteins, have a functional NES (Makita et al., 2006). 
 
4.1.3 ID protein degradation by the ubiquitin-proteasomal 
pathway 
 
The expression of the ID proteins is regulated at various levels, one of which is 
the post-translational level, through the ubiquitin-proteasome pathway (Bounpheng et 
al., 1999b; Fajerman et al., 2004). ID proteins are short-lived proteins with a half-life of 
20-60 min, depending on the cell type (Deed et al., 1996; Bounpheng et al., 1999b). 
Heterodimerisation of ID proteins with bHLH proteins stabilises the ID proteins, which 
become less susceptible to degradation (Bounpheng et al., 1999b; Trausch-Azar et al., 
2004; Lingbeck et al., 2005). ID3 interacts with Jun activating binding protein 1 (JAB1), 
which is related to factors present in the 19S complex of the 29S proteasome and ID1 
interacts with the S5a proteasome subunit (Bounpheng et al., 1999b; Anand et al., 
1997). ID1, ID2 and ID3 protein degradation can be blocked by treating cells with 
inhibitors of the 26S proteasome (Bounpheng et al., 1999b). The inhibitors of the 26S 
proteasome, lactacystin or Z-L3VS, lead to an increase in the accumulation of ID1, ID2 
and ID3 proteins. Also, when chloroquine, an inhibitor of lysosomal proteolysis, was 
used to treat cells it did not have an effect on the levels of ID proteins, suggesting that 
ID proteins are not degraded by this pathway. It has been demonstrated that ID proteins 
can be modified by ubiquitination (Bounpheng et al., 1999b). In order to identify the 
domain of the ID proteins that is targeted by the 26S proteasome, ID1 deletion mutants 
of the HLH domain, amino terminus and carboxyl terminus were tested in cells treated 
with the Z-L3VS inhibitor. The ID1 deletion mutants showed a higher accumulation, 
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implying that the mutants can also be targeted for degradation by the 26S proteasome 
(Christy BA, unpublished observations cited in Bounpheng et al., 1999b).  
Other studies have demonstrated that the ID1 and ID2 proteins are degraded by 
the ubuiquitin proteasome system following ubiquitination at its N-terminal residue 
(Fajerman et al., 2004; Trausch-Azar et al., 2004). Deleting the first 15 N-terminal 
residues of ID2 resulted in stabilisation of the protein, indicating that this particular 
domain possibly acts as a substrate for the E3 ubiquitin ligase. A mutant fibroblast cell 
line, ts20tg, with a temperature-sensitive defect in the E1 ubiquitin activating enzyme, 
was used to investigate if ID proteins are degraded by the ubiquitin-proteasomal 
pathway (Bounpheng et al., 1999b). The mutant cell line grows normally at 35°C; 
however, when the temperature is raised to 39°C, the cells grow more slowly. Blocking 
the function of the E1 ubiquitin activating enzyme causes proteins that are degraded by 
the ubiquitin pathway to accumulate (Chowdary et al., 1994). Transfection of ts20tg 
cells with ID cDNAs and increasing the temperature to 39°C led to the accumulation of 
ID1, ID2 and ID3 proteins. 
 
4.1.4 Phosphorylation of ID proteins 
 
 Protein modification is a significant step in the regulation of protein function. 
Phosphorylation sites for protein kinase A, protein kinase C, cell division cycle 2 (cdc2) 
kinase and CK2 have been found in the ID family proteins (Nagata et al., 1995). Cyclin- 
dependent kinases are thought to be involved in the regulation of the cell cycle, with 
cyclin E-CDK2 being important for G1 to S phase transition (Resnitzky & Reed, 1995). 
Studies have identified ID2 as a substrate for cyclin E-CDK2, and also for cyclin A-
CDK2 (Hara et al., 1997; Matsumura et al., 2002). Phosphorylation of a serine residue 
(Ser5) of ID2 by CDK2 inhibits ID2 from disrupting the formation of E-box DNA-
binding complexes (Hara et al., 1997). Phosphorylation of ID2 occurs during the late G1 
phase, together with the activation of cyclin E-CDK2. Furthermore, during late G1 the 
levels of ID2 expression and the E-box complex were both found to be maximal, in 
serum-stimulated fibroblasts. This is surprising, but, an explanation could be that the 
Chapter 4 ID1, ID2 and ID3 Association with the RNA Polymerase III Transcription 
Machinery  
123 
 
phosphorylated ID2 is not inactivated but changes its specificity for another protein 
which is involved in the G1 to S transition.  
To investigate the biological importance of the ID2 Ser5 phosphorylation site, 
vectors expressing ID2 and an ID2-S5A mutant which cannot be phosphorylated were 
transfected into cells. The ID2-S5A mutant exhibited a 50% reduction in colony 
formation, perhaps because phosphorylated ID2 is important for cell cycle progression 
from late G1 to S phase (Hara et al., 1997). In a later study, cell cycle regulated 
phosphorylation of ID3 was implicated in inhibiting homo- or heterodimer complex 
formation (Deed et al., 1997). Similar to ID2, ID3 becomes phosphorylated in the late 
G1 phase and contains a CDK phosphorylation site at Ser5 (Figure 4.1). The 
unphosphorylated ID3 can inhibit an E12 homodimer complex; however, it cannot 
disrupt the E12-MyoD heterodimer. Conversely, phosphorylation of ID3 at Ser5 resulted 
in inhibition of the E12-MyoD complex. This indicates that phosphorylation of ID 
proteins could result in a change of bHLH target specificity, rather than total loss of 
bHLH antagonism.  
In other studies, the role of ID2 in smooth muscle cell (SMC) proliferation was 
investigated (Matsumura et al., 2002). SMC proliferation is a significant component of 
vascular proliferative disorders. Overexpression of ID2 in SMCs increased entry into S 
phase and cell growth. The CDK2 phosphorylation site Ser5 of ID2 is required for p21 
inhibition. It has been found that mutation of Ser5 of ID2 results in inhibition of 
proliferation and entry into S phase. Wild-type ID2 and mutant ID2-S5A were co-
transfected into SMCs with a vector expressing a full length coding region of E47, 
which contained a nuclear localisation signal. It was found that the mutant ID2 was 
excluded from the nucleus whereas the wild type ID2 was localised in the nucleus. 
Therefore, the effect of CDK2 phosphorylation on ID2 may be due to regulation of 
nuclear transport or interaction with E47 (Matsumura et al., 2002).   
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Figure 4.1: Schematic representation of the human ID1, ID2 and ID3 protein 
structure. 
The helix-loop-helix domain region is shown in red. The ID2 and ID3 protein N-
terminal domains contain the CDK2 phosphorylation site at Ser5 represented as Y. The 
alignment of ID proteins was performed with the Lasergene software (version 1.62d1, 
acquired from DNAStar Inc., Madison, WI) and visualised using the program SeqVu 
(version 1.1, The Garvan Institute of Medical Research, Sydney, Australia). (adapted 
from Hasskarl & Münger, 2002). 
 
In the previous chapter it was suggested that ID proteins could stimulate the 
activation of pol III-transcribed genes. This chapter will address the possible 
mechanisms by which the ID family members affect pol III transcription. The 
localisation of ID proteins at the pol III templates in vivo will be investigated in human 
cells. Furthermore, the recruitment of ID1, ID2 and ID3 proteins to pol III-transcribed 
genes will be examined. The interaction of the ID members with one or more of the pol 
III specific factors will also be examined to provide an insight into how ID proteins 
regulate pol III transcription.  
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4.2 Results  
 
4.2.1 IDs localise at pol III-transcribed genes in vivo 
 
The results shown in chapter 3 suggest that ID1, ID2 and ID3 family members 
are involved in the upregulation of pol III transcription. ID proteins function by 
sequestering transcription factors from binding DNA, and themselves are unable to bind 
to DNA (Perk et al., 2005; Benezra et al., 1990). Therefore, one possible mechanism 
might be that IDs are interacting with the pol III transcription machinery and these 
associations with the pol III templates are required for the activation of pol III 
transcription. To determine whether endogenous ID1, ID2 and ID3 are found at pol III-
transcribed genes in vivo, ChIP assays were performed using HeLa cells. ID1, ID2, ID3, 
TAFi48, TBP and pol III antibodies were used to precipitate the proteins that cross-
linked to DNA. TBP and pol III were utilised as positive controls, and TAFi48 was used 
as the negative control. The results demonstrated that ID2 was present at the 5S rRNA 
and tRNALeu pol III templates, with ID3 shown present on tRNALeu genes, however, ID1 
was not found at pol III-transcribed genes (Figure 4.2). As expected, the positive 
controls, TBP and pol III, were present at these templates whereas with the negative 
control, TAFi48, no signal was detected. These results demonstrate that the association 
of endogenous IDs, mainly of ID2, with pol III-transcribed genes in vivo is specific. 
However, these experiments should be repeated in the future including serial dilutions of 
the inputs and stronger exposures should be taken. Also, endogenous ID1 does not 
appear to be present at pol III genes which may indicate that ID1 is not involved in 
direct regulation of pol III transcription. Presence of ID1 on pol III promoters should be 
determined in the future by overexpression of ID1. 
 Another type of cells, the HEK 293 cell line, was utilised to investigate whether 
ID2 was present at pol III-transcribed genes in vivo. Infection of cells was performed 
employing an adenovirus expressing ID2, with the cells harvested 30 hours after 
infection. ChIP experiments were performed in cells in which ID2 was overexpressed. 
The positive controls Brf1, TFIIIC and pol III were present at 5S rRNA, tRNALeu, 7SL 
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RNA and U6 snRNA genes as expected, whereas the negative controls TFIIA and beads 
gave no signal (Figure 4.3).  The results revealed that ID2 was found at pol III-
transcribed 5S rRNA, tRNALeu, 7SL RNA and U6 snRNA genes (Figure 4.3). 
Interestingly, E47 was also recruited to the above pol III templates. These interactions 
were specific and not because of over cross-linking of proteins to DNA, since no signal 
was present when using primers to amplify the pol II-transcribed ARPP P0 gene. 
Therefore, these data demonstrate that ID2 and E47 are present at pol III genes.  
Furthermore, a U2OS cell line stably expressing ID3 was used to determine 
whether ID3 can occupy pol III templates in vivo.  ChIP assays demonstrated that ID3 
was present at 5S rRNA, tRNALeu, tRNATyr and 7SL RNA genes, with E47 also 
recruited to the 7SL template (Figure 4.4). No signal was detected when primers were 
used to amplify the pol II-transcribed ARPP P0 gene (Figure 4.4). These results 
demonstrate that the binding of antibodies to the promoter regions is specific. In 
conclusion, these data revealed that IDs are present at pol III-transcribed genes in vivo.  
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Figure 4.2: Endogenous ID occupancy at pol III-transcribed genes. 
Chromatin immunoprecipitation assays were performed using HeLa cells. ID1 (C-20), 
ID2 (C-20) and ID3 (C-20) antibodies were used to determine the presence of IDs on pol 
III templates. The M19 antibody was used against the TAFi48 as negative control. TBP 
(MTBP-6) and pol III (1900) antibodies were used as positive controls. Primers were 
designed for 5S rRNA and tRNALeu genes and the immunoprecipitated DNA samples 
were analysed by PCR. The non-immunoprecipitated input samples were used as 
controls.  
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Figure 4.3: ID2 and E47 are associated with pol III-transcribed genes. 
Chromatin immunoprecipitation assays were performed using HEK 293 cells harvested 
30 hours after infection with the ID2 adenovirus. The TFIIA (FL-109) antibody was 
used together with the beads (no antibody) as negative controls. The ID2 (C-20) and E47 
(N-649) antibodies were used to test whether ID2 and E47 were present at pol III-
transcribed genes. The Brf1 (128), TFIIIC (Ab7) and pol III (1900) antibodies were used 
as positive controls. Primers were designed for 5S rRNA, tRNALeu, 7SL RNA and U6 
snRNA genes and the DNA samples were analysed by PCR. Input samples were used as 
controls.  
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Figure 4.4: ID3 and E47 are present at pol III-transcribed genes. 
Chromatin immunoprecipitation assays were performed using a U2OS cell line stably 
expressing ID3. The TFIIA (FL-109) antibody and beads were utilised as negative 
controls. The ID3 (C-20) and E47 (N-649) antibodies were used to determine whether 
ID3 localised at pol III-transcribed genes. The Brf1 (128), TFIIIC (Ab7) and pol III 
(1900) antibodies were utilised as positive controls. Primers designed were specific for 
5S rRNA, tRNALeu, tRNATyr and 7SL RNA genes and the immunoprecipitated samples 
were analysed by PCR. The non-immunoprecipitated inputs were used as controls. 
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4.2.2 ID2 is present at pol III promoters and co-localises with 
TFIIIB 
 
Previous experiments demonstrated that ID2 was found to localise at pol III 
templates (Figure 4.2; Figure 4.3). Studies using mapping ChIP assays have 
demonstrated that the c-Myc oncoprotein which is involved in the activation of pol III 
transcription, co-localises with the TFIIIB and this factor is likely to recruit c-Myc to pol 
III templates (Gomez-Roman et al., 2003; Kenneth et al., 2007). To investigate whether 
ID2 can localise at the promoters of pol III-transcribed genes and is associated with 
basal pol III factors, mapping experiments on the 7SL locus were performed. PCRs were 
performed using five set of primers designed for DNA regions, upstream of the pol III-
transcribed 7SL gene promoter, at the gene region and downstream of the 7SL promoter 
region (Figure 4.5, A). Cells were infected with an ID2 expressing adenovirus. HEK 293 
cells were harvested 30 hours post-infection and PCR was used for the amplification of 
DNA extracted from ChIP assays. The data demonstrated that the basal transcription 
factors TFIIIB and TFIIIC are localised at different positions on the 7SL promoter 
region (Figure 4.5, B). The results revealed that ID2 together with the Brf1 subunit of 
TFIIIB were distributed at the start of the gene exhibiting a similar pattern, with 
increased occupancy at the second position and displaying a decrease at the end of the 
gene at position 3 (Figure 4.5, C). Morover, TFIIIC and pol III are present at the second 
and third positions of the 7SL gene (Figure 4.5, C). Also, using this ID2 overexpressed 
cell line, E47 appears to be recruited to the 7SL promoter region. E47 shows an 
increased presence together with Brf1 at the start of the 7SL gene, and a decrease after 
the second position (Figure 4.5, C). These results demonstrate that ID2 co-localises with 
Brf1 rather than TFIIIC and it is more likely that ID2 is recruited by Brf1. To investigate 
the interaction of ID2 with Brf1, co-immunoprecipitation and in vitro transcription and 
translation studies are required to identify whether ID2 binds to Brf1 which could 
possibly lead to the recruitment of ID2 to pol III-transcribed genes. 
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Figure 4.5: ID2 occupancy on the 7SL locus. 
Chromatin immunoprecipitation assays were performed in HEK 293 cells harvested 30 
hours after infection with the ID2 expressing adenovirus. A. The diagram of the five 
positions amplified by sets of primers on the 7SL locus. B. The ID2 (C-20), E47 (N-
649), Brf1 (128), TFIIIC (Ab7) and pol III (1900) antibodies were used for ChIP assays, 
with the TFIIA (FL-109) and beads utilised as negative controls. C. Schematic 
representation of the intensity of 7SL ChIP signals. The x-axis displays the five sets of 
primers. The y-axis represents the ChIP signals that were normalised, by adjusting the 
samples accordingly against the input and the strength of signals with the TFIIA 
negative control. Quantification was performed using the ImageJ (version 1.42) 
software. 
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4.2.3 IDs co-immunoprecipitate with Brf1 
 
Previous ChIP assays here have demonstrated that IDs are present at pol III-transcribed 
genes in vivo (Figure 4.2; Figure 4.3; Figure 4.4). The fact that IDs are shown to be 
associated with pol III templates is interesting since IDs lack a DNA binding domain 
(Benezra et al., 1990). Therefore, it is possible that the association of IDs with the pol III 
templates might be through protein-protein interactions with basal factors of the pol III 
apparatus, and this may lead to the regulation of pol III-transcribed genes. Scanning 
ChIP assays revealed that ID2 can associate with the Brf1 factor at the 7SL gene 
promoter (Figure 4.5). These results suggested the possibility that IDs interact with the 
basal transcription factor TFIIIB. To investigate the interaction of ID2 with Brf1, co-
immunoprecipitation studies were performed. Western blotting using HeLa extracts in 
which Brf1 was expressed containing an HA tag, demonstrated that HA-Brf1 co-
immunoprecipitated with ID1 compared to the un-induced samples (Figure 4.6, A). In 
the future, additional experiments should be performed to investigate whether ID1 co-
immunoprecipitates with Brf1. Moreover, western blot analysis using HeLa cells 
revealed that Brf1 co-immunoprecipitated with endogenous ID2 (Figure 4.6, B). In the 
future, control western blotting experiments should be performed using an anti-ID2 
antibody as well as an anti-TFIIB antibody for the immunoprecipitation. This is 
important in order to demonstrate the opposite experiment that ID2 is also able to co-
immunoprecipitate with Brf1 to further support these results (Figure 4.6, B). Also, using 
an anti-TFIIB antibody for western blotting will determine whether TFIIB can 
immunoprecipitate itself, and it should not co-immunoprecipitate with ID2 and Brf1 
since it is used as a negative control. Also, a stable U2OS cell line expressing ID3 was 
used for western analysis of the immunoprecipitation and demonstrated that ID3 co-
immunoprecipitated with Brf1 (Figure 4.6, C). The TFIIB antibody and beads were used 
as negative controls and confirmed that these associations were specific.  
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Figure 4.6: Co-immunoprecipitations reveal interactions of ID1, ID2 and ID3 with 
Brf1. 
HeLa cells expressing HA-Brf1 as well as HeLa and U2OS cells stably expressing ID3 
nuclear extracts were utilised for co-IP studies. A. For the HeLa HA-Brf1 TET-ON 
expression system, cells were induced to express HA-Brf1 for 48 hours before 
harvesting. The extracts were immunoprecipitated with the ID1 (C-20), HA (F-7) and 
Brf1 (128) antibodies. The TFIIB (C-18) antibody was used as negative control. The “+” 
represents induction of Brf1 compared to the un-induced “-” control. B. Extracts were 
immunoprecipitated with ID2 (C-20) and Brf1 (330) antibodies. Beads and TFIIB (C-
18) were used as negative controls. C. Nuclear extracts were precipitated with ID3 (C-
20) and Brf1 (128) antibodies. The TFIIB (C-18) and beads were utilised as negative 
controls. The HA (F-7) (A), Brf1 (330) (B) and ID3 (C-20) (C) antibodies were used for 
western blotting.  
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4.2.4 ID1, ID2 and ID3 proteins interact with Brf1 
 
 Co-immunoprecipitation assays revealed that ID proteins can interact with the 
Brf1 subunit of TFIIIB in vivo (Figure 4.6). The above technique, however, cannot be 
used to distinguish between indirect or direct interactions. Since TFIIIB is a transcription 
factor that has been found to be associated with regulatory proteins like the RB and p53 
proteins (White et al., 1996; Cairns & White, 1998), the ability of IDs to interact with 
TFIIIB in vitro was examined. To investigate whether full length ID and mutant forms 
of these proteins can bind to TFIIIB, in vitro transcription and translation experiments 
using 35S-methionine were employed. Initially, the expression of the GST vector control 
and the GST-ID full length and mutant proteins was performed in E. coli cells. The 
results demonstrated that the GST-ID1, GST-ID2, GST-ID3, GST-ID2 HLH (containing 
only the HLH domain of ID2) and GST-ID2 δHLH (lacking the HLH domain of ID2) 
fusion proteins and the GST vector control were overexpressed and normalised against 
each other (Figure 4.7). The next step involved the in vitro translation of the Brf1 
subunit of TFIIIB followed by its labelling with 35S-methionine. The results visualised 
by autoradiography revealed that the GST-ID1, GST-ID2, GST-ID3, GST-ID2 HLH, 
GST-ID2 δHLH and GST-E47 proteins are bound by Brf1 (Figure 4.8). In the GST 
control no signal was detected, confirming the specificity of these interactions. From 
these findings it can be concluded that IDs can bind to Brf1 in vitro. Further experiments 
should be performed with additional negative controls to demonstrate the specificity of 
binding of ID proteins to Brf1. Other negative controls that could be used can include 
GST fusion proteins that are not known to interact with Brf1 such as the GST-Ras fusion 
protein. Another negative control could be a GST fusion protein whose expression is not 
induced.  This assay cannot distinguish between direct or indirect interactions because 
other proteins were present in the protein extracts used. Other methods could be 
employed to analyse protein-protein interactions such as yeast two-hybrid screening, x-
ray crystallography and fluorescence resonance energy transfer (FRET) techniques. 
Also, strategies for mapping interaction domains could be used such as creating mutants 
lacking various domains and regions of protein sequence as well as site-directed 
mutagenesis.    
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Figure 4.7: Overexpression of GST, GST-ID1, GST-ID2, GST-ID3 and GST-ID2 
mutants HLH and δHLH fusion proteins. 
Expression of GST, GST-ID1, GST-ID2, GST-ID3, GST-ID2 HLH and GST-δHLH 
fusion proteins was performed in E. coli cells. IPTG was used to induce the cells for 2 
hours before harvesting them. The cell pellets were resuspended and sonicated. The GST 
and GST-ID fusion proteins were incubated with glutathione-agarose beads. Protein 
samples were resolved on an SDS-10% polyacrylamide gel. A full length molecular 
weight marker was run next to the samples. 
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Figure 4.8: In vitro transcription/translation using 35S-methionine reveals 
interactions of ID1, ID2, ID3 and ID2 mutants ID2-HLH and ID2 δHLH with 
TFIIIB. 
In vitro translated Brf1 was labelled with 35S-methionine and incubated with GST which 
was used as the negative control or with the GST-ID1, GST-ID2, GST-ID3, GST-ID2 
HLH or GST-δHLH fusion proteins at 4°C with agitation. Proteins retained after 
washing were resolved on an SDS-7.8% polyacrylamide gel and visualised by 
autoradiography. 
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4.2.5 The Brf1 occupancy at a pol III template in vivo is 
specifically reduced in ID2 knockout cells 
 
The interactions of the ID family members with Brf1 might be involved in the 
recruitment of ID proteins to the promoter of pol III templates, leading to the 
transactivation of pol III genes. In a previous study, ChIP assays were performed to 
compare the 5S rRNA gene occupancy in MycER induced and uninduced fibroblasts. 
The results revealed that the induction of c-Myc stimulated the recruitment of Brf1 and 
pol III at 5S rRNA (Kenneth et al., 2007). To examine whether the occupancy of a pol 
III factor such as Brf1, pol III itself and E47 on 5S rRNA genes could be affected by ID2 
in vivo, ChIP assays were performed to determine the occupancy. In order to test this 
hypothesis, MEF ID2 wild-type and ID2 knockout cell lines were used. Initially, the 
genomic DNA inputs from the two cell lines were normalised and the samples adjusted 
accordingly. The occupancy of Brf1, pol III and E47 was diminished at the pol III 
template in the ID2 knockout cell line in comparison to the wild-type MEF cell line 
(Figure 4.9). Interestingly, in the ID2 null cell line, there is reduced enrichment of E47 at 
the 5S rRNA gene compared to the wild type cell line, suggesting that ID2 might be 
recruiting E47 to the promoter. Therefore, the significantly decreased presence of Brf1 
at the pol III template in the ID2 knockout cells reveals changes in the recruitment of 
this factor to the promoter region. In the future, this experiment should be repeated with 
the addition of controls that bind equally in ID2 wild type and ID2 knockout cells, such 
as a histone or TFIIIC for the ChIP assay, in order to exclude the possibility that these 
results do not reflect the decreased growth rate of ID2-/- cells. Also, the protein levels of 
E47, ID2, Pol III and Brf1 should be measured by western blot analysis. The knockdown 
of ID2 could result in the expression or suppression of E47, ID2, Pol III and Brf1 
directly or indirectly and could also result in cells growing at a decreased rate, which 
could then potentially lead to altered pol III transcription. 
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Figure 4.9: Knockout of ID2 decreases the occupancy of Brf1 on 5S rRNA genes.  
Chromatin immunoprecipitation assays were performed using MEF ID2 wild-type and 
ID2 knockout cell lines. ChIP experiments were performed using antibodies against E47 
(N-649), Brf1 (128) and pol III (1900). Beads (no antibody) were used as negative 
control. Samples were normalised by comparing the genomic DNA inputs. The samples 
were analysed by PCR performed on inputs alongside genomic DNA and primers for 5S 
rRNA were used. The “+/+” represents the MEF ID2 wild type compared to the “-/-” 
MEF ID2 knockout cell line.  
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4.3 Discussion 
 
One of the mechanisms that ID proteins use is the formation of complexes with 
transcription factors to sequester them, inhibiting their function and capability to bind 
DNA (Perk et al., 2005). The results presented here revealed that ID proteins are 
associated with pol III templates. In addition, studies have demonstrated that ID1 is 
involved in the stimulation of DNA binding of the transcription factor MIDA1 (mouse 
ID associated protein 1). ID1 is found at the MIDA1-DNA complex and interacts with 
MIDA1 in vivo and in vitro and increases the DNA binding activity of MIDA1 to a 
GTCAAGC sequence (Inoue et al., 1999). MIDA1 is required for cell growth in mouse 
erythroleukaemia cells, and antisense oligonucleotides that block MIDA1 caused 
inhibition of cell growth (Shoji et al., 1995). MPP11 (M-phase phosphoprotein 11) is the 
human orthologue of MIDA1 and overexpression of MPP11 has been observed in head 
and neck carcinomas. Therefore, MIDA1/MPP11 might present a modulator of the 
tumourigenic functions of ID1 (Resto et al., 2000).   
ChIP assays were performed to determine whether ID1, ID2 and ID3 could be 
interacting with the pol III templates to induce pol III-transcribed genes. The results 
revealed that in the HeLa cell line used, ID2 localised at different pol III templates such 
as 5S rRNA and tRNALeu in vivo (Figure 4.2). ID3 does not appear to be present on pol 
III-transcribed genes as strongly as ID2, and there was no signal detected for ID1. A 
possible explanation could be that the antibodies used, which were not ChIP grade, 
cannot efficiently detect ID1 and ID3 in these assays. HEK 293 cells were also used 
which were infected with an ID2-expressing adenovirus. ChIP assays demonstrated that 
when the ID2 protein was overexpressed it exhibited a high enrichment at the promoters 
of pol III templates such as 5S rRNA, tRNALeu, 7SL RNA and U6 snRNA and was 
present at more pol III genes in comparison to the endogenous ID2 protein (Figure 4.3). 
Moreover, in this cell line, overexpressing ID2 by adenovirus infection, E47 is recruited 
to the same pol III templates as above. In addition, ChIP assays performed using U2OS 
cells stably expressing ID3, showed that ID3 localised at the promoters of the pol III 
templates 5S rRNA, tRNALeu, tRNATyr and 7SL RNA (Figure 4.4). The next step 
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involved mapping experiments on the 7SL gene locus, to reveal a potential pol III factor 
that could recruit ID2 to the class III promoters. ID2 co-localised with Brf1 displaying a 
similar distribution pattern at the start of the 7SL gene (Figure 4.5). Therefore, these 
findings suggest that Brf1 might be recruiting ID2 to pol III promoters. These data 
support the theory that it is TFIIIB and not a DNA sequence that recruits ID2 to pol III 
templates. E47 was found to correlate with Brf1 at the same regions as ID2 suggesting a 
possible recruitment by ID2 (Figure 4.5). In conclusion, ID proteins are localised at 
different pol III templates in a number of cell lines. Also, ID2 and perhaps ID1 and ID3, 
might be recruited through a direct interaction by Brf1 to pol III promoters, to regulate 
pol III transcription.  
Previous studies have demonstrated that ID2 can regulate cell growth and cell 
cycle progression by interacting with RB and the related p107 and p130 proteins 
(Iavarone et al., 1994; Lasorella et al., 1996). The RB protein has been shown to affect 
the G1/S phase transition by regulating transcription of genes by pol I, pol II and pol III 
(White et al., 1996; Larminie et al., 1997; Ciarmatori et al., 2001). Specifically, RB 
represses pol III transcription by binding and sequestering the TFIIIB factor from pol III 
promoters (Sutcliffe et al., 2000). ID2 has been shown to interact with the RB family 
and inhibit its function. Furthermore, it has been revealed that ID2 competes with RB for 
TFIIIB and this could be one mechanism by which ID2 upregulates pol III transcription 
(Gomez-Roman N, unpublished observations). Also, the expression of ID2 in fibroblasts 
derived from RB knockout mice still resulted in activation of pol III transcription, 
although this was lower than in wild-type control cells, suggesting that ID2 can also 
stimulate pol III transcription by an RB-independent mechanism. 
 Since experiments described here demonstrated that ID2 and ID3 are present at 
the promoters of pol III templates, likely mechanisms were investigated that may be 
involved in this process. Given that the ID HLH proteins lack a basic region and cannot 
bind DNA, other possible associations were explored (Benezra et al., 1990). Therefore, 
protein-protein interactions of ID1, ID2 and ID3 with the basal transcription factors of 
the pol III apparatus were examined. One of the possible targets of ID proteins is the 
TFIIIB factor which has been shown to interact with and be recruited to TFIIIC by the 
positive regulators of cell growth c-Myc and ERK oncoproteins (Gomez-Roman et al., 
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2003; Felton-Edkins et al., 2003a,b). To determine whether ID proteins can bind to 
TFIIIB, and also to which subunit of TFIIIB they bind, co-immunoprecipitation assays 
were performed. ID1 co-immunoprecipitated with the Brf1 subunit of TFIIIB in vivo 
(Figure 4.6). Moreover, endogenous ID2 interacts with Brf1 (Figure 4.6). In addition, 
Brf1 co-immunoprecipitated with the ID3 protein (Figure 4.6). Since this technique 
cannot distinguish between direct or indirect interactions, the possibility that TFIIIB was 
in a complex with another factor such as TFIIIC could not be eliminated. To determine 
whether ID1, ID2, ID3, ID2 HLH and ID2 δHLH can bind to TFIIIB, in vitro 
transcription and translation studies with 35S-methionine were employed. Initially, the 
ID full length and mutant proteins as well as the control GST were expressed. The 
results revealed that the overexpression and purification of these GST proteins was 
successful (Figure 4.7). Next, data revealed that the ID1, ID2, ID3, ID2 HLH and ID2 
δHLH proteins bind to the radio-labelled Brf1 subunit of TFIIIB (Figure 4.8). The 
interaction of the two mutant ID2 proteins, ID2 with and without the HLH domain, 
suggests that there are two or more possible binding sites of ID2 that are involved in the 
interaction with Brf1. Therefore, ID proteins associate with Brf1 in vivo and in vitro. 
Furthermore, these ID-Brf1 interactions are in agreement with ChIP data establishing 
that Brf1 was present at pol III genes, suggesting that Brf1 could have a role in the 
recruitment of IDs to the promoters of pol III templates.  
The activation of Brf1 expression and therefore pol III transcription results in 
induction of cell cycle progression and proliferation in human and mouse fibroblasts 
(Marshall et al., 2008). The induction of Brf1 also results in tumour formation after the 
injection of clones overexpressing Brf1 into mice (Marshall et al., 2008). In another 
study, ChIP assays performed, comparing wild type and Myc null fibroblast cells, 
revealed that the occupancy of pol III at a tRNA template is lower in the knockout cell 
line (Kenneth et al., 2007; Ernens et al., 2006). p53 has been demonstrated to inhibit the 
association of Brf1 with TFIIIC and pol III. ChIP assays established that induction of 
p53 resulted in a reduction of Brf1 occupancy at a pol III template (Crighton et al., 
2003). Also, pol III occupancy was higher in the knockout p53-/- MEF cells compared to 
the wild type controls (Crighton et al., 2003). 
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The findings that ID proteins are present at pol III-transcribed genes (Figures 4.2, 
4.3 and 4.4) and form complexes with Brf1 in vivo and in vitro (Figures 4.7, 4.9) 
demonstrate recruitment of IDs to pol III templates. To determine whether ID2 is 
involved in the recruitment of Brf1, pol III and E47 on class III genes, MEF ID2 null 
and ID2 wild type cell lines were used. The results from ChIP experiments showed that 
in the ID2 knock-out cells, there was a decrease of Brf1, pol III and E47 enrichment at 
the promoter of the pol III template encoding 5S rRNA, in comparison to cells 
expressing physiological levels of ID2 (Figure 4.9). Since there is a reduction in the 
recruitment of Brf1 in response to ID2 knockout, it is possible that ID2 might be 
involved in the recruitment of Brf1 to pol III templates followed by recruitment of pol 
III and activation of pol III transcription. In addition, results from the decrease of the 
ID2 levels suggest a possible synergistic role for an ID-E47 complex that may be 
involved in the regulation, activation or repression of pol III-transcribed genes. The 
relative promoter binding ability of ID1, ID2 and ID3 could be assessed by expressing 
flag tagged ID1, ID2 and ID3 and chromatin immunoprecipitating using a flag antibody. 
If one of the IDs is present at the promoter more than the others, it can be assumed that 
this is not due to antibody specific issues. Chromatin immunoprecipitation experiments 
could be done using samples in which Brf1 has been overexpressed or depleted to assess 
whether Brf1 recruits IDs and E47 proteins. Also, ChIP on ChIP assays would be helpful 
to identify if Brf1 is present together with IDs and E47 at pol III promoters. 
 In conclusion, the results in this chapter reveal a role for ID1, ID2 and ID3 
proteins and a possible mechanism by which ID proteins may activate pol III 
transcription. This function might allow ID proteins to regulate cell growth and promote 
cancer progression.  
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5.1 Introduction 
 
5.1.1 E2A protein expression and activity 
 
 The E2A proteins were initially discovered in B cells, however northern blots, 
electrophoretic mobility shift assays (EMSA) and western blotting have shown that E2A 
is expressed in most human tissues (Vierra et al., 1994; Aronheim et al., 1993; Jacobs et 
al., 1994). E2A expression varied from cell to cell, with high levels of expression in 
specific areas of the central nervous system, in the lung and pancreas (Rutherford & 
LeBrun, 1998). E2A expression levels are higher in areas of rapid cell differentiation 
(Rutherford & LeBrun, 1998). Owing to the large number of HLH proteins, a sub-
classification system has been based on tissue distribution, dimerisation abilities and 
DNA binding specificities (Murre et al., 1994). The class I HLH proteins are known as 
the E-proteins and include E47, E12, E2-5, HEB and E2-2; they are structurally similar 
and ubiquitously expressed (Figure 5.1, A). The class II HLH proteins, which include 
MyoD, TAL1/SCL (stem cell leukaemia) and LYL1 (lymphoblastic leukaemia 1), show 
a tissue restricted expression (Figure 5.1, B); with a few exceptions they are not capable 
of forming homodimers and prefer to heterodimerise with the E-proteins (Massari & 
Murre, 2000). Class I and class II proteins can bind to E-box sites. Class III HLH 
proteins include the Myc and TFE3 (transcription factor E3) proteins and contain a 
leucine zipper adjacent to the HLH domain (Henthorn et al., 1991; Zhao et al., 1993). 
Class IV proteins, which include the Mad and Max proteins are capable of dimerising 
with Myc or with each other. Another class of proteins that can heterodimerise with 
class I and class II proteins are the class V proteins. These include the ID and emc 
proteins, which lack a basic region and cannot bind to DNA (Norton, 2000). Class V 
proteins inhibit DNA binding of class I and class II proteins, and therefore regulate their 
transcriptional activity (Massari & Murre, 2000).   
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Figure 5.1: Schematic diagram of bHLH protein and their domains. 
A. Schematic representation of the class I HLH proteins E47, E12, HEB and E2-2 
known as E-proteins. Important domains are shown such as activation domain (AD) 1, 
AD2 and bHLH. Different transcription initiation sites result in canonical (Can) and 
alternative (Alt) forms of HEB and E2-2 proteins. B. Stem-cell leukaemia factor SCL 
also referred as TAL1 and LYL1 belong to class II HLH proteins. Shading indicates 
regions of homology (taken from Kee, 2009). 
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5.1.2 The structure of the E2A gene and protein 
 
The crystal structure of the transcription factor E47 revealed a four-helix bundle 
with the two protruding helices being parallel to the DNA site (-CACCTG-) (Figure 5.2) 
(Ellenberger et al., 1994). The E47 and E12 transcription factor proteins were initially 
discovered as immunoglobulin enhancer-binding proteins binding to E-boxes (Murre et 
al., 1989). Also, they have been found at 5’-regulatory regions of lineage-restricted 
genes (Massari & Murre, 2000). The E47 and E12 proteins consist of a basic region, 
which is required for DNA binding, and an HLH structure that is critical for 
dimerisation. These bHLH proteins are involved in the regulation of cell growth and 
differentiation of cell-lineages including muscle cells and neurons (Reya & Grosschedl, 
1998; Massari & Murre, 2000). The E47 and E12 proteins arise from the E2A gene 
through differential splicing of the exon encoding the bHLH domain. The amino acid 
sequences of the bHLH domains of these two proteins differ by 20% (Murre et al., 
1989). Although both E47 and E12 transcription factors have the ability to form 
heterodimers with class II HLH members, E47 and E12 have distinct biochemical 
properties (Chakraborty et al., 1991; Lassar et al., 1991). The E47 homodimer binds 
with relatively high affinity to DNA, however, the E12 homodimer interacts weakly 
with DNA (Sun & Baltimore, 1991). 
The E2A gene is composed of four exons and one non-coding exon and spans 
about 16 kb (Hata & Mizuguchi, 2004). The promoter lacks TATA and CAAT boxes, 
but has possible binding sites for GATA -1/ -2 (Lowry & Atchley, 2000), CREB (Mayr 
& Montminy, 2001) and Sp1 (stimulating protein 1) (Briggs et al., 1986). TATA-less 
promoters are found in a number of genes that usually have a variable transcription 
initiation site and are expressed ubiquitously in cells (Azizkhan et al., 1993). Primer 
extension analysis has shown several transcription start sites in the E2A gene (Hata & 
Mizuguchi, 2004; Smale, 1997). A transient transfection assay using a 5’-flanking 
region has shown that the promoter activity can be regulated both by positive and 
negative ways, which is usual in the regulation of genes in eukaryotes (Ogbourne & 
Antalis, 1998; Hata & Mizuguchi, 2004). Deletion analysis revealed that the -257/ -238 
segment plays a crucial role in the basal promoter activity of the E2A gene. Mutational 
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analysis of the -257/ -238 region did not show a single cis-element responsible for basal 
promoter activity, therefore it is possible that positive regulatory elements might interact 
with the E2A promoter. EMSA assays have shown that a positive regulatory segment 
and putative transcription factor(s) might be required for the basal activity of the E2A 
gene (Hata & Mizuguchi, 2004). Sequence analysis of the E2A gene comparing the 
human, mouse and chicken sequences showed that the sequences that are highly 
conserved corresponded to important functional domains such as the bHLH domain 
(Conlon & Meyer, 2004). The DNA binding and dimer-assembly domains of the E47 
and E12 proteins are present at their C-terminal domain. The E2A gene transcriptional 
activation domains are mapped to the N-terminal regions (Murre et al., 1989).    
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Figure 5.2: Schematic representation of the E47 crystal structure.  
A. The E47 bHLH domain is a parallel four-helix bundle with two protruding helices 
shown in green and yellow. DNA (in red) contacts are made by the basic regions of the 
helices. B. Diagram of the E47 subunit contacts; each subunit of the E47 dimer interacts 
with one half of the -CACCTG- binding site. C. DNA base and phosphate contacts of 
the E47/DNA complex (taken from Ellenberger et al., 1994). 
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5.1.3 Activation of transcription by E-proteins  
 
E-proteins are involved in expression of B lineage-specific genes and have been 
found to function as transcriptional activators (Henthorn et al., 1990). It has been shown 
that the activation domains AD1 and AD2 of E2A are involved in the regulation of 
target genes in vivo (Qiu et al., 1998). When the N-terminal transactivation domain is 
deleted the E12 protein can no longer activate B lineage-specific gene expression in a 
macrophage cell line (Kee & Murre, 1998). The AD1 and AD2 domains of the E2A 
proteins are located in the N-terminal transactivation domain and contain the 
transcriptional activity (Aronheim et al., 1993; Massari et al., 1996). Furthermore, the 
AD1 and AD2 domains have been found to be functionally conserved in both 
mammalian cells and in the yeast S. cerevisiae (Quong et al., 1993; Massari et al., 
1996).  
The coactivator p300 has been shown to cooperate with tissue-specific bHLH 
proteins such as MyoD by binding to the bHLH domain of the protein and activating 
target genes (Figure 5.3) (Eckner et al., 1996). Because p300 has been demonstrated to 
contain HAT activity it is possible that the E47 protein can recruit proteins that are 
involved in chromatin modification; p300 can modify chromatin structure to a locally 
open transcriptionally active configuration (Bannister & Kouzarides, 1996; Ogryzko et 
al., 1996; Eckner et al., 1996). The binding of MyoD to p300 is mediated by the bHLH 
domain of MyoD, and this was unexpected because the bHLH motif does not contain 
intrinsic transactivation potential (Eckner et al., 1996). When p300/CREB binding 
protein (p300/CBP) antibodies where microinjected into myoblasts, terminal 
differentiation and transcriptional activity of myogenic bHLH proteins were blocked. 
These findings indicate that p300/CBP has an important role in cellular differentiation 
(Eckner et al., 1996). In another study, p300 was shown to interact with the E47 protein 
stimulating the transcription of the insulin gene (Qiu et al., 1998). However, the 
sequences of E47 required for this response span the activation domains AD1 and AD2 
(amino acids 1 to 99 and 325 to 432). The sequence of p300 involved in the interaction 
and activation of E47 is between amino acids 1 to 1257, which is within the N-terminal 
domain of p300 (Qiu et al., 1998).   
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Studies have identified a sequence LDFS, present in vertebrate HLH proteins and 
yeast HLH proteins, which is required for transactivation (Massari et al., 1999). The 
conserved LDFS motif induces transcription by recruiting a nuclear HAT complex 
termed SAGA. The AD1 transactivation domain directly interacts with the SAGA 
complex, which is conserved throughout evolution. The SAGA complex consists of 
many subunits such as the TAFs (TBP-associated factors), the Ada and Spt proteins, the 
HAT Gcn5 and Tra1 (Grant et al., 1998a,b). Activation by the LDFS domain requires 
functional Ada2 and Gcn5 proteins. Amino acid substitutions in the AD1 domain disrupt 
SAGA binding and inhibit transcriptional activation in vivo (Massari et al., 1999). Also, 
in a number of yeast strains that lack a functional SAGA complex, AD1 is unable to 
induce transcription (Massari et al., 1999). Furthermore, studies have shown that E2A is 
acetylated in vitro by p300, CBP and PCAF (p300/CBP-associated factor) (Bradney et 
al., 2003). In conclusion, these studies indicate that E47 may in some cases induce 
transcription by recruiting HAT complexes to target genes. 
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Figure 5.3: Schematic representation of E-protein dimers and their function. 
E-protein homodimers are bound to target genes and act as activators with the 
recruitment of co-activators such as p300/CBP. E-protein class II bHLH proteins are 
bound to target genes and can act as transcriptional repressors by the recruitment of co-
repressors like mSin3A or ETO (taken from Kee, 2009). 
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5.1.4 Regulation of E47 protein level by the ubiquitin-
proteasomal pathway 
 
 E47 proteins are degraded through the ubiquitin-proteasome system which is a 
basic cellular mechanism of post-translational regulation. The degradation of a protein is 
a three step process that is initiated with the formation of a ubiquitin-conjugate with a 
ubiquitin-activating enzyme (Haas & Siepmann, 1997). Ubiquitin is moved to a 
ubiquitin-conjugating enzyme, which transports ubiquitin to an amino group of a lysine 
residue on a substrate protein. The ubiquitin-conjugating enzymes consist of 12 families, 
which together with several ubiquitin ligases are required for ubiquitin conjugation 
(Haas & Siepmann, 1997). When the ubiquitin conjugate is made, a multi-ubiquitin 
complex is assembled that becomes a signal for proteolysis by the 26S proteasome. 
  The mammalian Ubc9 (mUbc9) is required for the degradation of the E47 
proteins by the ubiquitin-proteasomal pathway (Huggins et al., 1999). mUbc9 interacts 
with E47 at the 477-530 amino acid region (Kho et al., 1997). The mUbc9 sequence is 
highly conserved among the human, mouse and rat species (Kovalenko et al., 1996) and 
several mUbc9 binding partners are known (Firestein & Feuerstein, 1998). The region 
that is rich in proline, glutamic acid, serine and threonine (PEST) residues is thought to 
be the E47 (478-531) degradation domain (DD). E47 proteins with a deletion mutation 
lacking the region, E47∆ (478-531), were more stable than the wild-type E47, exhibiting 
a half-life of 6 hours compared to 55 minutes (Huggins et al., 1999). Also, 
overexpression of the full-length Ubc9 antisense construct reduces the degradation of 
E12 (Kho et al., 1997). Deletion of the DD domain of E47 had no effect on the 
transcriptional activity and E-box binding of E47. Two regions that interact with Ubc9 
were mapped in the E47DD, the 476-494 and 505-513 regions. The E47 (505-513) 
region interacts with Ubc9, but not with the Ubc5, ID3 and MyoD proteins. Substitution 
of the central hydrophobic residues of the E47 (505-513) region with basic residues 
inhibited its interaction with Ubc9. The E47 protein that lacks the second region which 
interacts with Ubc9 was more stable than the wild-type E47 (Huggins et al., 1999).  
When the E2A DD was reintroduced into the oncoprotein E2A-HLF this 
destabilised it, such that degradation was quicker than with the wild-type E2A-HLF 
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(half-life of 60 minutes compared to more than 2 hours); this hints that the DD domain 
can transfer a signal to a heterologous protein. The E2A-HLF-DD was stabilised by a 
proteasome inhibitor LLNL, which shows that the E2A-DD targets proteins for 
degradation through the proteasome. The E2A-DD domain is very important since every 
chromosomal translocation that produces a chimeric E2A-oncoprotein lacks the exon 
that encodes the degradation domain. The longer half-life of E2A-HLF may increase its 
transforming ability by allowing more protein to accumulate and activating transcription 
(Honda et al., 1999). The prolonged half-life of a stable protein can be decreased by the 
addition of a degradation domain (Hochstrasser & Varshavsky, 1990; Yaglom et al., 
1995).   
 It has been shown that E47 modulates cellular localisation and degradation of the 
ID1 protein (Lingbeck et al., 2005). Expression of E47 stabilises ID1 and causes an 
increase in the t1/2 from ~1 hour to ~8 hours. Also, co-transfection of an NLS deficient 
ID1 (ID1NLS) with E47 led to an altered intracellular localisation of ID1NLS from 27% 
nuclear to >95% nuclear. In another study, it was demonstrated that E47 is primarily 
localised in the nucleus in C2C12 myoblasts and myotubes (Sun et al., 2007). Incubating 
cells with MG132, a proteasome inhibitor, stabilised E47, which suggests that the 
ubiquitin-proteasomal pathway is responsible for degradation of E47.  
Notch signaling is also involved in E47 ubiquitination and degradation by MAP 
kinase activities (Nie et al., 2003). Studies have shown that activation of Notch 1 and 
Notch 2 inhibits the transcriptional activity of E47, which is crucial for B and T 
lymphocyte development (Ordentlich et al., 1998). Notch signaling is also important for 
lymphocyte development. In order to induce degradation of E47, Notch requires 
phosphorylation of E47 by p42/p44 MAP kinases. Notch-induced degradation of E47 
relies on RBP-Jκ, its downstream effector, to possibly activate expression of genes 
involved in E47 ubiquitination (Nie et al., 2003). Therefore, Notch signaling may 
regulate lymphocyte development by controlling E47 protein degradation.   
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5.1.5 E47 regulation by protein phosphorylation 
 
 E47 proteins are widely expressed and it is believed that B cell-restricted DNA 
binding by E47 homodimers is regulated by protein modifications. To investigate the 
properties of B cells that allow DNA binding by E47 homodimers, studies have 
concentrated on E47 phosphorylation (Sloan et al., 1996). Using an N-terminal 
truncation of E47, it was demonstrated that the phosphorylation of two serine residues 
was responsible for inhibition of DNA binding by E47 homodimers in vitro. The two 
serines N-terminal of the E47∆ mutant protein are phosphorylated in several cell types; 
however they are hypophosphorylated in B cells. When the two serine residues were 
phosphorylated in vitro this caused inhibition of DNA binding by E47∆ homodimers. 
However, E47∆-MyoD heterodimers were able to bind DNA. Therefore, 
hypophosphorylation may be important for the activity of E47 homodimers in B cells 
(Sloan et al., 1996). Phosphorylation affects the activity of several transcription factors 
(Karin, 1994). The CREB and TCF/Elk-1 are stimulated by serine phosphorylation and 
the STAT proteins are activated by tyrosine phosphorylation (Gille et al., 1992; Shuai et 
al., 1993). Studies have demonstrated that Ser-514 and Ser-529, which are located N-
terminal to the bHLH domain of E47, are phosphorylated by CK2 and protein kinase A 
(Sloan et al., 1996). Phosphorylation also has a role in regulating the degradation of 
many proteins such as cyclin D, IκBα and c-Jun (Diehl et al., 1997; Chen et al., 1996; 
Musti et al., 1997). The E47 degradation domain is rich in PEST residues, which often 
serve as phosphoacceptor sites (Huang et al., 1998). Studies show that cdc28 
phosphorylation of the cyclin 3 PEST domain reduces the half-life of Cln3 (Yaglom et 
al., 1995). The E47 protein has several possible phosphorylation sites and deleting the 
E47 degradation domain permits multiphosphorylated E47 to accumulate. It is possible 
that hyperphosphorylation of E47∆ (478-531) leads to events that initiate E47 protein 
degradation (Huggins et al., 1999).   
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5.1.6 The role of E47 in cell growth  
 
 A number of studies have indicated that E2A gene products are involved in 
regulating cell growth. Apart from the HLH region which is required for growth 
inhibition by the MyoD family, the E2A proteins also have two additional inhibitory 
regions that are active in the absence of the HLH domain. These regions are in the N-
terminal and central region of E47/E12 and correspond to the transactivation domain of 
the proteins (Aronheim et al., 1993; Quong et al., 1993). When E47 was overexpressed 
in colony-forming assays, this suppressed the growth of NIH3T3 cells (Peverali et al., 
1994). This growth suppressive effect was counteracted by the ID proteins. However, 
when E47 was used that lacked the HLH domain, ID proteins could no longer reverse 
the growth inhibition. When E47 was overexpressed or ID proteins were neutralised, this 
led to inhibition of proliferation in the G1 phase until 3-4 hours before entering the S 
phase. The antagonism between E47 and ID proteins appears to be involved in 
regulating critical G1 progression (Peverali et al., 1994). It has been shown that E2A null 
mice develop rapid T cell lymphomas, the B lymphocyte development is completely 
blocked and abnormalities appear in the αβ T cell development (Bain et al., 1994; Bain 
et al., 1997; Yan et al., 1997). Disruption of the ID1 gene improves the survival rates of 
E2A gene-null mice, suggesting that ID1 interacts with E2A and that the unbalanced 
function of ID1 affects E2A null mice (Yan et al., 1997). However, the E47/ID1 double 
knock-out mice continued to develop T cell tumours. Therefore, E2A might be involved 
in maintaining the homeostasis of T lymphocytes. Ectopic expression of E47 or E12 
induces the death of E2A-deficient lymphomas (Engel & Murre, 1999). E2A-expressing 
cells were eliminated from cultures into which E47 and E12 were introduced. This was 
not due to an arrest in cell cycle progression, but because E2A proteins activate a 
programmed cell death pathway in these lymphomas. Loss of mitochondrial 
transmembrane potential precedes the E2A-mediated cell death. These data imply that 
E47 and E12 proteins can act as tumour suppressors.  
Several forms of T cell acute lymphoblastic leukaemias (T-ALL) are 
characterised by high expression of class II HLH proteins, such as TAL1/SCL and 
LYL1 (Miyamoto et al., 1996; Voronova & Lee, 1994). The activation of the bHLH 
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TAL1/SCL gene occurs by chromosomal translocation or mutation in patients with T-
ALL who respond poorly to existing therapies. Studies have demonstrated that 
TAL1/SCL induces leukaemia by interfering with E47 and HEB target genes, which are 
important for thymocyte differentiation and survival (O’Neil et al., 2004). The 
TAL1/SCL oncogene was expressed in mice in an E2A or HEB heterozygous 
background resulting in differentiation arrest and disease progression, therefore 
decreased expression of E2A and HEB plays an important role. E47/HEB heterodimers 
are shown to regulate cluster of differentiation 4 (CD4) expression by recruiting the 
p300 coactivator. In TAL1/SCL/E2A+/- or TAL1/SCL/HEB+/- thymocytes CD4 
expression is decreased. Unlike ID proteins which operate by inhibiting the binding of 
E-proteins to DNA, TAL1/SCL represses gene transcription by recruitment of the 
mSin3A/HDAC1 (histone deacetylase 1) corepressor complex to the E47/HEB target 
CD4 and other genes (Figure 5.3) (Kee, 2009).  
The AML1-ETO fusion protein occurs due to a t(8;21) chromosomal 
translocation  and is implicated in 15% of acute myeloid leukaemia cases. The AML1-
ETO fusion protein binds to E-proteins and converts them to transcriptional repressors 
(Zhang et al., 2004). AML1-ETO inhibits E-protein mediated transcriptional activation 
by interactions that preclude recruitment of coactivators such as p300/CBP. The 
interaction of the AML1-ETO with the AD1 domain of the promoter-bound E-proteins 
reveals a silencing mechanism by directing an exchange of cofactors, HATs against 
histone deacetylases (HDACs) (Figure 5.3). Therefore, E-proteins are targets of AML1-
ETO and their deregulation may play a role in leukaemia, suggesting a mechanism 
which is different from differentiation-inhibitory proteins.  
The results discussed here demonstrate that E47 is involved in the regulation of 
cell growth (Pagliuca et al., 2000; Zheng et al., 2004). E47 negatively regulates cell 
growth by inhibiting cell cycle progression and promoting cell death (Rothschild et al., 
2006; Engel & Murre, 1999). Cells overexpressing E47 in several cell types grow at a 
slower rate than untreated control cells (Peverali et al., 1994). Pol III transcripts are 
important in determining growth rate, since they are involved in protein synthesis. 
Studies have demonstrated that suppressor proteins such as RB, p53 and Maf1 are likely 
to affect the rate of cell growth by regulating pol III transcription (Sutcliffe et al., 2000; 
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Crighton et al., 2003; Goodfellow et al., 2008). This chapter will address if E47 
regulates pol III transcription. Since E47 is an important regulator of cell growth and 
also transcripts of pol III are required in the same process, it is possible that E47 
expression may trigger repression of pol III activity. The following experiments were 
designed to assess if indeed this is occurring. The results in this chapter reveal that pol 
III transcription is downregulated by the expression of the E47 transcription factor 
protein and expose a mechanism by which E47 regulates pol III activity. In this chapter 
only the relationship between E47 and pol III transcription was investigated and not of 
other E-protein family members.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 Repression of RNA Polymerase III Transcription by E47  
158 
 
5.2 Results 
 
5.2.1 Knockdown of E2A by RNAi raises the levels of pol III 
transcripts 
 
E47 depletion has been demonstrated to promote cell growth (Zheng et al., 
2004). When cells were treated with siRNA against E47, this led to inhibition of 
expression of p16INKα and cells displayed an extended proliferative lifespan. E2A 
deficient mice develop abnormalities and are prone to malignancies (Bain et al., 1997; 
Yan et al., 1997).  Since pol III transcripts are required for steady cell growth, it is likely 
that negative regulators of this process would repress pol III transcription. To determine 
whether the E47 protein has an effect on pol III transcription in vivo in human cells, 
small interfering RNA was used. HeLa cells were transfected with siRNA against E2A 
and the control Oct-1. The cells were treated for 48 hours and harvested. Protein extracts 
and RNA were analysed. Western blot analysis revealed that E47 protein levels were 
significantly reduced compared to the control Oct-1. In addition, it was shown that in the 
E2A siRNA-transfected HeLa cells the associated ID1, ID2 and ID3 proteins remained 
at the same levels. Actin was used as a loading control (Figure 5.4, A). RT-PCR analysis 
demonstrated the knockdown of E2A RNA levels in comparison to the control Oct-1 
with the ARPP P0 mRNA used as a loading control (Figure 5.4, B).  
The next step was to identify if this knockdown of the protein and RNA levels of 
E47 and E2A respectively would have an effect on pol III transcription. RT-PCR 
analysis revealed that the knockdown of E2A has a significant effect on the levels of 5S 
rRNA, tRNAArg, tRNALeu, tRNASec, tRNATyr, 7SL RNA, 7SK RNA, MRP, and U6 
snRNA (Figure 5.5). The knockdown of E2A results in an increase in the levels of these 
pol III transcripts compared to the control. Also, another effect of this knockdown is the 
increase in the levels of a pol I transcript, the pre-rRNA (Figure 5.5). These effects are 
specific, as the pol II transcribed ARPP P0 mRNA does not change in response to E2A 
knockdown. From these results it can be concluded that E2A has a negative effect on pol 
I and pol III transcript expression in vivo. 
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Figure 5.4: Knockdown of E47 by RNAi. 
HeLa cells were transfected with E2A siRNA or the control Oct-1 siRNA. A. Western 
blot analysis of E47, ID1, ID2 and ID3 expression, following transfection with siRNA 
against E2A. Actin was used as the loading control. B. RNA was analysed by RT-PCR 
for E2A depletion by siRNA. The pol II-transcribed mRNA ARPP P0 was used as the 
loading control. 
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Figure 5.5: Knockdown of E47 by RNAi increases the levels of pol I and III 
transcripts. 
Effects of the E47 knockdown by siRNA against E2A in HeLa cells after transfection 
for 48 hours. RNA was analysed by RT-PCR for the expression of the pol III transcripts 
5S rRNA, tRNAArg, tRNALeu, tRNASec, tRNATyr, 7SL RNA, 7SK RNA, MRP, and U6 
snRNA. The pol I transcript pre-rRNA was also analysed. The ARPP P0 mRNA was 
used as a control. 
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5.2.2 Overexpression of E47 reduces the levels of pol III 
transcripts 
 
Overexpression of E47 has been found to cause growth arrest in NIH3T3 cells 
(Peverali et al., 1994). In addition, enforced expression of E47 suppresses the cell 
growth efficiency of several cell lines (Pagliuca et al., 2000). Ectopic expression of E47 
in lymphoma cell lines derived from E2A deficient mice results in cell death of E2A-
expressing cells (Engel & Murre, 1999). To investigate if E47 can downregulate pol III 
activity in vivo in human cells, adenovirus infection was used. HEK 293 cells were 
infected with an adenovirus expressing E47 (Ad-E47) or with the parental virus 
adenovirus-cytomegalovirus 5’ internal ribosomal entry site green fluorescent protein 
(Ad-Vector). The infection was left to proceed for 24 hours and the cells were harvested. 
RNA and protein extracts were analysed. Western blotting reveals that infection with the 
E47 adenovirus results in overexpression of the E47 protein, compared to the control 
vector (Figure 5.6, A). This effect is specific, since actin was used as loading control and 
remains at the same levels in both lanes. RT-PCR analysis demonstrated that the 
overexpression of E47 resulted in an increase in the RNA levels of E2A compared to the 
control empty vector (Figure 5.6, B). The ARPP P0 loading control did not change, 
which suggests that the effect is specific. To investigate if increased E47 protein and 
E2A RNA levels would have an effect on pol III transcripts, RT-PCR experiments were 
performed. The results revealed that the levels of 5S rRNA, tRNAArg, tRNALeu, tRNASec, 
7SK RNA and MRP, were reduced after overexpression of E47 (Figure 5.7). This effect 
is specific, since the pol II transcript encoding ARPP P0 remains unchanged. These 
results demonstrate that overexpression of E47 reduces pol III transcription.   
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Figure 5.6: Overexpression of E47 by adenovirus infection. 
HEK 293 cells were infected with an adenovirus expressing E47 or with the control 
vector. A. Western blotting of E47 with cells harvested 24 hours after infection with 
adeno-E47 (Ad-E47) or adenovirus vector (Ad-Vector). Actin was used as loading 
control. B. RT-PCR analysis for the overexpression of E2A. The pol II-transcribed 
mRNA ARPP P0 was used as control.   
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Figure 5.7: Overexpression of E47 by adenovirus infection decreases the levels of 
pol III transcripts. 
Effects from adenoviral expression of E47 in HEK 293 cells. Cells were harvested after 
24 hours infection with Ad-E47 or Ad-Vector. RNA was analysed by RT-PCR for the 
expression of 5S rRNA, tRNAArg, tRNALeu, tRNASec, 7SK RNA and MRP. The ARPP 
P0 mRNA was used as the control. 
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5.2.3 E47 localises at pol III-transcribed genes in vivo 
 
E47 has been found to bind to the promoters of the p16 and p21 genes, which 
leads to cell growth arrest (Prabhu et al., 1997; Zheng et al., 2004). E47 binds to E-box 
sequences of these promoters and other pol II-transcribed genes (Murre et al., 1989; 
Perez-Moreno et al., 2001). However, pol III templates rarely contain E-box DNA 
promoter sequences which could be potentially targeted by E47. The results so far have 
indicated that E47 can influence pol III transcription. The effects from knocking down 
and overexpressing E47 imply a possible mechanism by which E47 interacts with the 
pol III transcription apparatus. This interaction with the pol III templates could lead to 
the repression of pol III activity. To investigate if endogenous E47 is present on pol III-
transcribed genes in vivo, chromatin immunoprecipitation assays were performed in 
HeLa cells. Antibodies against E47, TBP, Brf1, pol III, TFIIIC, TFIIA and TFIIB were 
used to precipitate the proteins that were cross-linked to chromatin. TBP, Brf1, TFIIIC 
and pol III were used as positive controls, TFIIA, TFIIB and beads were used as 
negative controls. The results reveal that endogenous E47 is present at pol III-
transcribed genes such as 5S rRNA and tRNALeu (Figure 5.8). This experiment could be 
repeated in order to obtain a better exposure for figure 5.8, tRNALeu. The positive 
controls TBP, Brf1, pol III and TFIIIC are present on these templates as expected and 
the negative controls TFIIA, TFIIB are not detected. These data indicate that the 
association of endogenous E47 with pol III-transcribed genes in vivo is specific.  
 Another human cell line, HEK 293 cells, were used to investigate if E47 can 
occupy pol III-transcribed genes in vivo. Cells were infected with an adenovirus 
expressing E47 and harvested 24 hours post-infection. Chromatin immunoprecipitation 
assays were performed in cells in which E47 was overexpressed. The positive controls 
Brf1, TFIIIC and pol III are present at 5S rRNA and tRNALeu and 7SL genes, whereas 
the negative control TFIIA is not detected (Figure 5.9). It was found that overexpression 
of E47 results in strong detection on pol III-transcribed genes, like 5S rRNA and 
tRNALeu and 7SL genes (Figure 5.9). This interaction is specific and not due to over 
cross-linking of proteins to DNA, since no signal was detected when primers were used 
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for the pol II-transcribed ARPP P0 gene. These results demonstrate that the association 
of E47 with class III genes is specific. 
 A stable U2OS cell line stably expressing ID3 was also used to detect if E47 was 
present on pol III-transcribed genes in vivo. Chromatin immunoprecipitation assays 
revealed that E47 was recruited at tRNAArg and 7SL genes (Figure 5.10). E47 is not 
associated with the pol II-transcribed gene encoding ARPP P0. Therefore, these results 
demonstrate the binding of E47 to pol III-transcribed genes. Future experiments could 
include the use of a U2OS cell line expressing an empty vector control to allow 
comparison with U2OS cells expressing ID3. 
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Figure 5.8: Endogenous E47 occupancy on pol III-transcribed genes. 
Chromatin immunoprecipitations were performed using HeLa cells. The N-649 antibody 
was used against E47. FL-109 and C-18 antibodies were used against the TFIIA and 
TFIIB negative controls respectively. TBP (MTBP-6), Brf1 (128), TFIIIC (Ab7) and pol 
III (1900) antibodies were used as positive controls for pol III-transcribed genes. The 
immunoprecipitated DNA samples were analysed by PCR performed on inputs and 
primers against 5S rRNA and tRNALeu genes. 
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Figure 5.9: E47 is present at pol III-transcribed genes. 
Chromatin immunoprecipitations were performed using HEK 293 cells harvested 24 
hours after adenoviral expression of E47. The TFIIA (FL-109) antibody and beads were 
used as negative controls. The N-649 antibody was utilised for E47. The Brf1 (128), 
TFIIIC (Ab7) and pol III (1900) antibodies were used as positive controls. The samples 
were analysed by PCR performed on inputs and primers against 5S rRNA, tRNALeu and 
7SL RNA genes. 
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Figure 5.10: E47 is recruited to pol III-transcribed genes. 
Chromatin immunoprecipitations were performed using a U2OS cell line stably 
overexpressing ID3. The TFIIA (FL-109) antibody and beads were used as negative 
controls. The N-649 antibody was utilised for E47. Brf1 (128), TFIIIC (Ab7) and pol III 
(1900) antibodies were used as positive controls for pol III-transcribed genes. The 
samples were analysed by PCR performed on inputs and primers against tRNAArg and 
7SL RNA genes. 
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5.2.4 Mapping of E47 on the 7SL locus 
 
 Chromatin immunoprecipitation experiments have revealed that E47 localises to 
the promoter of pol III-transcribed genes. To determine if E47 co-localises with the 
basal transcription factors TFIIIB and TFIIIC on pol III promoters, mapping of the 7SL 
gene locus was carried out. Five sets of primers were designed, upstream of the gene, at 
the gene and downstream of the pol III-transcribed 7SL coding region (Figure 5.11, A). 
HEK 293 cells were infected with an adenovirus expressing E47. Cells were harvested 
after 24 hours and PCR was used to amplify the DNA extracted from chromatin 
immunoprecipitation assays. The results revealed that the basal transcription factors 
TFIIIB and TFIIIC exhibit a different distribution on the 7SL locus (Figure 5.11, B). 
E47 co-localises with Brf1 and TFIIIC on the second and third position of the pol III 
template (Figure 5.11, C). Also, a very exciting result, revealed by using this E47 
infected cell line, was that ID1 and ID2 are recruited to the 7SL locus. ID1 and ID2 co-
localise with Brf1 at the start of the gene on the second position, and decrease at the end 
of the gene at position three (Figure 5.11, C). However, ID3 does not appear to localise 
on the 7SL locus (Figure 5.11, B). Therefore, from these results E47 co-localises with 
Brf1 and TFIIIC. Co-immunoprecipitation experiments are required to test for 
interactions of E47 with these basal factors that might recruit E47 to pol III-transcribed 
genes. ID1 and ID2 appear to co-localise with Brf1 rather than TFIIIC, suggesting that 
ID1 and ID2 are recruited by TFIIIB. For the recruitment of IDs to pol III-transcribed 
genes, a HEK 293 cell line overexpressing GFP could be compared to the HEK 293 cells 
overexpressing E47. Also, the effect of overexpression of E47 on the protein levels of 
Pol III, TFIIIC, ID2, ID1 and Brf1 should be determined by western blotting. The 
overexpression of E47 could potentially lead to the expression or suppression of basal 
pol III factors or ID proteins directly or indirectly which could then result in affecting 
pol III transcription. In the future, western blotting experiments should be done in order 
to determine whether the levels of ID and E47 proteins change upon overexpression or 
knockdown of ID and E47 proteins. Results have demonstrated that when the ID2 or 
E47 proteins are overexpressed the protein levels of each other do not change 
(Rothschild et al., 2006). 
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Figure 5.11: Mapping of E47 on the 7SL locus. 
Chromatin immunoprecipitations were performed in HEK 293 cells harvested 24 hours 
after adenoviral expression of E47. A. Diagram of the five positions used to design 
primers on the 7SL locus. B. The ID1 (C-20), ID2 (C-20), ID3 (C-20), E47 (N-649), 
Brf1 (128), TFIIIC (Ab7) and pol III (1900) antibodies were used for ChIP assays. The 
TFIIA (FL-109) antibody and beads were used as negative controls. C. Graphical 
representation of the ChIP assay. The x-axis shows the five sets of primers. The Y-axis 
represents the ChIP signals that were normalised against the input and the signals with 
the TFIIA negative control. 
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5.2.5 E47 co-immunoprecipitation with Brf1 
 
 Chromatin immunoprecipitation assays have revealed that E47 can be recruited 
to pol III-transcribed genes in vivo. Mapping experiments on the 7SL locus indicate that 
E47 may co-localise together with TFIIIB and TFIIIC. It is therefore possible that E47 
could bind directly or indirectly to specific factors such as TFIIIB and TFIIIC. E47 can 
form homodimers or heterodimers and bind to DNA through E-box sequences on pol II-
transcribed genes (Murre et al., 1989). Pol III templates rarely contain E-box DNA 
sequences which could be targeted by E47. Thus, E47 is more likely to regulate pol III 
transcription by protein-protein interactions with one or more factors of the pol III 
apparatus. TFIIIB is a plausible target, since it is a transcription factor that is regulated 
by a number of different tumour suppressor proteins such as RB, p53 and Maf1 
(Sutcliffe et al., 2000; Crighton et al., 2003; Goodfellow et al., 2008). To determine if 
E47 can interact with endogenous TFIIIB, co-immunoprecipitation assays were 
performed. Western blot analysis revealed that the Brf1 subunit of TFIIIB was able to 
co-immunoprecipitate with endogenous E47 in HeLa nuclear extracts (Figure 5.12). This 
interaction is specific since no signal was detected with the negative control TFIIB. 
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Figure 5.12: Co-immunoprecipitation demonstrates interaction of E47 with Brf1. 
HeLa nuclear extracts were used for the co-IP experiments. The TFIIB (C-18) antibody 
and beads were used as negative controls. The extracts were immunoprecipitated with 
the E47 (N-649) and Brf1 (128) antibodies. Immunoprecipitated material was resolved 
on an SDS-7.8% polyacrylamide gel and analysed by western immunoblotting with the 
128 antibody against Brf1. 10% of input material was used. 
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5.2.6 E47 interacts with Brf1 and TFIIIC 
 
Protein co-immunoprecipitation experiments identified the interaction of E47 
with Brf1. However, using the above assay it is not possible to distinguish between 
direct or indirect binding. To determine if E47 can interact with TFIIIB and TFIIIC, in 
vitro transcription and translation assays using 35S-methionine were performed. In order 
to test this hypothesis the first step involved the expression of GST-fusion proteins, such 
as GST-E47, and the negative empty vector control GST. The results demonstrate that 
the overexpression of the GST-E47 fusion protein was successful (Figure 5.13). The 
GST-E47 protein has a molecular weight of about 103 kDa, however, there are 
breakdown products. The GST control vector has a molecular weight of about 25 kDa. 
The Brf1 and TFIIIC110 subunits were in vitro translated and labelled with 35S-
methionine. Incubating the GST and GST-E47 protein with Brf1 revealed that E47 binds 
to Brf1 (Figure 5.14, A). Also, E47 binds to the TFIIIC110 subunit (Figure 5.14, B). 
These interactions are specific, since in the control GST lane there is no signal. Taken 
together, the above results indicate that E47 can bind to Brf1 and TFIIIC in vitro. 
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Figure 5.13: Overexpression of GST and GST-E47 fusion protein.  
E. coli cells were used to overexpress GST and the GST-E47 fusion protein. Cells were 
induced with IPTG for 2 hours and harvested. Cell pellets were resuspended and 
sonicated. The GST and GST-E47 fusion protein were coupled to glutathione-agarose 
beads. The protein samples were resolved on an SDS-7.8% polyacrylamide gel.  
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Figure 5.14: In vitro transcription/translation using 35S-methionine reveals an 
interaction of E47 with TFIIIB and TFIIIC subunits. 
A. In vitro translated Brf1 was labelled with 35S-methionine and incubated with GST 
used as negative control or GST-E47 at 4°C with agitation. The samples were washed 
and resolved on an SDS-7.8% polyacrylamide gel and visualised by autoradiography. B. 
In vitro translated TFIIIC110 was radiolabelled with 35S-methionine and incubated with 
GST control or GST-E47 at 4°C with agitation. Proteins retained after washing were 
resolved on an SDS-7.8% polyacrylamide gel and visualised by autoradiography. 
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5.2.7 The ID2 protein is recruited to pol III-transcribed genes in 
an E47-dependent manner 
  
E47 has been shown to regulate the cellular localisation of the ID transcription 
factor family members. Studies have demonstrated that expression of E47 leads to 
modulation of ID1 localisation, from cytoplasmic to nuclear (Lingbeck et al., 2005). 
Also, E47 can stabilise ID1 resulting in an increased half-life of ID1. In another study, 
co-transfection of E47 and ID3 resulted in translocation of ID3 to the nucleus, whereas 
E47 was not sequestered into the cytoplasm (Deed et al., 1996). Chromatin 
immunoprecipitation assays have indicated that in a U2OS cell line stably expressing 
ID3, E47 was recruited to the promoters of pol III templates (Figure 5.8). Also, in a 
mapping experiment on the 7SL locus, E47 was overexpressed by adenoviral infection 
and ID1 and ID2 were found present on the 7SL gene (Chapter 4). To determine whether 
E47 can recruit ID2 to pol III-transcribed genes in vivo or the opposite, HEK 293 cells 
were infected with an adenovirus expressing ID2 (Ad-ID2), E47 (Ad-E47) or with the 
control vector (Ad-Vector). Cells were harvested after 30 hours and chromatin 
immunoprecipitation was performed. The inputs from the three different infections of 
the control vector, E47 and ID2 were normalised against each other. The results revealed 
that upon infection of cells with E47 or ID2 this led to an increase in the levels of these 
proteins on the promoters of 5S rRNA and tRNALeu genes (Figure 5.15). It is interesting 
that the expression of E47 appears to recruit ID2, since the ID2 ChIP signal increases in 
response to Ad-E47. These interactions are specific and not due to over cross-linking of 
proteins to DNA, since minimal signal was detected using the control TFIIA antibody. 
The ChIP assay cannot show whether ID2 and E47 are present together at pol III-
transcribed genes.  However, sequential chip analysis could be performed to determine 
whether these proteins with opposite functions in cell growth are present together at pol 
III-transcribed genes. These results will indicate whether recuitment of ID2 by E47 
shows presence of these proteins on active or inactive pol III-transcribed genes. PCRs 
could be done using serial dilution of the DNA templates to confirm that the assay is 
linear. The effect of overexpression of ID2 and E47 on each other can be determined by 
western blot analysis to detect the protein levels.  
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Figure 5.15: ID2 and E47 interact with pol III-transcribed genes in vivo.   
Chromatin immunoprecipitations were performed using HEK 293 cells harvested 30 
hours after infection with the adeno-Vector (Ad-Vector), adeno-E47 (Ad-E47), or 
adenovirus ID2 (Ad-ID2). The TFIIA (FL-109) antibody was used as negative control. 
The N-649 and C-20 antibodies were used for E47 and ID2 respectively. The samples 
were analysed by PCR performed on inputs and primers against 5S rRNA and tRNALeu 
genes. ChIP signals were normalised against the inputs. 
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5.3 Discussion 
 
Studies have identified E47 to be involved in regulation of cell proliferation. 
Expression of E47 has been demonstrated to suppress cell growth in HeLa, Saos-2 and 
U2OS cell lines (Pagliuca et al., 2000). It was found that E47 decreased the proliferation 
rate by promoting cell death associated with the induction of apoptosis. E47 is the 
strongest transcriptional activator of the CDK inhibitors p15, p16 and p21 compared to 
the other E-protein family members E12, E2-2 and HEB indicating a mechanism by 
which E-proteins negatively control cell growth (Zheng et al., 2004; Prabhu et al., 1997; 
Pagliuca et al., 2000). Another CDK inhibitor targeted by E47 in human neuroblastoma 
cells is p57kip2. Overexpression of E47 by adenoviral infection prevents progression into 
S phase and induces cell cycle arrest (Rothschild et al., 2006). These studies indicate 
that E47 is a negative regulator of cell proliferation through mechanisms that involve 
programmed cell death and enhancement of the expression of CDK inhibitor genes. 
In order to investigate if E47 can regulate pol III transcription in human cells in 
vivo an RNAi approach was employed. Transfection of human HeLa cells with siRNA 
against E2A resulted in significant reduction of protein and mRNA of E47 and E2A 
respectively compared to the controls (Figure 5.4). Also, the knockdown of E2A by 
siRNA did not result in overexpression or silencing of the associated ID1, ID2 and ID3 
proteins. The next step involved the determination of whether this depletion of E2A 
would have an effect on pol III transcription. When the protein and mRNA levels of E47 
and E2A respectively were reduced, pol III transcription was clearly upregulated. The 
levels of 5S rRNA, tRNAArg, tRNALeu, tRNASec, tRNATyr, 7SL RNA, 7SK RNA, MRP, 
and U6 snRNA were significantly increased (Figure 5.5). Also, the E2A knockdown 
results in an increase in the levels of the pol I transcript pre-rRNA (Figure 5.5). These 
results indicate that the knockdown of E2A demonstrates a repressing role in pol I and 
pol III transcription in vivo. An adenoviral infection approach was used to determine the 
effect of expressing E47 in human cells in vivo. HEK 293 cells were infected with 
adenoviruses expressing E47 or the vector control. Infection with the E47 expressing 
adenovirus resulted in overexpression of E47 protein and E2A mRNA in comparison to 
Chapter 5 Repression of RNA Polymerase III Transcription by E47  
179 
 
the control (Figure 5.6). The overexpression of E47 caused a reduction in the levels of 
the pol III transcripts 5S rRNA, tRNAArg, tRNALeu, tRNASec, 7SK RNA and MRP 
compared to the control (Figure 5.7). 
The use of Oct-1 as a control siRNA has limitations because it is a basal pol III 
transcription factor. Oct-1 is present on type III promoters and its removal leads to a 
delay of 30 minutes for the onset of transcription. In addition, Oct-1 is involved in 
transcription of type III genes, although it is not essential for basal transcription (Hu et 
al., 2003). The knockdown of E2A using siRNA experiments, should lead to the 
knockdown of its two known splice variants, the E47 and E12 transcription factors. In 
the future, siRNAs should be used against either the E47 or the E12 proteins to be able 
to determine which of them or if both can affect pol III transcription. Western blot 
experiments could be performed to determine whether the E12 protein levels are also 
reduced upon treatment of cells with siRNA against E2A, as has been observed for E47 
protein levels. Controls other than the Oct-1 control to compare the knockdown of E2A 
and the effects on pol III transcripts such as mock or non-silencing controls could be 
employed. The use of a non-silencing control could also be used since it does not target 
a protein and should avoid non-specific targeting but leads to the activation of the 
siRNA response pathway. Furthermore, a mock control using only lipofectamine 2000 
without adding siRNA should be used to determine whether there is an effect mediated 
by the transfection reagent on the cells. In addition, the implementation of other 
techniques for determining the effects of the knockdown of E47 proteins could be 
employed. Since the RT-PCR technique is semi-quantitative the more sensitive Q-PCR 
technique could be used. In the future western blot experiments could be performed to 
detect the expression levels of the other E-protein family members such as HEB and E2-
2 and also of the associated ID1, ID2 and ID3 proteins upon overexpression of E47. 
Studies have shown that when the E47 or ID2 proteins are overexpressed the protein 
levels of each other do not change (Rothschild et al., 2006). Also, immunofluorescence 
techniques could be employed in order to investigate where E47 and ID proteins are 
localised in the cell and whether they co-localise.   
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Overexpression of E-protein family members (E47, E12, E2-2 and HEB) using 
HeLa, U2OS and SaOS-2 cell lines results in suppression of cell colony formation 
(Pagliuca et al., 2000). Also, it has been demonstrated that the p15, p16 and p21 
promoter sequences, which contain E-box sequences, can be activated by E-protein 
members. In contrast to previous experiments where overexpression of E47 lead to 
inhibition of cell growth arrest due to block of G1 progression (Peverali et al., 1994), 
later work showed that the mechanism responsible for this effect does not involve arrest 
of G1 progression (Pagliuca et al., 2000). After ectopic expression of E-protein family 
members, the cell cycle profiles of cells were determined using FACS analysis. Flow 
cytometry demonstrated that cells transfected with E-proteins showed an increase in the 
number of cells in S phase and an increase of cells with subdiploid DNA content 
(Pagliuca et al., 2000). In addition, trypan blue dye exclusion experiments demonstrated 
an increase in cell death after ectopic expression of E-proteins. TUNEL assays showed a 
significant induction of apoptosis levels following transfection of cells with E-proteins. 
Furthermore, BrdU incorporation assays showed that a significant fraction of cells were 
in S phase (Pagliuca et al., 2000). These results demonstrate that overexpression of E-
proteins promotes cell death associated with apoptosis.  
Other studies have revealed that the E47 protein is involved in promoting cell cycle 
progression (Zhao et al., 2001). A tissue culture based system was employed where E47 
protein levels were regulated in an inducible manner, using an E47 oestrogen fusion 
construct. Also, a dominant negative E47 oestrogen construct was used. These 
constructs were expressed in several cell lines such as in the pre-B-cell line 697, an NIH 
3T3 cell line and the myeloid progenitor cell line K562. Suppression of E47 led to 
inhibition of cell cycle progression and FACS analysis demonstrated a decrease in the 
fraction of cells being in S phase, suggesting an inhibition of G1 cell cycle progression 
(Zhao et al., 2001). BrdU incorporation experiments also confirmed that suppression of 
E47 led to decrease in cell cycle progression. Furthermore, the overexpression of E47 in 
NIH 3T3 cells promoted entry into S phase, which was monitored by FACS analysis 
(Zhao et al., 2001). Further experiments could be performed on pol III transcription to 
investigate the biological response on cell growth and apoptosis after knockdown or 
overexpression of E47 proteins. FACS analysis could be used to determine the 
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biological consequences such as cell cycle progression and cell viability mediated by the 
knockdown or ectopic expression of E47. Furthermore, TUNEL assays could be 
employed to measure the percentage of apoptotic cells upon knockdown or 
overexpression of E47 proteins. Because the E47 protein appears to be involved in cell 
growth and apoptosis the effect of overexpressing or knocking down E47 should be 
further investigated to determine the possible biological effects mediated by expressing 
or depleting E47. A potential explanation for the effects on pol III transcription seen 
here by knocking down or overexpressing E47 could be attributed to indirect effects. 
These indirect effects could result in affecting cell proliferation, which in turn could 
affect pol III transcription. The slower growth of cells could result in the reduction of 
pol III transcription. However, chromatin immunoprecipitation and co-
immunoprecipitation experiments argue that the effects demonstrated by altering E47 
levels could be due to direct effects of E47 on pol III activity. Thus, a possible 
explanation for the role of E47 on pol III transcription could be that E47 is capable of 
regulating cell proliferation and cell viability by directly affecting pol III transcription, 
since pol III transcription is involved in cell growth. In order to address indirect effects 
caused by the overexpression or knockdown of E47, cell lines containing functional RB 
and p53 that represent a more physiological condition should be employed instead of 
HeLa cells. In addition, the siRNA used to target the E47 protein should be designed to 
be specific for E47 and also reduce the possibility of off-target effects in order to avoid 
indirect effects. Also, in vitro transcription assays should be performed to demonstrate 
whether E47 can affect pol III transcription in vitro, because the results obtained from 
these experiments might be less expected to be affected by indirect consequences. 
 In conclusion, the results shown here demonstrate that in both cases, knockdown 
or overexpression, E47 is involved in the repression of pol III transcription, suggesting a 
mechanism by which E47 regulates cell growth. 
Studies have demonstrated that E47 is found at the promoters of CDK inhibitors 
and their activation leads to cell cycle arrest (Prabhu et al., 1997). The E47 transcription 
factor is thought to activate or repress transcription by interacting with the E-box 
promoter sequences of pol II-transcribed genes (Zheng et al., 2004; Perez-Moreno et al., 
2001). Since the results have shown that E47 can repress pol III transcription it would be 
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interesting to investigate if E47 could be interacting directly with the pol III machinery 
to repress pol III activity. Chromatin immunoprecipitation assays were used to 
demonstrate whether E47 localises at pol III-transcribed genes in vivo. In the HeLa cell 
line used, endogenous E47 was found at pol III-transcribed genes like 5S rRNA and 
tRNALeu (Figure 5.8). In another cell line, (HEK 293) cells were infected with an 
adenovirus expressing E47. ChIP assays revealed that this protein showed a high 
enrichment and at 5S rRNA and tRNALeu and 7SL genes (Figure 5.9). Also, a stable cell 
line expressing ID3 was used to identify if E47 localises at pol III-transcribed genes. The 
results demonstrate that E47 is present at the tRNAArg and 7SL genes indicating a 
possible recruitment by ID3 (Figure 5.10). When E47 was expressed in HEK 293 cells 
this protein was found at the 7SL gene. This led to investigate, by mapping experiments 
on the 7SL locus, the association of E47 with potential factors that could recruit E47 to 
pol III promoters. The results revealed that E47 co-localises with Brf1 and TFIIIC at 
different positions on the 7SL gene (Figure 5.11). Therefore, a possibility is that in vivo 
Brf1 and/or TFIIIC could recruit E47 to pol III templates. Interestingly, there is 
recruitment of ID1 and ID2 which are present at the start of the 7SL gene but not at the 
end of the gene displaying a similar pattern with Brf1 (Figure 5.11). These data indicate 
that ID1 and ID2 co-localise with Brf1 and not TFIIIC or pol III. This suggests that Brf1 
could be a factor recruiting ID1 and ID2 to the promoters of pol III-transcribed genes. 
Overall, these results demonstrate that E47 is present at pol III-transcribed genes in 
several cell lines. This suggests that E47 may regulate pol III activity through a direct 
interaction with one or more components of the pol III apparatus.  
Given that E47 was demonstrated to localise on pol III-transcribed genes, 
possible mechanisms involved in this process were investigated. One possibility could 
be that E47 recognises a specific DNA sequence in pol III templates. However, the pol 
III genes rarely contain the E-box sequences that E47 could target and bind to. 
Therefore, protein-protein interactions of E47 with factors of the pol III apparatus were 
investigated. A possible target is TFIIIB, which has been demonstrated to be regulated 
by a number of oncoproteins, like c-Myc and ERK (Gomez-Roman et al., 2003; Felton-
Edkins et al., 2003a,b) and tumour suppressor proteins such as RB, p53 and Maf1 
(Sutcliffe et al., 2000; Crighton et al., 2003; Goodfellow et al., 2008). To investigate if 
Chapter 5 Repression of RNA Polymerase III Transcription by E47  
183 
 
E47 can bind to endogenous TFIIIB, co-immunoprecipitations assays were performed. 
The results revealed that the Brf1 subunit of TFIIIB co-immunoprecipitates in vivo with 
E47 and this effect is specific, since no signal is detected in the negative control (Figure 
5.12). However, using this assay it cannot be distinguished whether an interaction is 
direct or indirect. Therefore, it cannot be excluded that TFIIIB could be present in a 
complex with TFIIIC. To investigate if E47 binds to TFIIIB or TFIIIC, in vitro 
transcription and translation assays using 35S-methionine were performed. The first step 
involved the expression of the GST and GST-E47 fusion proteins. These proteins were 
overexpressed and purified, although in the GST-E47 protein there were breakdown 
products (Figure 5.13). The results demonstrate that E47 binds to the Brf1 subunit of 
TFIIIB and the TFIIIC110 subunit of TFIIIC (Figure 5.14). Thus, E47 is associated with 
Brf1 and TFIIIC110, and these interactions could be responsible for recruitment of E47 
to the promoters of pol III-transcribed genes.  
The correct subcellular localisation is important for the function of numerous proteins. 
E47 can act as a nuclear chaperone for ID proteins. When ID2 was co-transfected in 
SMCs with a vector containing full length E47, the wild type ID2 was localised in the 
nucleus (Matsumura et al., 2002). Studies have investigated if the nucleo-cytoplasmic 
shuttling of ID2 is involved in the regulation of E-box mediated transcription. It was 
demonstrated that decreased nuclear export of ID2 enhances repression of E47-mediated 
transcription (Kurooka & Yokota, 2005). These results suggest that the nuclear export of 
ID proteins has an inhibitory role in their suppressive ability against E47. The bHLH 
protein E47 has also been demonstrated to regulate the cellular localisation of ID1 and 
ID3 proteins from cytoplasm to nucleus when co-transfected with these proteins (Deed 
et al., 1996; Lingbeck et al., 2005). Also, when E47 was co-expressed with ID proteins, 
E47 remained mainly nuclear. Therefore, E47 can regulate the available pool of its 
binding inhibitory partners, by modulating the nuclear localisation of ID proteins. To 
investigate whether E47 and ID2 can recruit one another to the promoters of pol III-
transcribed genes in vivo, ChIP assays were performed using HEK 293 cells infected 
with adenovirus expressing E47, ID2 and the control vector. After infection with E47 or 
ID2, these proteins demonstrated a higher occupancy on the 5S rRNA and tRNALeu gene 
promoters (Figure 5.15). Also, ID2 appears to be present on pol III templates in an E47 
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sensitive manner, and demonstrates a higher enrichment on pol III-transcribed genes 
compared to ID2 recruiting E47. In addition, it would be interesting to investigate if E47 
and ID2 could increase DNA binding of pol III-specific factors and this association is 
important for downregulation or upregulation of pol III activity. In the future, ChIP on 
ChIP assays of IDs and E47 will be required to dissect recruitment issues and whether 
IDs and E47 proteins are present together at pol III templates. Also, sequential ChIPs of 
various mutants lacking interaction domains of IDs and E47 could be employed to 
investigate further their presence at pol III promoters and whether these proteins can be 
found together with pol III at active or inactive pol III-transcribed genes. By 
overexpressing ID or E47 mutants it could be possible to determine whether E47 is 
capable of recruiting ID proteins using the HLH domain of E47. Mutants of E47 lacking 
the HLH domain or containing point mutations in this domain, which is required for the 
interaction with ID proteins, may not be able to recruit ID proteins at the promoters of 
pol III genes.  
In conclusion, the data in this chapter suggest a new function for E47, in 
repressing pol III transcription. Furthermore, it is possible that other members of the E-
protein family could regulate pol III activity since they show similar functional 
properties. 
 
 
 
 
 
 185 
 
 
Chapter 6 
 
 
 
 
 
Discussion and 
Conclusions
Chapter 6 Discussion and Conclusions  
186 
 
6.1 RNA polymerase III transcription, cell growth and 
cancer 
 
High rates of protein synthesis are needed for increased growth, since 80-90% of 
a cell’s dry mass is mainly constituted of protein (Zetterberg & Killander, 1965). 
Therefore, the growth rate is proportional to the rate of protein accumulation (Baxter & 
Stanners, 1978). Moreover, cells can withdraw from the cell cycle and become quiescent 
if there is a 50% decrease in the translational output (Brooks, 1977; Rønning et al., 
1981). Since 5S rRNA and tRNA availability is essential for protein synthesis, increased 
pol III transcription is required to maintain rapid cell growth. These observations may 
explain a requirement for stimulation of pol III transcription by tumour cells.   
 Pol III transcription has been frequently found to be abnormally elevated in 
transformed cells and tumours. Early studies demonstrated that pol III is deregulated in 
mice with myelomas, even though pol II activity remains normal (Schwartz et al., 1974). 
Several types of transformed cells have been shown to overexpress products of pol III, 
including cell lines transformed by RNA tumour viruses (e.g., human T cell leukaemia 
virus 1), DNA tumour viruses (e.g., simian virus 40, hepatitis B virus) and chemical 
carcinogens (e.g., methylcholanthrene) (Gottesfeld et al., 1996; Liebhaber et al., 1978; 
Larminie et al., 1999; Wang et al., 1995; Scott et al., 1983; White et al., 1990; Singh et 
al., 1985). These studies have focused on cell lines, however, their relevance has also 
been explored in tumours in situ. In particular, increased levels of 5S rRNA and tRNATyr 
have been found in ovarian cancers (Winter et al., 2000). In another study, analysis of 80 
tumours revealed raised levels of 7SL RNA in each of the tumour samples representing 
19 types of cancer (Chen et al., 1997b). Moreover, carcinomas of the lung, breast and 
tongue demonstrated elevated levels of pol III transcripts in neoplastic cells in 
comparison to healthy control tissue (Chen et al., 1999b). Therefore, increased pol III 
activity appears to be associated with the transformed state. 
 The deregulation of pol III transcription in cancer can be attributed to and 
categorised into three general mechanisms. The first mechanism involves the activation 
of pol III transcription by oncoproteins such as c-Myc, Ras and CK2 (Figure 6.1) 
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(Gomez-Roman et al., 2003; Wang et al., 1997; Johnston et al., 2002). Pol III 
transcription can also be activated through loss of tumour suppressors such as RB, p53 
and PTEN and this constitutes the second mechanism (Figure 6.1) (White et al., 1996; 
Crighton et al., 2003; Woiwode et al., 2008). Finally, the third mechanism involved in 
the deregulation of pol III transcription is mediated by the overexpression of a specific 
pol III factor such as TFIIIB or TFIIIC (Felton-Edkins & White, 2002; Larminie et al., 
1999). Increased levels of the Brf1 subunit of TFIIIB have been found in patients with 
cervical carcinomas (Daly et al., 2005). Also, other cases where Brf1 is elevated in 
prostate and bladder cancers can be found in microarray databases 
(http://www.oncomine.org). This last mechanism has been recently re-examined 
revealing very interesting findings.  
Specifically, studies have focused on the effects of Brf1 overexpression on 
mammalian systems. To determine whether Brf1 is limiting for pol III transcription, 
Brf1 levels were raised in Brf1-inducible MEF cells and an increase in the levels of pol 
III transcripts was observed (Marshall et al., 2008). These effects were specific since 
there was no change in the levels of pol I and pol II transcripts tested. In addition, 
increased occupancy of Brf1 and pol III was observed at the promoters of 5S rRNA and 
tRNA genes when Brf1 was induced. Increased proliferation was observed in MEF cells 
containing the inducible Brf1 construct and in MEFs infected with a Brf1 expressing 
adenovirus (Marshall et al., 2008). Since activation of pol III transcription is observed in 
transformed and tumour cells, the role of Brf1 in stimulating transformation was 
investigated. Brf1 induction in MEF and CHO cells resulted in oncogenic transformation 
of these cells. The cells displayed morphological changes, focus formation and grew in 
an anchorage-independent manner. Moreover, mice injected with clones overexpressing 
Brf1 developed tumours (Marshall et al., 2008). One of the targets of Brf1 is the gene 
encoding the tRNAiMet. Overexpression of tRNAiMet displayed similar effects to the 
induction of Brf1 such as increased protein synthesis and formation of tumours in mice. 
Therefore, the effects demonstrated by expression of Brf1 may be attributed to raised 
expression of tRNAiMet. Interestingly, the levels of Myc and cyclin D1 were elevated in 
response to overexpression of Brf1 and tRNAiMet. Therefore, it is likely that the capacity 
of Brf1 and tRNAiMet to regulate oncoproteins like Myc may be responsible for their 
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transforming ability. These observations suggest a possible requirement for the 
activation of pol III transcription in cancer progression.       
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Figure 6.1: The transcription factor TFIIIB is regulated by several activators and 
repressors. 
The blue boxes indicate proteins that have been demonstrated to repress pol III 
transcription through TFIIIB, and those in red boxes have been shown to function as 
activators. Dotted lines represent indirect interactions. The growth repressors p53, RB, 
p107, p130 and Maf1 can repress TFIIIB by direct interactions. Their function can be 
blocked by viral proteins such as HPV E7 and the cellular oncoprotein mouse double 
minute 2 (MDM2). Also, the MDM2 oncoprotein causes p53 degradation, thereby 
increasing TFIIIB activity. RB, p107 and p130 phosphorylation by CDK2, CDK4 and 
CDK6 leads to release of TFIIIB from suppression. The tumour suppressor INK4A 
inhibits the phosphorylation mediated by CDK4 and CDK6, thus leading to TFIIIB 
repression by RB, p107 and p130. The ARF tumour suppressor inhibits p53 degradation 
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by MDM2 and therefore causes TFIIIB suppression. In contrast, a variety of activators 
have been shown to bind and activate TFIIIB directly, including CK2, Myc, ERK and 
HTLV1. Ras and Raf signalling activate ERK, and Ras also stimulates 
phosphatidylinositol 3-kinase - Akt signalling. PTEN can antagonise the PI3K-Akt 
pathway (adapted from Marshall & White, 2008). 
 
 6.2 Induction of pol III transcription by ID1, ID2 and ID3 
 
 The findings of this thesis have shown that the ID1, ID2 and ID3 oncoproteins 
can regulate pol III transcription. The ID transcription factor proteins were considered 
because they are known to be targets of the Myc oncogene (Lasorella et al., 2000), 
which has been shown to induce pol III transcription (Gomez-Roman et al., 2003). 
Studies have shown that ID2 expression is upregulated in neuroblastoma cell lines 
(Lasorella et al., 2002). These cell lines show amplification of neuronal Myc (N-Myc), 
and overexpression of ID2 is possibly due to direct control by N-Myc expression. Other 
studies have identified that ID2 is also a target of c-Myc, and that the transcription of the 
ID1, ID2 and ID3 genes is activated by Myc via E-boxes within their promoters 
(Swarbrick et al., 2005; Lasorella et al., 2000; Light et al., 2005). Also, the ID2 family 
member has been demonstrated to bind and inhibit the function of the 
hypophosphorylated form of RB, which is known to repress pol III transcription (White 
et al., 1996; Larminie et al., 1997). Therefore, the ID2 protein directly and the ID1 and 
ID3 proteins indirectly may have oncogenic activity by interfering with the RB tumour 
suppressor pathway. In addition, p53 has been shown to be involved in the regulation of 
ID proteins (Qian & Chen, 2008; Yan et al., 2008; Wilson et al., 2001; Hernandez-
Vargas et al., 2006). The expression levels of the ID1, ID2 and ID3 proteins correlate 
with mitotic index and with p53 expression levels in human colorectal adenocarcinomas 
(Wilson et al., 2001). ID protein levels are increased in p53 knockout mice and 
knockdown of ID proteins in colorectal adenocarcinomas resulted in growth arrest 
(Wilson et al., 2001). It has been demonstrated that the ID1 protein becomes down 
regulated in HCT116 and U2OS cells treated with chemotherapeutic drugs in a p53 
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dependent manner (Qian & Chen, 2008). Also, ID1 has been found to be regulated by 
DEC1, which is a bHLH transcription factor that is targeted by p53. ChIP assays showed 
that the DEC1 protein is present at the promoter of the ID1 gene and leads to the 
inhibition of ID1 expression (Qian & Chen, 2008).  
Previous studies have demonstrated that ID proteins play a crucial role in the 
regulation of cell growth (Barone et al., 1994). Experiments have shown that the 
silencing of ID proteins reduces cell proliferation (Hara et al., 1994; Peverali et al., 
1994). Furthermore, the depletion of IDs by silencing results in the induction of 
expression of representative genes involved in proliferation such as the cyclin-dependent 
kinase inhibitors p16 and p21 (Zheng et al., 2004; Asirvatham et al., 2007). In chapter 3 
it was investigated whether the partial depletion of endogenous ID1, ID2 and ID3 
proteins by RNAi would affect pol III transcription in vivo. It was demonstrated that the 
knock-down of ID proteins by RNAi resulted in downregulation of the expression of the 
5S rRNA, tRNAArg, tRNALeu, 7SL RNA, 7SK RNA, MRP RNA and U6 snRNA pol III 
transcripts in human cells. Furthermore, it was shown that the ID2 and ID3 but not ID1 
proteins may be involved in the regulation of pol I transcription, since knocking-down 
these proteins reduced the levels of the pol I transcript pre-rRNA. The difference in the 
regulation of the expression of pre-rRNA between ID proteins could be attributed to 
differences in the sequences of these members. The four ID family members share a 69-
78% similarity in their HLH domain, however the rest of their sequences are unrelated 
(Deed et al., 1994; Norton et al., 1998). Even a few amino acid changes can play a 
crucial role in protein-protein interactions, an example is the association of ID2 with the 
RB protein. ID2 binds directly to RB and the related p107 and p130 pocket proteins 
through the HLH domain of ID2 (Lasorella et al., 1996). However, ID1 and ID3 cannot 
bind to RB and its related proteins, which suggests that a few amino acid changes even 
in the homologous HLH domain can be important for the specificity of these proteins for 
RB and possibly pol I factors. In the future it would be interesting to further investigate 
these preliminary findings on the regulation of pol I transcription by ID proteins, in 
order to understand in more detail the role that these proteins exert on cell proliferation. 
Immunoprecipitation experiments could be carried out to investigate whether ID 
proteins intetact with pol I basal transcripion factors. 
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Several cancer types and tumour cell lines overexpress the ID1 protein. In 
particular, ID1 is overexpressed in squamous cell carcinoma and small cell lung cancer 
cell lines (Langlands et al., 2000; Kamalian et al., 2008). ID1 has also been found to be 
overexpressed in human tumours such as cervical cancer and pancreatic carcinomas 
(Schindl et al., 2001; Maruyama et al., 1999). Evidence for the oncogenic role of ID2 
has been demonstrated in transgenic mice where expression of ID2 resulted in the 
development of lymphomas (Morrow et al., 1999). Overexpression of ID2 by 
adenovirus infection can upregulate the expression of the tRNALeu, 5S rRNA, tRNATyr, 
MRP RNA, tRNALeu and U6 snRNA pol III transcripts in vivo in human cells. Studies 
have linked ID3 to tumourigenesis as well. ID3 is expressed at high levels in 
hepatocellular carcinomas and prostate tumours (Damdinsuren et al., 2005; Li et al., 
2004). 
In order to ensure that the depletion of ID1, ID2 or ID3 by RNAi was specific for 
each of these proteins, western blotting was performed to determine the expression 
levels of these proteins. It was shown that upon depletion of each ID specifically by 
RNAi, the expression levels of their related proteins remained unaltered. These results 
are in agreement with studies where ID1, ID2 or ID3 silencing did not result in 
overexpression or suppression of other ID family members, and other work establishing 
that the knockdown of ID1 protein levels had no effect on the levels of the related ID 
proteins (Asirvatham et al., 2007; Zheng et al., 2004). Furthermore, it has been 
demonstrated that overexpression of ID2 by adenovirus infection does not result in 
repression or overexpression of the other ID family members and the E47 protein 
(Rothschild et al., 2006). 
To further confirm the in vivo effects of knocking-down ID proteins by RNAi on 
pol III transcription, in vitro transcription was employed. In vitro experiments revealed a 
reduction in the levels of pol III transcription when ID2 was depleted. The results in this 
thesis suggest that ID proteins can positively affect pol III transcription, and therefore 
play a crucial role in the regulation of cell growth.  
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6.3 Interactions of ID1, ID2 and ID3 with the pol III 
transcription machinery 
 
 ID proteins are known to function by sequestering bHLH proteins, inhibiting 
their DNA binding ability, with ID proteins being unable to bind DNA (Benezra et al., 
1990). In chapter 4, ChIP experiments demonstrated that endogenous ID2 is present at 
the promoters of the pol III-transcribed 5S rRNA and tRNALeu genes. Furthermore, 
overexpression of ID2 by adenovirus infection resulted in strong enrichment of the ID2 
protein at other pol III templates, such as 5S rRNA, tRNALeu, 7SL RNA and U6 snRNA. 
Interestingly, E47 was present at the same pol III-transcribed genes as ID2, suggesting a 
possible recruitment of E47 by ID2. In addition, ID3 was found to localise at the 5S 
rRNA, tRNALeu, tRNATyr and 7SL RNA pol III-transcribed genes using a U2OS cell line 
stably expressing this protein. In the same cell line, E47 was also recruited to the 
promoters of pol III templates demonstrated in chapters 4 and 5. A possible explanation 
for the presence of endogenous ID2 and not ID1 and ID3 on pol III genes could be that 
in the cell lines tested the antibodies used, which were not ChIP grade, were unable to 
detect ID1 and ID3 convincingly, even though they are expressed. From these results, it 
can be concluded that ID proteins are present at pol III-transcribed genes of promoter 
types I, II and III in vivo in human cells (Figure 6.2).  
  Furthermore, scanning ChIP assays indicated that ID2 co-localises with TFIIIB 
at the promoters of pol III templates. Studies have demonstrated that another 
oncoprotein, c-Myc, is able to co-localise with TFIIIB using promoter mapping 
experiments (Kenneth et al., 2007).  The results showed that ID2 and the TFIIIB factor 
were present at the start of the gene, rather than the end of the gene where TFIIIC and 
pol III localise. Therefore, these data suggest that TFIIIB and more specifically Brf1 
may be involved in the recruitment of ID2 to pol III-transcribed genes. Moreover, in the 
HEK 293 cell line where ID2 was overexpressed, E47 was also recruited to the promoter 
of the pol III gene and E47 localises with ID2 at the beginning of the gene. These 
findings indicate that ID2 might recruit E47 and that an ID2-E47 complex may exist, 
which localises with TFIIIB at pol III promoters. These data are very interesting since 
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the HLH ID proteins are shown to localise at DNA and, as mentioned earlier, ID 
proteins lack a DNA binding domain and the pol III factors examined have no HLH 
domain.      
Since ID proteins are localised at the promoters of pol III-transcribed genes they 
may be recruited by a specific mechanism. Experiments employing co-IPs revealed that 
ID1, ID2 and ID3 can interact with TFIIIB in vivo, results which are in agreement with 
the findings from ChIP data. Furthermore, in vitro transcription and translation 
experiments showed that GST-ID1, GST-ID2, GST-ID3, GST-ID2 HLH and GST-ID2 
δHLH fusion proteins interacted with TFIIIB and in particular Brf1. These results 
suggest that ID2 containing the HLH (ID2-HLH) and ID2 lacking the HLH domain 
(ID2-δHLH) might both have binding sites for Brf1, therefore ID2 may have more than 
two binding domains available for the interaction with the Brf1 subunit of TFIIIB. The 
ID proteins can interact with their target proteins (e.g. E47, MyoD and RB) through their 
HLH domain (Murre, 2005; Hasskarl & Münger, 2002). If the HLH domain of ID2 is at 
some point masked by the binding of another protein, such as E47, the amino or 
carboxyl domain may be able to interact with Brf1. Therefore, if ID2 and E47 are 
localised as a complex together at pol III templates, this may be a mechanism by which 
ID2 and possibly other IDs can still exert their function by utilising another domain 
other than the HLH.   
Previous studies have demonstrated that the overexpression of Brf1 stimulates 
the occupancy of Brf1 and pol III at class III templates, inducing the transcription of 5S 
rRNA and tRNA genes (Marshall et al., 2008). Other studies have shown that induction 
of Myc resulted in enhanced recruitment of Brf1 and pol III at 5S rRNA genes (Kenneth 
et al., 2007). Furthermore, when wild type and Myc null rat fibroblast cell lines were 
compared, the occupancy of pol III at a tRNA template was reduced in the cell line in 
which the Myc oncogene was knocked-out (Kenneth et al., 2007; Ernens et al., 2006). 
Also, stimulation of the tumour suppressor p53 led to a decrease of Brf1 recruitment to a 
pol III template (Crighton et al., 2003). The results have shown that in p53 knockout 
MEF cell lines the pol III occupancy on pol III templates was higher than in wild type 
cells (Crighton et al., 2003). Interestingly, knockout of ID2 in MEF cells results in a 
decrease in the promoter occupancy of Brf1, E47 and pol III. This suggests that ID2 may 
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be involved in the recruitment of Brf1, which then leads to recruitment of pol III and 
stimulation of pol III transcription. These findings also reveal a possible role for the 
recruitment of E47 by ID2 and the existence of an ID-E47 complex that might be 
involved in the regulation of pol III-transcribed genes.  
Future experiments will be required to determine whether increased pol III 
transcription mediated by ID proteins plays a role in oncogenesis. The pol III 7SK RNA 
has been implicated in cell transformation and tumourigenicity by regulating the 
expression of the c-Myc oncoprotein (Luo et al., 1997). Other studies suggest that the 
induction of pol III transcription might play a role in the transforming effect of c-Myc 
(Johnson et al., 2008). When RNAi was used to deplete Brf1 and to inhibit c-Myc 
stimulating pol III transcription, this compromised the ability of c-Myc to drive tumour 
growth in mice (Johnson et al., 2008). From these results it might be concluded that the 
control by c-Myc and possibly ID proteins of pol III genes may present a positive 
feedback towards their own expression, in addition to affecting cell growth and cancer 
progression. In the future, Q-PCR experiments could be done in order to precisely 
calculate the differences in the levels of pol III transcripts upon altering the levels of ID 
proteins. FACS analysis could be performed to determine the cell viability and to 
measure the percentage of apoptotic cells upon overexpression or knockdown of ID 
proteins. Also, mouse knockouts of ID1, ID2 and ID3 could be created to study pol III 
target gene expression in various mouse tissues. In addition, tumour samples from 
patients showing ID upregulation can be used in order to study pol III target gene 
expression.  
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Figure 6.2: Possible model for the induction of pol III transcription by the ID 
proteins. 
Schematic representation of changes to the pol III transcription machinery which might 
be occurring in transformed cells due to ID protein expression. Most pol III genes have 
internal promoters within the transcribed region. TFIIIC (red) binds to the promoter 
DNA sequences of tRNA genes. In turn, TFIIIC recruits TFIIIB (green) by protein-
protein interactions. TFIIIB recruits pol III (gold) at the transcription initiation site. 
Considerable levels of pol III transcription are maintained in all cells, such as 
untransformed cells. In transformed cells, increased levels of ID proteins (violet), might 
stimulate recruitment of TFIIIB followed by recruitment of pol III and activation of pol 
III transcription.  
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6.4 Suppression of pol III transcription by E47 
 
The E47 protein has been shown to be involved in processes such as cellular 
growth and apoptosis. Increased or decreased levels of E47 activity can lead to cell 
death, suggesting that lymphocytes can only survive in an optimum range of E47 
activity (Kim et al., 1999; Engel & Murre, 1999; Park et al., 1999). Studies using mouse 
models have demonstrated that E2A null mice develop malignant T cell lymphomas 
(Bain et al., 1997; Yan et al., 1997). Restoring the E47 or E12 activity in cells obtained 
from E2A-deficient lymphomas led to apoptosis (Engel & Murre, 1999). Furthermore, 
when E47 was ectopically expressed in human T cell acute lymphoblastic leukaemia cell 
lines cell cycle progression was inhibited and programmed cell death was activated 
(Park et al., 1999; Quong et al., 2002). Therefore, it is thought that E47 functions as a 
tumour suppressor and its inactivation is a crucial step in the development of human 
leukaemias (Engel & Murre, 1999; Park et al., 1999). In chapter 5, it was determined 
whether the partial depletion of endogenous E47 would affect pol III transcription. The 
knockdown of E47 by RNAi resulted in upregulation of the expression of the 5S rRNA, 
tRNAArg, tRNALeu, tRNASec, tRNATyr, 7SL RNA, 7SK RNA, MRP RNA, and U6 
snRNA pol III transcripts in human cells in vivo (Figure 5.5). Moreover, it was 
demonstrated that the E47 protein might be involved in the regulation of pol I 
transcription, since the depletion of E47 induced the expression levels of the pre-rRNA 
transcript (Figure 5.5). These data suggest that E2A might target type I, type II and type 
III promoters and negatively coordinate the regulation of both pol I and pol III 
transcription. Since components synthesised by pol I and pol III are constituents of the 
translational apparatus, it might be a beneficial strategy for the cellular economy to 
utilise the same protein to regulate expression of ribosomal proteins. Overexpression of 
E47 by adenovirus infection results in downregulation of the expression of the 5S rRNA, 
tRNAArg, tRNALeu, tRNASec, 7SK RNA and MRP RNA pol III transcripts in vivo in 
human cells. These results demonstrate that overexpression of E47 reduces pol III 
transcription, suggesting a mechanism by which E47 is involved in the regulation of cell 
growth.  
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6.5 Possible mechanism of repression of pol III 
transcription by E47 
 
 E47 proteins have a dual function since they can activate or repress gene 
expression (Ikawa et al., 2004; Murre, 2005). The AD1 and AD2 domains mediate the 
transactivation and repression activities of E-proteins. In eukaryotic cells, DNA can be 
condensed into nucleosomes which are composed of histones. The modification of 
histones through acetylation by HATs and deacetylation by HDACs, can have a positive 
or negative effect, respectively, on transcription. The modulation of acetylation levels by 
activators or repressors which are involved in the recruitment of HATs or HDACs, 
respectively, can influence transcriptional activity. The AD1 domain of E-proteins also 
has the capability to repress transcription by recruiting a family of corepressors known 
as ETO (Zhang et al., 2004). There are three known ETO members, ETO, ETO-2 and 
MTGR1 (myeloid transforming gene-related protein 1), which are highly related and are 
found in the mammalian genome. The ETO family members have been demonstrated to 
interact with the nuclear corepressors N-CoR (nuclear receptor corepressor) and Sin3A. 
Furthermore, the ETO members have the ability to recruit the HDAC1 and HDAC3 
complexes in order to modulate chromatin accessibility (Zhang et al., 2004).   
 In chapter 5 the repression of pol III transcription by E47 was shown to be 
possibly mediated by recruitment of this protein to gene promoters by specific pol III 
factors. The mechanism of this suppression, however, remains to be addressed. Since the 
expression of a number of E47 target genes is modulated by histone deacetylation, this 
could be a potential mechanism for the regulation of pol III transcription. Studies have 
revealed that chromatin remodelling can affect pol III activity (Tse et al., 1998; Sutcliffe 
et al., 2000; Kenneth et al., 2007). Therefore, E47 might be involved in the recruitment 
of HDACs to pol III-transcribed genes. It has been demonstrated that the AML1-ETO 
fusion protein interacts with the AD1 domain of E-proteins leading to a silencing 
mechanism of E-protein target genes (Zhang et al., 2004). This results in recruitment of 
HDACs to target promoters. Other studies have shown that TAL1/SCL interferes with 
E47 target genes which are important for cell differentiation and survival. The repression 
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is regulated by the recruitment of the mSin3A/HDAC1 corepressor complex to E47 
target promoters (O’Neil et al., 2004). Evidence suggests that ETO and ID family 
members have the ability to regulate the activity of E-proteins and this occurs in 
different ways. ID proteins inhibit the activity of E-proteins, interfering with both 
positive and negative regulation by sequestering them. However, the ETO members 
could be recruited to a particular set of genes to modulate transcriptional repression. 
Whether E-proteins can recruit HDAC members to their target pol III genes is an issue 
that remains to be addressed.   
 E47 has been reported to occupy several pol II genes in mammalian cells (Zheng 
et al., 2004; Prabhu et al., 1997; Perez-Moreno et al., 2001). In chapter 5, ChIP assays 
demonstrated that endogenous E47 was present at the 5S rRNA and tRNALeu pol III-
transcribed genes in vivo in human cells. In addition, the overexpression of E47 revealed 
that E47 was strongly enriched at the promoters of 5S rRNA, tRNALeu and 7SL genes. 
Furthermore, the use of the U2OS cell line stably expressing ID3 showed that E47 was 
recruited to the tRNAArg and 7SL pol III templates. This result represented an indication 
that recruitment between E47 and ID proteins might be occurring at pol III-transcribed 
genes. These results demonstrate that the E47 protein is present at several pol III 
templates of promoter types I and II and in a number of cell lines of human origin.  
Moreover, mapping ChIP assays suggested that E47 localises with TFIIIB and 
TFIIIC in vivo at the pol III promoter examined. These results indicate that TFIIIB 
and/or TFIIIC might be involved in the recruitment of E47 to the promoter of pol III 
templates. Furthermore, using the HEK 293 cell line in which E47 was overexpressed, 
ID1 and ID2 were also recruited; however, they co-localised with TFIIIB at the start of 
the gene. These findings indicate that E47 might be involved in the recruitment of ID1, 
ID2, and possibly other ID family members which are known to interact with the E47 
protein, to the promoters of pol III-transcribed genes.  
In chapter 5, experiments were employed to identify possible factors that might 
be involved in the recruitment of E47 to the promoters of pol III-transcribed genes. The 
results from co-IPs demonstrated that E47 interacts with TFIIIB in vivo, an observation 
which is consistent with ChIP data. In addition, in vitro transcription and translation 
assays revealed that the GST-E47 fusion protein binds to the Brf1 and TFIIIC110 
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subunits. However, the above technique cannot distinguish between direct or indirect 
interactions and thus it is possible that the TFIIIC subunit may be in a complex together 
with another pol III factor, representing an indirect interaction with the E47 protein. 
Therefore, these results suggest that E47 is able to repress pol III transcription through a 
direct mechanism, since E47 is present at pol III templates and is demonstrated to be 
recruited to pol III-transcribed genes, possibly through protein-protein interactions 
(Figure 6.3). Future experiment could include Q-PCR, which could be performed in 
order to precisely calculate the differences in the levels of pol III transcripts upon 
altering the levels of E47 proteins. Furthermore, FACS analysis could be done in order 
to determine the cell viability and to measure the percentage of apoptotic cells upon 
overexpression or knockdown of E47 proteins. An E47 mouse knockout model could be 
created to study pol III target gene expression in various mouse tissues. In addition, 
tumour samples from patients showing chromosomal translocations or deletions 
affecting E47 can be used in order to study pol III target gene expression.  
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Figure 6.3: Possible model for the repression of pol III transcription by E47. 
Schematic illustration of effects on the pol III transcription machinery that might be 
occurring under growth repression conditions due to E47 protein expression. Most pol 
III genes have internal promoters within the transcribed region, which are recognised by 
TFIIIC (red). TFIIIC binds to the promoter region of tRNA genes. TFIIIC recruits 
TFIIIB (green) by protein-protein interactions. TFIIIB then recruits pol III (gold) at the 
transcription start site. Transformation is associated with increased levels of pol III 
transcription, with several oncoproteins stimulating pol III activity. The restraint on cell 
growth may involve the interaction of E47 (aquamarine) with TFIIIB, preventing the 
recruitment of pol III and therefore leading to suppression of pol III transcription. 
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6.6 Proposed models of regulation of pol III 
transcription by the ID and E47 proteins 
 
The findings in this thesis demonstrate that the ID proteins are involved in the 
induction of pol III transcription, whereas, E47 represses pol III output. E47 has been 
shown to modulate the cellular localisation and degradation of ID proteins. Expression 
of E47 results in nuclear localisation of ID1, ID2 and ID3 proteins (Lingbeck et al., 
2005; Matsumura et al., 2002; Deed et al., 1996). Also, the expression of E47 stabilises 
ID members leading to an increased half-life of ID proteins (Lingbeck et al., 2005; Deed 
et al., 1996). In chapter 5, it is shown that when E47 or ID2 are overexpressed, this 
results in increased enrichment of either protein at the promoters of pol III-transcribed 
genes. The expression of E47 was shown to result in recruitment of ID2, since the ID2 
signal observed in the ChIP experiments increases in Ad-E47 infected cells. 
Furthermore, the knockout of ID2 in MEF cells results in reduced promoter occupancy 
of E47, as shown in chapter 4. In addition, scanning ChIP assays showed that upon 
expression of E47, the ID1 and ID2 proteins were recruited to the 7SL promoter and co-
localised with TFIIIB. Also, overexpression of ID2 resulted in recruitment of E47 to the 
above promoter, and both proteins localised with TFIIIB at the start of the gene 
examined. These findings suggest that the ID and E47 proteins might exert their function 
on pol III activity by a regulatory cross talk between these transcription factors. Future 
experiments will be needed to determine the mechanism by which ID and E47 proteins 
regulate the expression of pol III-transcribed genes. In proposed models of pol II 
transcription, the ID proteins act by binding and sequestering E47 proteins, the ratio of 
ID proteins to E47 proteins ultimately determining the level of ID protein activity. 
Studies have shown that the overall effect of ID proteins on proliferation can be 
independent of E-proteins (Asirvatham et al., 2007). However, in some cases the E-
proteins can determine the magnitude of the effect or reverse the ID-mediated target 
expression (Asirvatham et al., 2007).  
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In this thesis, it is demonstrated that both ID and E47 proteins are present at the 
pol III templates, however, several possible models for the induction or repression of pol 
III transcription are proposed. ID proteins are shown to bind to TFIIIB in the absence of 
DNA by co-immunoprecipitation and in vitro transcription and translation experiments 
(Figure 4.6; Figure 4.8). This might suggest that there is an initial interaction in the 
cytoplasm preceding DNA binding, which may lead to the activation of TFIIIB that 
increases its affinity for TFIIIC. ID proteins might activate TFIIIB by precluding a 
TFIIIB/suppressor complex interaction, by competing for binding sites with pol III 
suppressor proteins RB and p53 (Sutcliffe et al., 2000; Crighton et al., 2003). In 
addition, the ID members might induce a conformational change to the TFIIIB complex 
by binding or through a post-translational modification by an ID-associated factor (such 
as a HAT complex). Moreover, ID proteins might function through sequestration of their 
target proteins such as RB, E47 and the ETS family proteins, leading to the induction of 
pol III transcription (Figure 6.4). Furthermore, the E47 transcription factor may promote 
the translocation of ID proteins to the nucleus by forming an E47-ID complex, which 
interacts with TFIIIB leading to the repression of pol III transcription. However, it is not 
known whether an E47-ID complex is present at pol III templates, or if these proteins 
are present separately at different sites of the pol III transcription complex. Another 
model might also involve the E47 protein acting as a molecular switch repressing pol III 
transcription (Figure 6.5). The models proposed here serve as hypotheses of what might 
be occurring for the regulation of pol III transcription by the ID and E47 proteins, 
however, different mechanisms may apply. Sequential ChIPs will be required to 
determine whether IDs and E47 proteins are present together at pol III templates. 
Sequential ChIPs can also be used to investigate if these proteins can be found together 
with pol III at active pol III-transcribed genes. Knockout E47 cell lines would be helpful 
to address the possible recruitment of IDs by E47 on pol III promoters.    
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Figure 6.4: Possible model of activation of pol III transcription by ID proteins. 
Activation of pol III transcription by ID proteins through sequestration of their target 
proteins. In undifferentiated cells large amounts of ID proteins translocate from the 
cytoplasm to the nucleus where they directly bind to and inactivate their targets, the E47, 
RB and ETS transcription factors (1). ID proteins also bind directly to TFIIIB (2) which 
promotes the recruitment of pol III, stimulating transcription.  
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Figure 6.5: Possible models of repression of pol III transcription through 
interaction with the pol III machinery. 
Following the activation of differentiation programs, the expression of E47 increases. 
E47 binds (1) and translocates ID proteins to the nucleus (2). The E47-ID complex binds 
to TFIIIB (3) and inhibits the activation of pol III transcription. E47 (4) and ID (5) 
proteins are present individually at different sites at TFIIIB interfering with the pol III 
machinery, leading to repression of pol III activity. ID proteins bind to TFIIIB (6), 
followed by E47 binding to IDs (7). Here, E47 acts as a molecular switch suppressing 
pol III transcription.  
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6.7 Possible role of ID and E47 proteins in the 
recruitment of HATs and HDACs to pol III-transcribed 
genes 
In the 1960s, it was discovered that histone acetylation levels correlate with gene 
activity (Allfrey et al., 1964). Histone acetylation and deacetylation is controlled by the 
interplay between HATs and HDACs, which modify chromatin structure and regulate 
transcription. It is thought that HAT activity results in increased gene transcription 
through the opening of the chromatin architecture by the addition of acetyl groups (Yang 
& Seto, 2007; Norton et al., 1990; Lee et al., 1993; Hebbes et al., 1988). In contrast, 
HDACs remove acetyl groups and their activity is linked to the repression of gene 
expression through chromatin condensation (Ekwall, 2005; Taunton et al., 1996; 
Rundlett et al., 1996). It has been demonstrated that HATs and HDACs associate with 
several transcriptional activator and repressor proteins, such as c-Myc and MeCP2 
(methyl CpG binding protein 2), which leads to the recruitment of HATs and HDACs 
and results in the regulation of gene expression (Vervoorts et al., 2003; Jones et al., 
1998). c-Myc interacts with HATs such as CBP- and GCN5-containing complexes, 
which leads to the recruitment of these complexes to gene promoters (Vervoorts et al., 
2003; McMahon et al., 2000). c-Myc has been shown to recruit GCN5 and the cofactor 
TRRAP to pol III-transcribed genes, which leads to the hyperacetylation of histone H3, 
followed by recruitment of pol III and activation of transcription (Kenneth et al., 2007). 
The ID1 protein has been demonstrated to induce the activity of the hypoxia-inducible 
factor-1α (HIF-1α) in the breast cancer cell line MCF-7 (Kim et al., 2007). This 
enhancement of the transcriptional activity of HIF-1α by overexpressing ID1 is due to 
the recruitment of CBP. However, previous experiments that have been performed in 
order to investigate whether ID proteins interact with HAT complexes have not shown 
an interaction between these proteins (Lasorella et al., 1996). A possible mechanism by 
which ID proteins may activate pol III transcription could involve the recruitment of 
HAT complexes to pol III-transcribed genes (Figure 6.6). In this model, overexpression 
of ID proteins might lead to binding to TFIIIB to promote the formation of the TFIIIB-
TFIIIC interaction. ID proteins could recruit HAT complexes including p300/CBP and 
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GCN5 to pol III-transcribed genes. The recruitment of the HAT complexes could then 
result in histone acetylation, which may result in recruitment of pol III and induction of 
pol III transcription (Figure 6.6). 
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Figure 6.6: Possible model for the activation of pol III transcription by ID proteins, 
mediated by the recruitment of histone acetylases. 
A. tRNA gene with TFIIIC bound in an inactive state. B. Activation of ID proteins leads 
to the recruitment of an ID-TFIIIB-HAT complex to the tRNA promoter, which in turn 
leads to the acetylation of histones. C. This is then followed by the recruitment of the 
polymerase and the subsequent activation of pol III transcription. 
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Future experiments are required to determine whether ID1, ID2 and ID3 proteins can 
associate with HAT complexes.  
 The tumour suppressor RB and p53 proteins have been demonstrated to repress 
pol II transcription by recruiting HDAC complexes to promoters (Brehm & Kouzarides, 
1999; Luo et al., 1998; Murphy et al., 1999; Luo et al., 2000). It has been shown that 
HDAC function contributes to regulation of pol III gene expression (Sutcliffe et al., 
2000). However, it has been demonstrated that HDAC activity is not required for RB 
and p53 to repress pol III transcription (Sutcliffe et al., 2000; Crighton et al., 2003). It is 
suggested that RB and p53 use an HDAC-independent mechanism to regulate pol III 
transcription in vivo. This may be explained by the interaction of RB and p53 with 
TFIIIB, which results in inhibiting promoter occupancy by TFIIIB (Sutcliffe et al., 2000; 
Crighton et al., 2003). Interestingly, E-proteins can function as transcriptional repressors 
by recruiting co-repressors such as ETO and mSin3A (Zhang et al., 2004; Kee, 2009). 
Also, it has been shown that the E-protein HEB recruits HDAC1 and HDAC3 to its AD1 
domain, this AD1 domain is conserved with other E-protein family members, including 
the E47 protein, suggesting that E47 may also interact with HDAC1 and HDAC3 
(Zhang et al., 2004). Experiments in this thesis have shown that E47 represses pol III 
transcription (Figure 5.5; Figure 5.7) and that E47 localises at pol III-transcribed genes 
(Figure 5.8; Figure 5.9; Figure 5.10; Figure 5.11), and this repression may be due to the 
recruitment of HDAC complexes to pol III-transcribed genes. In a potential mechanism 
the levels of ID proteins decrease during differentiation, which then allows E47 to 
interact with TFIIIB, since it is not sequestered by ID proteins. E47 may recruit HDAC 
complexes leading to the repression of pol III transcription (Figure 6.7). Therefore, IDs 
and E47 proteins might recruit HATs and HDACs respectively, leading to increases or 
decreases in localised histone acetylation surrounding pol III-transcribed genes. The 
mechanisms proposed here provide hypotheses for the regulation of pol III transcription; 
however, different mechanisms may apply as well or instead.  
 One mechanism by which HAT and HDAC complexes could be responsible for 
the patterns of acetylation and regulation of transcription would be to remain in the 
vicinity during replication and reassociate with the newly synthesised chromatin 
following the passage of the replication fork.  
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Figure 6.7: Possible model for the repression of pol III transcription by E47, 
mediated by the recruitment of histone deacetylase complexes. 
The levels of ID protein members decrease during differentiation, which correlates with 
a reduction of pol III transcription. E47 is not under the control of ID proteins which 
results in binding of E47 to TFIIIB. E47 may then recruit a co-repressor-HDAC 
complex, leading to the suppression of pol III transcription. 
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Modification of histones, such as acetytation of the histone tails, can alter the chromatin 
structure by weakening the histone-histone and histone-DNA contacts leading to the 
opening of chromatin to assist the interaction of transcription complexes with DNA 
(Wolffe & Hayes, 1999; Hansen et al., 1998). HDACs could be recruited to methylated 
DNA through their association with methyl-DNA-binding proteins, like MeCP2 and 
MBD2 (methyl-CpG binding domain protein 2), and also with the DNA methyl 
transferase itself (Fuks et al., 2000; Ng & Bird, 2000). Furthermore, acetylated histone 
tails form interaction domains for the binding of molecules containing bromodomains 
(brm [brahma]-like domains). Bromodomains are present in HAT and chromatin 
remodeling complexes and associate with acetylated lysines (Zeng & Zhou, 2002). 
Sequential recruitment of bromodomain-containing factors and complexes to promoter 
regions is important for the regulation of gene expression (Agalioti et al., 2002; Hassan 
et al., 2002). Acetylation of histones surrounding the promoters of pol III-transcribed 
genes might form interaction domains on the chromatin for bromodomain-containing 
complexes to serve as co-activators (Fischle et al., 2003; Turner, 2000). It has been 
shown that the Brg1 ATPase, which is a subunit of SWI/SNF (switch/sucrose 
nonfermentable) complex and contains a bromodomain, associates with pol III genes 
and it may be that histone acetylation can recruit ATP-dependent chromatin remodelling 
proteins (Sif, 2004). 
 In addition to regulating gene transcription by histone modification, HATs and 
HDACs can control the function of a wide range of proteins, including transcription 
factors (Lee & Workman, 2007). CBP acts as a co-activator for the transcription factor 
p53, and acetylates p53 on a lysine residue adjacent to the DNA-binding domain (Gu & 
Roeder, 1997). This modification enhances DNA-binding and increases transcriptional 
activity of p53 (Luo et al., 2004). p53 has also been shown to interact with HDAC1, by 
forming a complex with the co-repressor mSin3a, leading to the deacetylation of lysine 
residues of p53 by HDAC1 (Murphy et al., 1999; Luo et al., 2000). As a result, the free 
lysine residues are targeted for ubiquitination, leading to the degradation of p53 (Ito et 
al., 2002; Rodriguez et al., 2000). The pol II basal transcription factors TFIIB, TFIIF 
and TFIIEβ have been shown to be acetylated, with deacetylation also occurring 
suggesting that this is a reversible catalytic process, in order to control their functions 
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(Choi et al., 2003; Imhof et al., 1997). The ID and E47 proteins might form a complex 
with TFIIIB, preceding DNA localisation, recruiting HATs or HDACs to acetylate or 
deacetylate this complex to regulate TFIIIB activity. Future experiments are required to 
investigate this possible mechanism of activation or inhibition of TFIIIB by ID or E47 
proteins, respectively. Another possibility may be that the recruitment of ID-HAT or 
E47-HDAC complexes could lead to acetylation or deacetylation of other factors of the 
pol III machinery, resulting in activation or repression of transcription. 
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6.8 Conclusions 
 
 Products of pol III transcription include the 5S rRNA and tRNAs which play an 
important role in the biosynthetic capacity of cells and subsequently in growth. Work in 
this present study demonstrates that the ID1, ID2 and ID3 family members, which have 
been implicated in the development and progression of tumour growth, are involved in 
the upregulation of pol III transcripts. Furthermore, the results described in this thesis 
showed that the E47 protein, a transcription factor thought to play a critical role in the 
regulation of cell growth and survival, participates in the repression of pol III 
transcription. The ID family members appear to target the TFIIIB factor and specifically 
Brf1 in order to induce pol III activity. Also, E47 is demonstrated to interact with the 
Brf1 subunit to downregulate pol III transcription. Both IDs and E47 members are 
thought to interact directly with Brf1 and appear to localise at pol III genes. The pol III 
transcriptional machinery has been demonstrated to be the target of several oncogenes 
and tumour suppressors. Recently, induction of Brf1 has been shown to stimulate cell 
proliferation and lead to oncogenic transformation. Therefore, components of the pol III 
machinery could be explored as potential therapeutic targets. It will be interesting to 
investigate whether the E47 protein functions by altering the histone code and the 
methylation status of pol III genes, and whether ID proteins can stimulate transcription 
after pol III genes become accessible through recruitment of chromatin-modifying 
factors. Therefore, the ID and E47 protein functions are branching out, adding to their 
abilities the control of expression of pol III-transcribed genes. Deregulated ID and E47 
proteins may utilise a mechanism involving pol III transcription to affect cancer 
progression. Finally, the knowledge concerning pol III transcription should be aimed to 
provide therapy to benefit patients.  
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